The influence of environmental contaminants on time to pregnancy by Velez Gomez, Maria del Pilar
 Université de Montréal 
 
 
 
The Influence of Environmental Contaminants on Time to 
Pregnancy 
 
 
par  
 
 
Maria del Pilar Vélez Gómez 
 
 
Département de médecine sociale et préventive  
Faculté de médecine  
 
 
 
Thèse présentée à la Faculté des études supérieures 
en vue de l’obtention du grade de Philosophie Doctor (Ph.D.) 
en Santé Publique 
option: Épidémiologie 
 
August, 2014 
 
 
 
© María del Pilar Vélez Gómez, 2014 
  
  
 
 
 i 
 
Résumé 
Cette thèse porte sur l’évaluation de l’impact de certains composés environnementaux 
sur la fécondité féminine, tel que mesuré par le délai de conception (« time to pregnancy » en 
anglais, ou TTP). Cette recherche a été réalisée dans le cadre de l’Étude mère-enfant sur les 
composés chimiques de l’environnement (MIREC), une cohorte de grossesse de 2001 femmes 
recrutées durant le premier trimestre dans  dix villes canadiennes de 2008 à 2011. Les données 
des questionnaires et les échantillons biologiques ont servi à évaluer l’effet de deux groupes de 
composés : les persistants [composés perfluorés – perfluorooctanesulfonate (PFOS), 
perfluorooctanoate (PFOA) et  perfluorohexane sulfonate (PFHxS)] et les non persistants 
(bisphénol A, triclosan et phtalates). Cette thèse comprend également une analyse du potentiel 
du ratio index-annulaire (2D:4D) comme mesure de sensibilité endocrinienne. À ce jour, des 
mesures anthropométriques ont été collectées sur environ 800 mères-enfants dans le cadre de 
l’Étude mère-enfant sur les composés chimiques de l’environnement : biomonitoring et 
neurodéveloppement à la petite enfance (MIREC CD Plus), un suivi de la cohorte MIREC 
portant sur la croissance et le développement des enfants jusqu’à 5 ans. 
Sur l’ensemble, les résultats de cette thèse permettent d’étoffer les preuves concernant 
les effets adverses potentiels de plusieurs contaminants environnementaux sur la fécondité 
féminine, telle que mesurée par le TTP. Dans le premier article, nous avons montré une 
association entre les PFOA et les PFHxS et une baisse de fécondité, ce que d’autres recherches 
avaient déjà révélé. Dans le deuxième article, nous avons évalué l’effet du triclosan sur le 
TTP, ce qui n’avait jamais été examiné, pour montrer un délai plus élevé chez les femmes du 
quartile supérieur d’exposition. De plus, nos résultats sont en accord avec ceux de la seule 
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étude ayant évalué l’effet du Bisphénol A sur la fécondité féminine, qui n’avait pas détecté 
d’effet. Finalement, nos données semblent indiquer une association entre l’exposition des 
femmes aux phtalates et un TTP plus court, mais ces résultats ne sont pas statistiquement 
significatifs. 
En ce qui a trait au potentiel du ratio index-annuaire (2D:4D) pour mesurer la 
sensibilité endocrinienne chez les femmes, nos données ne permettent pas d’établir une 
association entre ce ratio et le TTP. Pour ce qui est des enfants, nous n’avons pas trouvé 
d’effet adverse entre le tabagisme de la mère durant la grossesse et leur ratio 2D:4D. Par 
conséquent, nos données ne semblent pas justifier l’utilisation du ratio 2D:4D pour mesurer la 
sensibilité endocrinienne en lien avec le potentiel reproducteur (basé sur le TTP) ou 
l’exposition des enfants au tabac durant le premier trimestre de grossesse. 
 
 
Mots-clés : fécondité, délai de conception, composés perfluorés, bisphénol A, triclosan, 
phtalates, perturbateurs endocriniens, ratio index-annuaire, 2D:4D   
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English Summary: 
 
In this thesis, we aimed to evaluate the impact of selected environmental compounds 
on female fecundity as measured by time to pregnancy (TTP). This research was conducted in 
the framework of the Maternal-Infant Research on Environmental Chemicals (MIREC) study, 
a pregnancy cohort of 2001 women recruited during the first trimester of pregnancy in ten 
cities across Canada between 2008 and 2011. Questionnaire data and biological samples were 
analyzed to assess the effect of two groups of compounds: persistent [perfluorinated 
compounds - perfluorooctane sulfonate (PFOS), perfluorooctanoate (PFOA), and 
perfluorohexane sulfonate (PFHxS)-] and nonpersistent chemicals (Bisphenol A, Triclosan, 
and phthalates). In addition, this thesis aimed to examine the potential of the second to fourth 
finger digit ratio (2D:4D) as a sensitive-endocrine endpoint. To this end, anthropometric 
measurements were obtained in about 800 children and their mothers during the Early 
Childhood Biomonitoring and Neurodevelopment Study (MIREC-CD Plus), a MIREC follow-
up conducted to measure growth and development up to age five.  
Overall, the results of this thesis have contributed to the evidence regarding the 
potential adverse effect of several environmental contaminants (ECs) on female fecundity as 
measured by TTP. In the first article, we found that PFOA and PFHxS were associated with 
diminished fecundity, supporting previous evidence that suggested a similar effect. In the 
second article, we assessed for the first time the effect of Triclosan on TTP, presenting 
evidence of delayed fecundity at the highest quartile of exposure. In addition, our findings 
agreed with those of the only study that has assessed the effect of Bisphenol A on female 
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fecundity, and which showed no effect. Finally, we found some indication that female 
exposure to phthalates might be associated with a shorter TTP, although this finding did not 
reach statistical significance. 
With regard to the potential of the digit length ratio (2D:4D) as an endocrine-sensitive 
endpoint in women, our data do not support a strong association between 2D:4D and TTP. In 
children, we did not find an adverse impact of maternal smoking during pregnancy on 
children’s 2D:4D. Thus, our data do not support evidence to suggest that 2D:4D could be used 
as a potential reproductive endocrine-sensitive endpoint in women as measured by TTP, and in 
their offspring as measured by exposure to maternal smoking during the first trimester of 
pregnancy. 
 
Key Words: fecundity, time to pregnancy, perfluorinated compounds, Bisphenol A, 
Triclosan, phthalates, endocrine disruptors, digit ratio, 2D:4D 
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INTRODUCTION 
There is increasing concern about the potential effects of environmental contaminants 
(ECs) on human reproduction, including fecundity and fertility. Fecundity impairments appear 
to be increasing in males, as suggested by the declining semen quality reported by several (1-
5) but not all authors, as recently reviewed (6). In addition, the prevalence of urogenital 
malformations seems to be higher in men having fecundity impairments or cancers of the 
reproductive system compared to unaffected individuals (7-9). In women, as proposed by 
Buck Louis (10), the relatively high prevalence of reproductive endocrinology disorders such 
as fibroids, polycystic ovarian syndrome, and endometriosis (11-13) may be associated with 
impaired female fecundity, while increasing infertility rates may be indicative of diminished 
couple fecundity (14, 15). Such observations, together with increased awareness of the 
reproductive toxicity of several ECs in wildlife and experimental animals, have led to 
increased research attention on the effect of ECs on human reproduction. Nonetheless, little is 
known about the effect of most ECs on human fecundity and fertility. 
Terminology for describing human reproduction differs across disciplines. Fecundity 
denotes the biological capacity to reproduce, irrespective of pregnancy intentions (16). 
Fecundity is difficult to measure due to the complex interaction of many biological factors. 
Therefore, fecundability, the probability of conceiving in any given menstrual cycle (or 
month), conditional on not achieving pregnancy in the previous cycle, has been used as a 
measurement tool for the study of fecundity. This measure depends on the health and 
environment of both the male and female partners, as well as the interaction between them 
(17, 18). 
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Fecundability is often measured by time to pregnancy (TTP). This metric was first 
developed in response to the need for a sensitive and convenient screening tool to identify 
environmental risk factors for conception (19). TTP provides an estimate of the per-cycle 
probability of conceiving a clinically detectable pregnancy. An increase in the time to 
pregnancy can indicate reproductive loss in any of several conditional processes underlying 
human conception, implantation, and the viability of the conceptus (20). TTP studies 
complement more mechanistic research on the biological processes necessary for fertility and 
studies of specific medical conditions (21). 
Subfertility generally describes any form of delayed fecundity with a prolonged 
undesired delay in conception (22). Clinically, a couple is considered to be subfertile after 
more than six menstrual cycles of unprotected intercourse with unsuccessful conception, while 
infertility refers to more than 12 or 24 months (23, 22). However, the clinical dichotomy of 
subfertility and infertility is an arbitrary oversimplification that can result in misclassification 
(19, 20). Biologically, there is a wide range of reproductive capacity, even among couples who 
achieve pregnancy. This heterogeneity within populations is expressed in the gradual decrease 
in conception rates during successive months of trying (19, 20), which is not a true time effect, 
but evidence of sorting among a population who are heterogeneous in their capacity to 
conceive (20). Heterogeneity among couples raises the possibility that some of this variation 
may be explained by identifiable factors. If so, well-conducted epidemiological studies are 
needed to identify the potential adverse effect of ECs on human fecundity. 
It is estimated that one in seven couples experiences some period of subfertility during 
their reproductive life (24). Approximately 50% of these couples can conceive spontaneously, 
with the remainder requiring some form of infertility treatment (25). Compared with women 
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who have no difficulties conceiving, delayed conception appears to be associated with 
increased obstetric and perinatal risks, independently of infertility treatment. Taken together, 
delayed time to pregnancy brings substantial physical, emotional, and socioeconomic burdens 
to individuals, families, and societies.  
The life-cycle approach provides a useful framework for assessing environmental 
chemicals and human fecundity (26). In this paradigm, health depends on interactions across 
the lifespan, extending from the genome to the interplay of the individual with the 
environment. As an example, the testicular dysgenesis hypothesis (TDS) has been proposed as 
an endpoint of the early origins of male fecundity and later onset disease (27). The TDS 
suggests that poor semen quality, testis cancer, undescended testis and hypospadias are a 
common entity, which results from the disruption of embryonal programming and gonadal 
development during fetal life. In addition, some evidence suggests that the ubiquitous 
exposure to environmental contaminants is associated with the increased prevalence of TDS 
today (27). In counterpart, ovarian dysgenesis syndrome (ODS) has been proposed as a 
framework for conceptualizing an early origin for female fecundity, and subsequently, health 
across the woman’s lifespan. ODS is defined as an alteration in ovarian structure or function 
that may manifest as a fecundity impairment, a gynecologic disorder, a pregnancy disease, or a 
later-onset adult disease (26). As well, the widespread presence of chemicals, especially those 
that interfere with any aspect of hormone action (known as endocrine-disrupting chemicals or 
EDCs) (28), has been linked to its etiology. 
There is a paucity of solid endocrine-sensitive endpoints that allow the assessment of 
diverse life-course stressors on developmental and reproductive functions. Epidemiological 
studies have linked a number of outcome measurements (e.g., anogenital distance, breast size, 
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vaginal cytology, location of the testis, testicular size, and penis growth, among others) with 
exposure to EDCs (29). However, little is known about how predictive these endpoints are of 
later reproductive health or other chronic health conditions. A new endpoint that has been 
proposed as an indicator of sexual development is the 2nd-to-4th-finger digit ratio (2D:4D). 
The 2D:4D reflects sexual differentiation early in life and is likely an endpoint for the 
organizational effects of prenatal androgens in the human body (30). Associations between 
digit ratios and several health outcomes including male fertility, sexual orientation, physical 
performance, and autism have been reported. The direction and magnitude of these 
associations, however, have not been consistent. Moreover, as in most of the literature 
regarding the effect of ECs on reproductive outcomes, the 2D:4D has been mainly studied in 
males.  
The purpose of the present thesis is to assess the effect of selected ECs on female 
fecundity as measured by TTP. In addition, this research program aims to evaluate the 
predictive role of 2D:4D as a sensitive-endocrine endpoint in women and their offspring. To 
this end, questionnaire and biomonitoring data from approximately 2000 pregnant women 
recruited in ten cities across Canada as part of the Maternal-Infant research on Environmental 
Chemicals (the MIREC Study) were analyzed (31) (Appendix 1). To assess the potential of 
2D:4D as a sensitive-endocrine endpoint, anthropometric measurements were obtained in 
about 800 children and their mothers during a MIREC follow-up conducted to measure growth 
and development up to age five: the Early Childhood Biomonitoring and Neurodevelopment 
Study (MIREC-CD Plus).  
 
  
Chapter 1 -  REVIEW OF THE LITERATURE 
1.1 Environmental contaminants (ECs) and reproductive function 
The production and use of chemicals continue to grow worldwide. There are currently 
more than 80,000 synthetic chemicals, and most of these were introduced after 1950 (32).   
However, only a small fraction of these substances has undergone human toxicity testing for 
safety. Furthermore, approximately 2800 chemicals are produced in quantities of more than 1 
million tons per year (32). These high-production-volume chemicals are dispersed 
ubiquitously in the environment: in the air, in soil, in water, in food, and in consumer 
products.  
Numerous studies have been conducted to evaluate risks to human reproduction by 
exposure to various chemicals, principally in animal models. Nonetheless, only a limited 
number of ECs have been studied with respect to their effects on human reproduction. 
Although some chemicals are highly toxic, their exposures are often restricted to certain 
occupational sub-populations or residents close to specific plants or pollutant dumping sites. 
However, some pollutants are widespread and exist almost ubiquitously in the environment. 
Additionally, some of these can be enriched through the food chain and accumulate in specific 
tissues, raising the exposure levels in the human body to well beyond their concentrations in 
natural habitats (33). In this manner, ubiquitous chemicals as well as persistent pollutants are 
of particular public health concern and are major health research targets.  
The recognition that several environmental contaminants have the capacity to interfere 
with hormone biosynthesis, metabolism, or action resulting in a deviation from normal 
homeostatic control or reproduction,  has increased concern that exposure to these chemicals 
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may have serious adverse consequences on human health (34). These compounds are 
generally referred to as endocrine-disruptor chemicals (EDCs)  and include, among other 
elements, several metals (35-39), polybrominated diphenyl ethers (PBDEs) (40), 
polychlorinated biphenyls (PCBs), bisphenol A (BPA) (41), and phthalates (42).  
Detection of contaminant residues in human serum, ovarian follicular fluid, and 
seminal plasma (43-45), together with reports of a decline in semen quality (1-5), have raised 
concern that exposure to ECs is affecting fertility. Reports of impaired fecundity linked with 
occupational exposure to pesticides further support this hypothesis (46, 47). However, the 
number of studies that have assessed the effect of ECs at current levels of exposure is limited, 
as recently reviewed (10).  
The organization of the endocrine control of reproduction does not end at birth, but 
remains sensitive to the interaction of steroids or ECs throughout the life course, as has been 
shown for the control of ovulation in rodents (34, 48, 49). Moreover, there are coexisting 
mechanisms not directly mediated in the hypothalamic-pituitary-gonadal (HPG) system that 
may alter fecundity. For instance, fertility impairments in women exposed to ECs might be 
mediated through menstrual cycle alterations (50), thyroid disruption (51), or other 
gynecologic endocrine disorders such as the polycystic ovary syndrome (PCOS) (49), and 
endometriosis (52). 
1.2 Assessment of exposure to environmental contaminants 
The quality of exposure measurement is often the most critical determinant of the 
validity of epidemiological studies assessing the health effects of ECs. While toxicological 
studies draw on relatively precise dosing information, epidemiological studies must rely on 
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other sources of exposure information such as questionnaires, environmental monitoring, or 
measurements of biological samples (biomonitoring) to measure exposure (53). Indirect 
techniques, primarily questionnaires, have been used historically to estimate the degree and 
frequency of exposure. However questionnaires rely on human knowledge and memory, and 
hence, are subject to error. Personal interviews may also elicit the underreporting of many 
phenomena (54). Today, the emphasis is shifting to biomonitoring, which is an important tool 
to assess human exposures and health risk. Biomonitoring provides information as to which 
chemicals are being absorbed into the body and in which quantities. Nonetheless, 
biomonitoring studies generally only have samples collected from individuals at a single point 
in time due to the high cost of collecting and analyzing biological specimens for ECs. The 
accuracy of this snapshot of exposure will depend on the chemical of interest, the life stage of 
the population, the availability and proper collection of the biological sample, the critical 
developmental stage of interest, the consistency of exposure over the time period, and the half-
life of the chemical (53, 55). Biomonitoring studies provide physicians and public health 
officials with reference values so that they can determine whether people have been exposed 
to higher levels of ECs than are found in the general population. Biomonitoring data can also 
help scientists plan and conduct research on exposure and health effects. 
Human biomonitoring surveys at the population level such as the National Health and 
Nutrition Examination Survey (NHANES) (56) in the U.S.A. and the recent Canadian Health 
Measures Survey (CHMS) (57, 58) have identified quantifiable levels of a number of ECs in 
most of the people tested. Biomonitoring for ECs with a focus on women of reproductive age 
is rare in most countries. In Canada, maternal or umbilical cord blood heavy metals have been 
studied in small select populations such as the Cree First Nation, (59) the Inuit, (60) 
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subsistence fishing groups, (61), and populations in Montreal (62) and southern Quebec (63-
65). More recently, the Maternal-Infant Research on Environmental Chemicals (the MIREC 
study) (31), a pregnancy and birth cohort of 2000 pregnant women recruited during the first 
trimester of pregnancy from 2008 to 2011, started releasing much-needed national data on the 
exposure of the Canadian general population and of pregnant and lactating women to several 
priority ECs (66, 67). 
1.3 Time-to-pregnancy (TTP) studies 
Time to pregnancy is a measure of how long a couple takes to conceive. Studies using 
TTP obtain more detailed information, beyond the usual dichotomy of fertile and infertile 
couples. TTP measures can be collected retrospectively or prospectively. Both designs have 
their strengths and limitations, and their roles are complementary (21).  
The gold standard for TTP is prospective data collection (68, 16). In studies using 
prospective design, couples who intend to conceive or are attempting to conceive can enroll, 
exposures are ascertained, and the participants are followed until they either achieve 
pregnancy, change their minds and resume contraception, or reach a certain maximum follow-
up time without achieving pregnancy (20). Although it is difficult to define a representative 
population sample if the study is conducted outside an occupational setting (69), recent efforts 
have proven to be successful using population-based sampling frameworks (70-72). A 
limitation, however, is that due to research protocols that are very time-consuming and/or 
require invasive procedures, prospective studies may result in selection bias due to the 
participation of select highly motivated participants (21). 
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Another feasible design is the current duration approach (73, 74). This uses a cross-
sectional survey design and focusses on couples who are currently having unprotected 
intercourse, asking participants about the duration of their ongoing attempt. In addition, a 
combination design is possible with follow-up of the couples, based on principles from the 
case-cohort design (75). 
On the other hand, women (or their partners) can be asked to reconstruct their TTP 
retrospectively for a particular pregnancy. In this retrospective approach, both the exposures 
and the time to an index pregnancy are based on recall (20). Retrospective designs, although 
lacking detailed information about the duration of exposure, have good response rates and are 
simpler and less expensive to conduct than prospective studies (21). One strength of the 
retrospective design is that it allows researchers to obtain a sample that is representative of the 
target population. Additionally, validity studies suggest that retrospective TTP is a valid 
measure when collected within a short time frame (76, 77).  
To ensure validity, retrospective TTP information should be derived from a well-
defined source population (21). The three main sampling frames are: pregnancy-based studies, 
cross-sectional population-based or occupationally-based studies, and population-based birth 
cohort studies. In pregnancy-based studies, the recall bias is minimal, as women are asked 
about their current pregnancy. The disadvantage is that sterile couples are excluded, resulting 
in systematic underrepresentation of subfertile women (21). Thus, an exposure that causes 
complete sterility in a subpopulation and has no effect on the remainder of the population 
would be missed in the pregnancy-based retrospective TTP design (20). Nonetheless, these 
studies have been successful in identifying male and female exposures with adverse effects on 
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fertility, as most reproductive toxicants can be expected to cause fecundity impairments 
among the exposed couples who have not been rendered sterile (20). 
Attention should also be paid to those pregnancies that are the consequence of 
inconsistent use and/or failure of a contraceptive method (21). These couples are generally 
excluded from the main pregnancy-based analysis as they do not have an eligible TTP value. 
A screening question is therefore recommended, asking whether the pregnancy resulted from 
contraceptive failure.  However, if one exposure group (e.g., smokers) has a higher degree of 
risk-taking and/or a lower degree of conscious planning, the members of this group are more 
likely to have accidental pregnancies that are excluded from the main TTP analysis, so that 
their eligible pregnancies apply only to a subset who are less prone to “accidents”, and very 
likely associated with lower fecundity, resulting in “planning bias” (78). In addition, some 
couples may change their attitude about the pregnancy when retrospective questioning is used, 
reporting it as planned even though it resulted from contraceptive failure. This has been called 
“wantedness bias” (78), as reporting the pregnancy as an accident could be considered as 
saying the child was unwanted. This would cause bias if differential propensity to reinterpret 
one’s recall were associated with one or more covariates.  
Another behavioural factor that could result in a bias is differential persistence in 
trying to conceive, for example, when couples do not pursue the attempt to have a child with 
similar persistence according to their age group (79).  
1.4 Time to pregnancy and adverse health effects 
Delayed TTP has been reported to be associated with adverse pregnancy and perinatal 
adverse outcomes independently of infertility treatment. The suspected relationship is 
 11 
 
 
grounded in the assumption that impaired fecundity may be associated with adverse health 
implications for human conception, implantation, and fetal growth and development (80, 26). 
One possible explanation may be that exposures at critical windows of human development 
are manifested in varying adverse outcomes. Hence, the timing of an exposure may dictate the 
type of outcome observed. Some have suggested a shared aetiology for the diverse outcomes 
(81-83). An alternative explanation could be that conception delay is a marker of past 
exposure adversely impacting the gametes in one partner or the other (80, 26). Thus, impaired 
fecundity as measured by delayed conception may be an early marker of eventual disturbances 
in human development.  
However, despite the high proportion of babies born to subfertile couples, only a few 
studies have evaluated the association between delayed fecundity and pregnancy or perinatal 
outcomes. In the Danish National Birth Cohort, the prevalence of congenital malformations 
increased with a longer TTP (84), as did the need for a caesarean section (85), preeclampsia 
(86), small-for-gestational age (87), and neonatal mortality (88). In one study, women who 
required more than 12 months to conceive experienced approximately a 70% increase in the 
baseline risk of delivering a preterm infant in comparison with women requiring less time 
(83). Similarly, women who delivered a preterm infant were reported to require a 15% longer 
time for conception compared with women delivering at term (82). However, no association 
was reported in a subsequent study (80). With respect to the risk of low birth weight, a longer 
TTP increased the risk in one study (81), but no relationship was observed in a second study 
(82).  
Delayed TTP generates high emotional and socioeconomic burdens for individuals, 
couples, and society. The same is true for adverse pregnancy and perinatal outcomes. The 
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identification of exposures and the underlying biological mechanisms that can cause fertility 
impairments and adverse perinatal outcomes would have dual benefits for preventing both 
adverse outcomes. 
1.5 Contaminants of emerging concern (CECs) and time to pregnancy  
Contaminants of emerging concern are chemicals that had not been previously detected 
in the environment or have been detected at higher levels than expected (89). The uncertainty 
about the risk to human health associated with their presence, frequency of occurrence, and 
routes of exposure is a cause for concern.  
Some of these chemicals have long half-lives, allowing bioaccumulation and 
persistence in the environment. On the opposite end of the spectrum are those chemicals with 
short elimination half-lives considered nonpersistent, although their high-volume production 
makes them a common source of human exposure. Recently, Buck Louis summarized the 
available literature regarding persistent environmental pollutants and couple fecundity (10). 
Basically, ten cohort studies constitute the principal source of information to date. Except in 
two studies, fecundability odds ratios (FORs) were always lower than 1, which is indicative of 
a longer TTP, although not all findings were statistically significant. Persistent chemicals 
associated with reduced couple fecundity as measured by a longer TTP included β-HCH, 
cadmium, lead, mercury, p,p’-DDE, TCCD dioxin, select polybrominated diethers (PBDEs), 
polychlorinated biphenyls (PCBs), and perfluorinated compounds (PFCs). For the purpose of 
this thesis, we reviewed the literature regarding our priori-defined exposures of interest, which 
were categorized within two groups: persistent (perfluorinated compounds - PFOA, PFOS, 
and PFHxS-) and nonpersistent chemicals (Bisphenol A, Triclosan, and phthalates). 
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1.5.1 Perfluorinated compounds 
Perfluorinated chemicals (PFCs) have received attention because of their high-volume 
production and ubiquitous environmental presence. PFCs are widely used in the manufacture 
of both domestic and industrial products, having applications as grease-or-water repellents, 
protective coatings for clothes, furniture and other products, and  components of floor polish, 
adhesives, firefighting foam, and insulate for electrical wiring (56).  
The two PFCs made in the largest quantities in the United States were perflurooctanoic 
acid (PFOA) and perfluorooctane sulfonic acid (PFOS) (90). The key producer of PFOS 
phased out worldwide production in 2002 and a replacement for PFOA was introduced 
recently, which resulted in the withdrawal of PFOA in manufacturing processes (91, 92).  In 
spite of this, national biomonitoring surveys in the U.S.A. (56) and in Canada (57, 58) have 
shown that nearly all participants contained low levels of PFOA, PFOS, and perfluorohexane 
sulfonic acid (PFHxS) in their blood. 
There is concern about the potential adverse developmental and reproductive effects of 
PFCs. PFOS, PFOA, and PFHxS have long serum elimination half-lives (i.e., 5.4, 3.8 and 8.5 
years, respectively) (93). Toxicological studies evaluating the potential role of PFCs as 
endocrine-disrupting chemicals (EDCs) are limited. In vitro, some PFCs have the potential to 
affect estrogen-receptor and androgen-receptor transactivity (94). In rats, exposure to PFOS 
has shown estrous cyclicity disruption and neurotransmitter imbalance (95).  
In humans, recent studies have explored the potential association between PFCs and 
fecundity, as measured by time to pregnancy. In a retrospective pregnancy-based TTP study 
Fei et al. (96) utilized banked biospecimens for the quantification of plasma PFOA and PFOS 
concentrations among 1,240 pregnant women participating in the Danish National Birth 
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Cohort. Significant inverse trends were observed for both PFOA and PFOS and TTP, 
reflecting an approximate 30% reduction in fecundity for women in the highest three quartiles 
in comparison to women in the lowest. In a case-control study including 910 pregnant women 
from the Norwegian Mother and Child Cohort (MoBa), Whitworth et al. (97) reported twofold 
higher odds of subfecundity (TTP >12 months) at increasing concentrations of PFOA and 
PFOS in parous but not nulliparous women. Moreover, a recent analysis of the same MoBa 
cohort testing different statistical approaches reported significant diminished fecundity at 
increasing PFOA concentrations (98). In prospective couple-based cohort designs, 
Vestergaard et al. (99) observed no consistent pattern between eight PFCs and TTP in the 
Danish Cohort, and Buck Louis et al. (71) reported just one (perfluorooctane sulfonamide, 
PFOSA) of the seven PFCs assessed in the LIFE Study (Michigan and Texas) associated with 
decreased fecundability.  
1.5.2 Bisphenol A 
Bisphenol A (BPA) is a high-production-volume chemical used in a variety of 
commonly used consumer products. Most notably, BPA is present in polycarbonate plastics, 
the epoxy resin liners of aluminum cans, and in thermal receipts (100). Exposure to BPA is 
common, with over 90% of the populations of the U.S.A. and Canada having detectable 
urinary concentrations (101, 58). 
BPA has recognized endocrine-disrupting properties in animals (102), however, there 
is limited information regarding the effect of BPA exposure on human fecundity.  
As recently reviewed (102), BPA may have ovarian and uterine toxicity.  In the ovary, 
BPA affects the onset of meiosis in animal and in-vitro models, interferes with germ-cell nest 
breakdown in animal models, accelerates follicle transition in several animal species, alters 
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steroidogenesis in multiple animal models and in women, and reduces oocyte quality in animal 
models and in women undergoing IVF (102). In the uterus, BPA exposure is associated with 
impaired uterine endometrial proliferation, decreased uterine receptivity, and increased 
implantation failure in animal models (102).   
While several studies conducted in infertile couples seeking assisted reproductive 
technologies (ART) suggest adverse reproductive effects, only one study has assessed the 
impact of BPA on couple fecundity in a population-based setting (72). In the context of ART, 
higher concentrations of BPA have been associated with hormonal imbalances in both women 
and men (103-105), diminished antral follicle counts (106), decreased number of oocytes 
retrieved after ovarian stimulation (107, 108), lower fertilization rate (108), and implantation 
failure (109). At the population level, the only epidemiological study to date assessing the 
effect of BPA on TTP reported no association between female or male BPA urinary 
concentrations and TTP among participants from the LIFE Study, a prospective cohort of 
couples attempting pregnancy in the U.S.A. (72).  
1.5.3 Triclosan 
Triclosan (TCS), a halogenated phenol, is a broad-spectrum antimicrobial used as an 
ingredient in disinfectants, soap, detergent, toothpaste, mouthwash, fabric, deodorant, 
shampoo, and plastic additives, in addition to innumerable other personal care, veterinary, 
industrial, and household products (110, 111). TCS is effective against many types of bacteria 
and certain types of fungi, preventing bacterial propagation and/or eventually resulting in cell 
death. The use of TCS is not highly regulated, as the antimicrobial has a low acute toxicity and 
is generally accepted as well tolerated and safe (110, 111). 
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TCS was detectable in about 75% of the urine samples collected as part of the 
NHANES 2003-2004 survey of the U.S. population (112) and in the 2009-2011 Canadian 
Health Measures Survey (58). TCS has a similar structure to known EDCs, including 
polychlorinated biphenyls (PCBs), polybrominated diphenyl ethers (PBDEs), and BPA, and to 
thyroid hormones (110). These structural similitudes, together with some limited evidence in 
laboratory animals of effects on diverse hormones, suggest that TCS may influence endocrine 
function, and possibly the reproductive axis (110). Epidemiological studies on TCS are 
limited. Two studies reported no significant impact of prenatal exposure to TCS on birth size 
(113, 114). A recent analysis of urine samples from NHANES 2003-2008 showed a positive 
association between TCS and body mass index (BMI) (115). No studies assessing the effect of 
TCS on TTP have been conducted to date. 
1.5.4 Phthalates 
Phthalates are a group of synthetic EDCs used as plasticizers in industrial production. 
They have received special attention because of their high-volume production, ubiquitous 
environmental presence, and possible association with adverse reproductive health outcomes 
(56). Human exposure to phthalates may result in changes to tissues in the testes and reduced 
sperm counts; lower levels of testosterone; increased prenatal mortality; decreases in fetal 
growth, birth weight, and anogenital distance; and a number of biological malformations 
(116). 
Phthalates are used to impart flexibility and resilience to polyvinyl chloride (PVC) 
plastics (56). Many consumer products contain phthalates, including vinyl flooring, adhesives, 
detergents, lubricating oils, solvents, automotive plastics, some medical pharmaceuticals, 
plastic bags, blood-storage bags, intravenous medical tubing, children’s toys, and personal 
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care products such as soap, shampoo, deodorants, fragrances, hair spray, and nail polish (56). 
Di-(2-ethylhexyl) phthalate (DEHP) is the most abundant phthalate in the environment, and 
mono-(2-ethylhexyl) phthalate (MEHP) is its primary metabolite, created by the breakdown of 
DEHP in the body (116). 
Because phthalates are not chemically bound to PVC plastics, they gradually separate 
from consumer products over time. As a result, humans can experience phthalate exposure 
during their entire life cycle, whether it be through digestion, inhalation, dermal contact, the 
indirect leaching of phthalates into other products, or general environmental contamination 
(117). Although phthalates tend to rapidly metabolize in the body, their widespread use and 
ubiquitous presence in dust, soil, and indoor and outdoor air results in continuous human 
exposure to these chemicals and possible health effects as a result. Additionally, as phthalates 
metabolize in the body, they are better able to interfere with biological function (118). 
Experimental studies have indicated that the effect of phthalates on human health is 
very much related to the time of exposure. Exposures during critical windows of vulnerability 
may have adverse effects in the short and long term. Phthalate exposure during periods 
regulated by steroid hormone levels, such as ovarian and testicular development in the womb 
and during puberty, pregnancy, and menopause, can lead to reproductive effects later in life. 
Evidence is also building regarding the cumulative health effects of simultaneous exposure to 
multiple phthalates and other EDCs (119, 120). For example, studies have demonstrated 
associations between male reproductive malformations in rats and the presence of a 
combination of phthalates and EDCs in the body (119). 
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Most phthalate studies to date have focused on male exposures and reproductive 
effects. There continues to be limited research exploring the effects of phthalates on women’s 
health, despite the fact that female reproductive function and development are equally, if not 
uniquely, susceptible to exposure to hormonally active chemicals (121). Evidence is now 
emerging that shows females are more highly exposed to phthalates than males. For example, 
the Fourth U.S. National Report on Human Exposure to Environmental Chemicals examined 
data from National Health and Nutrition Examination Surveys (NHANES, 1999-2000, 2001-
02, and 2003-2004) on urinary levels of phthalates in a subsample of the U.S. population aged 
six and over (56). The analysis identified gender differences in the concentration of the 
phthalates under assessment, with higher urinary phthalate levels observed in women than in 
men. This pattern was also observed more recently in the Canadian Health Measures Survey 
(57), where biomonitoring of phthalate metabolites in the urine samples of 3,236 individuals 
ranging from six to forty-nine years of age reported significantly higher concentrations in 
females than in males (122). 
There is a paucity of studies assessing the effect of phthalates on women’s fecundity. 
In Generation R, a large pregnancy cohort study conducted in the Netherlands, occupational 
exposure to phthalates was assessed using a job-exposure matrix, and was reported as being 
associated with a longer TTP (123, 124). In Italy, concentrations of several phthalate 
metabolites were assessed in 56 infertile couples from an ART centre, and were found to be 
significantly higher than in the control group of fertile couples (125).  Recently, in the LIFE 
Study, no phthalate metabolite in female urine was statistically associated with a longer TTP, 
although one metabolite [mono (3-carboxypropyl) phthalate] was associated with a shorter 
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TTP. In men, urinary concentrations of monomethyl, mono-n-butyl, and monobenzyl 
phthalates were associated with a longer TTP (72).  
In summary, epidemiologic evidence for the role of ECs in general, and particularly for 
perfluorinated compounds, BPA, TCS, and phthalates in TTP is limited. Moreover, in most 
cases, relationships supported by inadequate evidence reflect the scarcity of evidence as 
opposed to the strong evidence for no effect (126). There are major knowledge gaps and a 
need for better research data on the effects of ECs on fecundity. As mentioned above, the 
effects of ECs on reproductive health have been less studied in women than in men. However, 
female reproductive function and development are susceptible to endocrine toxicants, and 
effects on female reproductive organs and pregnancy outcomes are a major health concern 
(127). Prospective cohorts of couples attempting pregnancy, along with the utilisation of 
stored biological samples from existing pregnancy cohort studies with larger sample sizes and 
valid assessments of exposure (i.e., biomarkers) will be of great value in better characterizing 
degrees of risk. 
1.6 The digit length ratio as an endocrine-sensitive endpoint  
The second to fourth digit length ratio (2D:4D) reflects sexual differentiation early in 
life and has been suggested as an endpoint for the organizational effects of prenatal androgens 
in the human body (30). 2D:4D is a sexually dimorphic trait, with males having relatively 
shorter 2nd digits (index fingers) with respect to their 4th digits (ring fingers) (128). As such, 
lower 2D:4Ds may be potential indicators of greater androgen exposure during fetal 
development. Associations between digit ratios and several health outcomes including male 
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fertility have been reported. The direction and magnitude of these associations, however, have 
not been consistent.  
Several cross-sectional studies have reported low sperm counts and impaired hormonal 
status in men having higher 2D:4D ratios (129-131).  However, studies with larger sample 
sizes have failed to replicate these associations (132-137). In addition, two retrospective 
studies reported associations between lower 2D:4D ratios and delayed age at menarche (138, 
139), while a prospective cohort found lower ratios as predictors of early age at menarche 
(140). Concerning fertility, the evidence is sparse and usually assessed by means of indirect 
markers. Thus, lower female digit ratios have been associated with low offspring counts (141), 
congenital adrenal hyperplasia (CAH) (142, 143), and polycystic ovary syndrome (PCOs) 
(144), although this finding was challenged by Lujan et al. (145, 146). TTP is an 
epidemiological metric widely used for the assessment of human fecundity (19, 16). In males, 
one study reported decreased fecundity (i.e., delayed TTP) at higher 2D:4Ds (130). However, 
the predictive role of 2D:4D on TTP has never been assessed in females.  
Smoking has a recognized detrimental impact on fertility, both male and female (147, 
16). Furthermore, maternal smoking during pregnancy has been associated with adverse 
reproductive outcomes in offspring (148), including impaired fecundity (149). The causal 
mechanism by which smoking adversely affects fertility is still the subject of active research. 
In rats, prenatal exposure to nicotine has been linked to increased testosterone levels (150). In 
humans, maternal smoking during pregnancy has been positively associated with 
concentrations of maternal testosterone (151). Thus, if the adverse effect of maternal smoking 
on the offspring’s subsequent fertility acts through the homeostasis of fetal androgens, and 
under the hypothesis that the 2D:4D ratio is an indicator of the fetal concentrations of 
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androgens, then 2D:4D might differ among children whose mothers smoked during pregnancy 
compared to those whose mothers did not smoke. Only one cross-sectional study has assessed 
the impact of maternal smoking during pregnancy on 2D:4D (152), reporting lower digit ratios 
in boys prenatally exposed to smoking, although this association was not observed in females.  
To sum up, there is limited information about the predictive role of 2D:4D as a 
reproductive endocrine-sensitive endpoint and additional research in this area is required. 
 
 
  
Chapter 2 -  RATIONAL AND OBJECTIVES 
The Centers for Disease Control and Prevention (CDC) has declared fertility 
impairment as an emerging public health priority in the United States (153, 154). Data from 
the U.S 2006-2010 National Survey of Family Growth (NSFG) showed that infertility affects 
about 6% of married women 15–44 years of age, and that an additional 12% of women ages 
15-44 suffer from impaired fecundity (i.e., the ability to become pregnant or carry a pregnancy 
to a live birth). As for the men, 9% reported male-related infertility (155). Moreover 12% (7.3 
million women) or their husbands or partners had used infertility services (including 
counseling and diagnosis) in their lifetime (156). In the recently-released CDC National Public 
Health Action Plan for the Prevention, Detection and Management of Infertility, data gaps in 
knowledge related to fertility impairments were identified in many areas. Regarding research 
needed for primary prevention, the investigation of environmental exposures was evoked as a 
priority (153, 154). 
While there is strong animal evidence of the reproductive toxicity of many 
environmental chemicals, epidemiologic studies are limited. There is mounting concern that 
exposure to chemicals with endocrine-disrupting activity causes reproductive disorders in 
human populations such as delayed time to pregnancy, precocious puberty, estrogen-sensitive 
cancers, and declines in semen quality, among others.  
There is a paucity of adequate epidemiologic studies on the reproductive health effects 
of environmental contaminants (157). Furthermore, additional studies are needed to strengthen 
the limited or inadequate evidence suggesting that low doses of some biologically active 
contaminants can alter reproductive function; that periconceptional exposure can have long-
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term adverse effects, including reproductive health effects; and that multiple exposures can act 
synergistically (157).  
Epidemiologic studies are warranted, given that biomonitoring studies show varying 
body burdens in the general population, and preliminary animal toxicity data provide evidence 
of potential endocrine disruption for numerous environmental contaminants. It is of primordial 
importance that the impact of selected ECs (i.e., perfluorinated compounds, phenols, and 
phthalates) on reproductive health be elucidated.  
The potential for exposure to ECs and evidence of the sensitivity of the developing 
reproductive system from studies in animals and humans, as well as the many current 
knowledge gaps, justify continuing concern about this issue. 
The present research program aims to determine the effect of selected environmental 
contaminants (i.e., perfluorinated compounds, phenols, and phthalates) in women’s time to 
pregnancy, making use of questionnaire and biomonitoring data, to assess periconceptional 
hazard exposures in a population of pregnant women. In addition, the study aims to assess the 
potential of 2D:4D as a reproductive endocrine-sensitive endpoint in women and their 
offspring. 
The specific objectives of this thesis include: 
2.1 Study #1 
To evaluate the association between selected PFCs (i.e., PFOA, PFOS, and PFHxS) and time 
to pregnancy in women participating the MIREC Study 
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2.2 Study #2 
To assess the effect of BPA, TCS, and phthalates on women’s fecundity, as measured by TTP 
in the context of the MIREC Study 
2.3 Study #3 
In examining the potential of 2D:4D as a reproductive endocrine-sensitive endpoint, the 
objectives were: 
1. To evaluate the association between female 2D:4D and fecundity, as measured by 
time to pregnancy (TTP) in women from the MIREC Study; 
2. To evaluate the effect of prenatal exposure to maternal smoking on the 2D:4D of 
children born to women from the MIREC cohort. 
 
  
Chapter 3 -  PERFLUORINATED CHEMICALS AND 
FECUNDITY: THE MIREC STUDY (ARTICLE 1) 
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3.1 Abstract 
Study question: What is the effect of maternal exposure to perfluorooctane sulfonate 
(PFOS), perfluorooctanoate (PFOA), and perfluorohexane sulfonate (PFHxS) on Time to 
Pregnancy (TTP)? 
Summary answer: Evidence is presented that increases in maternal plasma 
concentrations of PFOA and PFHxS may be associated with reduced fecundability and 
infertility. 
What is known already: Endocrine-disrupting chemicals (EDCs) can alter hormone 
functions essential to development and reproduction. Perfluorinated chemicals (PFCs) are 
a group of synthetic EDCs used in industrial production. There is increasing concern 
about the effect of PFCs on fecundity, as measured by Time to Pregnancy (TTP). 
Although recent studies suggest that increasing concentrations of PFCs may decrease 
fecundity, divergences in the methodological approaches used to evaluate this association 
have prevented firm conclusions. 
Study design, size, duration: The Maternal-Infant Research on Environmental 
Chemicals (MIREC) Study is a pregnancy and birth cohort of 2,001 women recruited 
before 14 weeks of gestation in 10 cities across Canada between 2008 and 2011. The 
present study utilizes a pregnancy-based retrospective TTP approach. 
Participants/materials, setting, methods: A questionnaire was administered and 
medical chart data and biospecimens were collected from participants. After excluding 
women who withdrew, those for whom data was incomplete, and those whose 
pregnancies followed birth-control failure, and accounting for the male infertility factor, 
1743 participants remained. TTP was defined as the number of months of unprotected 
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intercourse needed to become pregnant in the current pregnancy, as self-reported in the 
first trimester of pregnancy. Plasma concentrations of PFOA, PFOS, and PFHxS 
measured in the first trimester were considered as a proxy of preconception exposure. 
Fecundability odds ratios (FORs) were estimated using Cox proportional hazard models 
for discrete time. FORs <1 denote a longer TTP and FORs >1 a shorter TTP. The odds of 
infertility (TTP > 12 months or infertility treatment in the index pregnancy) were 
estimated using logistic regression. Each chemical concentration (ng/ml) was log 
transformed and divided by its standard deviation. Potential confounders were maternal 
age, household income, and body mass index (BMI). 
Main results and the role of chance: The probabilities of pregnancy at 1, 6 and 12 
months were 0.42 (95% CI 0.40-0.45), 0.81 (95% CI 0.79-0.83) and 0.90 (95% CI 0.89-
0.92), respectively. The mean maternal age was 32.8 (SD 5.0) years. Half of the women 
had at least one prior pregnancy with a live birth, and about 15% were obese or active 
smokers during the preconception period. Maternal and paternal age, pre-pregnancy BMI, 
and parity were associated with TTP. Maternal or paternal active smoking, gestational 
age at which the sample was collected, country of birth, household income, and education 
were not associated with TTP. The geometric means (ng/ml) of PFOA, PFOS, and 
PFHxS were 1.66 (95% CI 1.61-1.71), 4.59 (95% CI 4.46-4.72) and 1.01 (95% CI 0.97-
1.05), respectively. Crude FORs per one standard deviation increase in log-transformed 
serum concentrations of PFOA, PFOS, and PFHxS were 0.91 (95% CI 0.86-0.96), 0.97 
(95% CI 0.92-1.03), and 0.94 (95% CI 0.89-1.00), respectively. After adjustment for 
potential confounders, PFOA and PFHxS were associated with a 11% and 9% reduction 
in fecundability per one standard deviation increase (FOR= 0.89; 95% CI 0.83-0.94; 
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p<0.001 for PFOA, and FOR=0.91; 95% CI 0.86-0.97; p=0.002 for PFHxS), while no 
significant association was observed for PFOS (FOR=0.96; 95% CI 0.91-1.02; p=0.17). 
In addition, the odds of infertility increased by 31% per one standard deviation increase 
of PFOA (OR=1.31; 95% CI 1.11-1.53; p=0.001) and by 27% per one standard deviation 
increase of PFHxS (OR= 1.27; 95% CI 1.09-1.48; p=0.003), while no significant 
association was observed for PFOS (OR= 1.14; 95% CI 0.98-1.34; p=0.09). 
Limitations, reasons for caution: Pregnancy-based TTP studies may exclude women 
with the highest concentrations of PFCs if there is causal association with infertility. We 
did not assess the concentrations of PFCs in males, nor their semen quality. As well, 
information on menstrual cycle characteristics, ovulation, and intercourse frequency was 
not available. 
Wider implications of the findings: Our results add to the evidence that exposure to 
PFOA and PFHxS, even at lower levels than previously reported, may reduce 
fecundability. The mechanism involved in this endocrine-disrupting effect needs to be 
assessed. 
Study funding/competing interest(s): The MIREC Study is supported by the Chemicals 
Management Plan of Health Canada, the Canadian Institutes for Health Research (CIHR, 
grant # MOP – 81285), and the Ontario Ministry of the Environment. M.P. Velez is 
supported by a CIHR Fellowship Award. W.D Fraser is supported by a CIHR Canada 
Research Chair. 
  
 29 
 
 
3.2 Introduction: 
Perfluorinated chemicals (PFCs) have recently received attention because of their high-
volume production, ubiquitous environmental presence, and possible association with 
adverse health effects. PFCs were introduced in 1950 and have since been widely used in 
the manufacture of both domestic and industrial products having applications as grease-
or-water repellents and protective coatings for clothes, furniture, and other products, and 
also as constituents of floor polish, adhesives, firefighting foam, and insulation of 
electrical wire (CDC 2009).  
The two PFCs made in the largest quantities in the U.S. were perflurooctanoic acid 
(PFOA) and perfluorooctane sulfonic acid (PFOS) (ATSDR 2009). The key producer of 
PFOS phased out worldwide production in 2002 and a replacement for PFOA was 
introduced recently which resulted in PFOA no longer being used in manufacturing 
processes (DuPont 2013, 3M 2014).  Direct uses in Canada have largely been phased out 
(Health Canada 2008); voluntarily, by most of the manufacturers of PFOA, and by 
federal regulation through the Canadian Environmental Protection Act (CEPA) for PFOS 
(Environment Canada 2012). Nonetheless, the production of PFOS has continued in 
China, and therefore, products containing their precursors may be still entering the 
Canadian market (Lim et al. 2011). 
Although the production of several PFCs has declined during the last decade, recent 
national biomonitoring surveys in the United States (Centers for Disease Control and 
Prevention 2009) and Canada (Health Canada 2010, 2013) have shown that nearly all 
participants were found to have low levels of PFOA, PFOS, and perfluorohexane sulfonic 
acid (PFHxS) in their blood . These PFCs have also been detected in cord blood 
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(Arbuckle et al. 2013) and breast milk (Fromme et al. 2010). While the primary source of 
exposure in the general population is food (Tittlemier et al. 2007), water is an important 
source in contaminated areas, for example, in communities near production facilities 
(Hoffman et al. 2011). In addition, PFCs have been detected in dust (Bjorklund et al. 
2009) and in indoor and outdoor air (Shoeib et al. 2004, Shoeib et al. 2011). 
There is concern about the potential adverse developmental and reproductive effects of 
PFCs. PFOS, PFOA and PFHxS have long serum elimination half-lives (i.e., 5.4, 3.8 and 
8.5 years, respectively) (Olsen et al. 2007). Toxicological studies evaluating the potential 
role of PFCs as endocrine-disrupting chemicals (EDCs) are limited. In vitro, some PFCs 
have the potential to affect estrogen-receptor and androgen-receptor transactivity 
(Kjeldsen and Bonefeld-Jorgensen 2013). In rats, exposure to PFOS has shown estrous 
cyclicity disruption and neurotransmitter imbalance (Austin et al. 2003).  
In humans, several studies have explored the potential association between PFCs and 
fecundity, as measured by Time to Pregnancy (TTP). In a retrospective pregnancy-based 
TTP study within the Danish National Birth Cohort, Fei et al. (2009) observed a strong 
association between higher concentrations of PFOA and PFOS and longer TTP. In a case-
control study within the Norwegian Mother and Child Cohort (MoBa), Withworth et al. 
(2012) reported higher odds of subfecundity (TTP >12 months) at increasing 
concentrations of PFOA and PFOS. A recent analysis of the same MoBa cohort testing 
different statistical approaches replicated the association between PFOA and longer TTP 
(Ding et al. 2014). Nonetheless, Whitworth et al. (2012), under the assumption of reverse 
causation suggested by Olsen et al. (2009) (i.e., parous women with longer Time to 
Pregnancy have higher PFCs levels because they have long interpregnancy intervals 
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allowing re-accumulation of PFCs), found no association among nulliparous women after 
stratification by parity. The same stratification was further reapplied by Fei et al. (2012), 
which resulted in stronger associations for PFOS and PFOA in nulliparous women and 
for PFOA in multiparous women. In prospective couple-based cohort designs, 
Vestergaard et al. (2012) observed no consistent pattern between eight PFCs and TTP in 
a Danish cohort, and Buck Louis et al. (2013) reported just one (perfluorooctane 
sulfonamide, PFOSA) of the seven PFCs assessed in the LIFE Study (Michigan and 
Texas) associated with decreased fecundability. Questions remain on why these studies 
have reported conflicting results on the association between PFCs and Time to 
Pregnancy. 
The aim of the present study was to evaluate the association between selected PFCs (i.e., 
PFOA, PFOS, and PFHxS) and Time to Pregnancy in the MIREC Study, a Canadian 
pregnancy and birth cohort. 
  
 32 
 
 
3.3 Methods: 
Population and study design 
The Maternal-Infant Research on Environmental Chemicals (MIREC) Study was 
established to examine potential adverse health effects of exposure to priority 
environmental chemicals on pregnancy and infant health in Canada. The cohort profile of 
the MIREC Study was recently published (Arbuckle et al. 2013). Briefly, pregnant 
women from the general population who were attending early prenatal clinics in 10 cities 
across Canada between 2008 and 2011 were invited to participate, reaching a 
participation rate of 39%. Some two thousand women were followed during each 
trimester of pregnancy, at delivery, and in the early post-natal period. 
In this specific pregnancy-based retrospective TTP study, socio-demographic and 
lifestyle data, as well as biospecimens collected during the first trimester of pregnancy (6 
to less than 14 weeks) from 1743 participants were analyzed (Appendices 2 and 3). 
Pregnancies following birth control failure were excluded (Figure 1). Sixteen patients 
who became pregnant with sperm donation, three with egg donation, and fifteen whose 
male partners required some infertility treatment were also excluded.  
The MIREC study was approved by the Research Ethics Board of Health Canada, the 
research ethics committee of the coordinating centre of Ste-Justine’s Hospital in 
Montreal, and the academic and hospital ethics committees of the 10 study sites across 
Canada.  All the participants signed informed consent forms. 
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Study variables 
Time to Pregnancy 
Time to Pregnancy was collected as a discrete variable (i.e. number of months of 
unprotected intercourse before conception) by this question: “How long did it take you to 
get pregnant with this pregnancy?” (number of months)  
Infertility was defined as having a TTP of more than 12 months or requiring infertility 
treatment for this pregnancy.  
PFOA, PFOS, and PFHxS exposure 
Maternal blood samples collected during the first trimester of pregnancy were considered 
a surrogate of the preconception exposure to PFOS, PFOA and PFHxS.  Maternal blood 
was collected in 10-ml sterile vacutainer tubes.  Within 2 hours of the blood draw, the 
samples were centrifuged and the plasma aliquoted into smaller cryovials to be stored at -
80 °C until analysis.  
Chemical analyses were carried out by the toxicology laboratory of the Institut national 
de santé publique du Québec (INSPQ), https://www.inspq.qc.ca/ctq/, which is accredited 
by the Standards Council of Canada under ISO 17025 and CAN-P-43.  The analytes were 
extracted at alkaline pH with methyl tertbutyl ether, and ion-pairing done with 
tetrabutylammonium hydrogensulfate, evaporated to dryness and dissolved in the mobile 
phase. Samples were analyzed with a Waters Acquity UPLC-MS-MS (Milford MA) 
operated in the MRM mode with an electrospray ion source in negative mode. 
Statistical Analysis 
Descriptive statistics, including the percentage detected, medians, and geometric means 
were computed for all chemicals, and arithmetic means were found for important 
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demographic variables. Concentrations below the limit of detection (LOD) were set to the 
LOD divided by two. Each chemical concentration (ng/ml) was log-transformed and 
divided by its standard deviation to facilitate the biologic interpretation of the effect 
measure (Buck Louis et al. 2013).  
Fecundity odds ratios (FOR) were estimated using the Cox model, modified for discrete 
time data (Allison PD 2010). FORs estimate the odds of becoming pregnant each cycle, 
given exposure to the specific PFC, conditional on not being pregnant in the previous 
cycle. FORs less than 1 denote reduction in fecundity or longer TTP, and FORs greater 
than 1 denote a shorter TTP. TTP was censored at the 13th month. The proportional 
hazard assumptions were verified for the discrete-time models (Allison PD 2010). In 
addition, we used logistic regression to estimate the odds ratios (ORs) for infertility (TTP 
> 12 months or infertility treatment). Statistical significance was assessed using an alpha 
level of 0.05. 
Potential confounders included gestational age at blood draw, maternal age, country of 
birth, education, household income, maternal and paternal smoking, and pre-pregnancy 
body mass index (BMI). Maternal and paternal age where highly correlated (r= 0.73), 
which precluded inclusion of paternal age into the model. Variables with a p-value <0.20 
in the univariate analysis were potentially eligible for the multivariate model. In a second 
step, based on our literature review and the statistical assessment of covariates, we 
depicted a directed acyclic graph (DAG) to represent the covariates included in our 
causal model (Figure 2).  
There is controversy on how to consider parity in the assessment of the toxicological 
effect of PFCs on TTP. Biologically, parity is influenced by a woman’s fecundability. 
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TTP is used as an epidemiological metric for the assessment of women’s fecundability. 
Thus, we consider that conditioning (i.e., adjusting, stratifying, or restricting) on parity is 
redundant and would cause over-adjustment, as parity is the result, among other factors, 
of proven fecundability.  This argument proposes that parity is a type of covariant known 
as a collider in the modern theory of diagrams for causal inference using Directed 
Acyclic Graphs (DAGs) (Hernan and Robins 2013). A collider is a covariate that is 
affected, directly or indirectly, by two other covariates. In our DAG, parity lies in 
between the determinants of fecundability included in our analysis (i.e., age, BMI, 
income), and TTP (Figure 2). Conditioning on a collider is susceptible to collider-
stratification bias (Greenland 2003, Schisterman et al. 2009). It would open the blocked 
backdoor path between exposure and outcome, inducing conditional bias for at least one 
stratum of parity (Howards et al. 2012, Hernan and Robins 2013). 
Statistical analysis was performed using STATA 10.0 (Stata Corporation, College 
Station, TX) and SAS 9.3 (SAS Institute Inc., Cary, NC), specifically for the discrete-
time Cox proportional models.  
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3.4 Results 
The probabilities of pregnancy for the cohort at months 1, 6 and 12 were 0.42 (95% CI 
0.40-0.45), 0.81 (95% CI 0.79-0.83), and 0.90 (95% CI 0.89-0.92), respectively. Socio-
demographic characteristics of the population and their association with TTP are 
presented in Table 1. The mean maternal age was 32.8 (SD 5.0) years. About two thirds 
of the women had a university degree, most were born in Canada, more than one third 
reported a household income higher than $100.000 CAD, half had at least one prior 
pregnancy with a live birth, and about 15% were obese or active smokers during the 
preconception period. Maternal and paternal age, pre-pregnancy BMI, and parity were 
associated with TTP. Maternal or paternal active smoking, gestational age at which the 
sample was collected, country of birth, household income, and education were not 
associated with TTP.  
Table 2 presents the distribution of PFC concentrations in maternal plasma. PFOA, PFOS 
and PFHxS were detected in at least 95% of the samples. The geometric means (ng/ml) of 
PFOA, PFOS, and PFHxS were 1.66 (95% CI 1.61-1.71), 4.59 (95% CI 4.46-4.72), and 
1.01 (95% CI 0.97-1.05), respectively.  
Crude FORs per one standard deviation increase in log-transformed serum concentrations 
were significantly lower for PFOA 0.91 (95% CI 0.86-0.96) and PFHxS 0.94 (95% CI 
0.89-1.00), while there was no statistically significant association with PFOS 0.97 (95% 
CI 0.92-1.03) (Table 3). Fecundability decreased by 4% per one year increase in maternal 
age (FOR=0.96; 95% CI 0.95-0.97). Obesity (BMI >30) was associated with a 25% 
reduction in fecundability (FOR=0.75; CI 95% 0.63-0.90), and annual household income 
 37 
 
 
> $100.000 CAD with a 21% decrease (FOR=0.79; CI 95% 0.67-0.93). Education and 
smoking status were not associated with fecundability reduction.   
In models adjusted for maternal age and BMI, PFOA and PFHxS were associated with an 
11% (FOR=0.89; 95% CI 0.83-0.94) and 9% (FOR=0.91; 95% CI 0.86-0.97) reduction in 
fecundability per one standard deviation increase in log-transformed serum 
concentrations, respectively; no significant association was observed for PFOS 
(FOR=0.96; 95% CI 0.91-1.02) (Table 4).  When added to the model with the other 
variables, household income was no longer significant. 
The adjusted odds of infertility (TTP > 12 months or infertility treatment to become 
pregnant) increased by 31% per one standard deviation increase of PFOA (OR=1.31; 
95% CI 1.11-1.53) and by 27% per one standard deviation increase of PFHxS (OR=1.27; 
95% CI 1.09-1.48). No significant association was observed between concentrations of 
PFOS and the odds of infertility (OR=1.14; 95% CI 0.98-1.34) (Table 5). 
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3.5 Discussion 
The MIREC Study is the largest cohort of pregnant women to date measuring the 
concentrations of PFOA, PFOS and PFHxS in plasma samples collected during the first 
trimester of pregnancy. The participation rate of 39% in the MIREC Study is consistent 
with participation rates of several large prospective cohort studies. There is evidence 
from similar pregnancy cohorts that this level of participation does not increase the risk 
of bias (Nohr et al. 2006). The time-frame of the study, from 2008 to 2011, reflects 
current levels of exposure to these chemicals, especially after the move to reduce and 
phase out several PFCs over the last decade. We observed that increased concentrations 
of PFOA and PFHxS were associated with decreased fecundability as measured by a 
longer TTP, and increased odds of infertility, even at lower levels of exposure than 
previously documented.  The median concentrations in our participants (1.7 ng/ml for 
PFOA, and 4.7 ng/ml for PFOS) were lower than those reported for women in the Danish 
National Birth Cohort conducted between 1996 and 2002 (5.3 ng/ml for PFOA and 33.7 
ng/ml for PFOS) (Fei et al. 2009), the Norwegian Mother and Child Cohort Study 
conducted between 2003 and 2004 (2.2 ng/ml for PFOA and 13.0 ng/ml for PFOS) 
(Whitworth et al. 2012), and a Danish study conducted among trade union workers 
between 1992 and 1995 (5.6 ng/ml for PFOA and 36.3 ng/ml for PFOS) (Vestergaard et 
al. 2012). Also, our geometric mean concentrations (1.66 ng/ml; 95% CI 1.61-1.71 for 
PFOA and 4.59 ng/ml; 95% CI 4.46-4.72 for PFOS) were lower than those reported in 
the LIFE Study conducted in Texas and Michigan between 2005 and 2007 (3.11 ng/ml; 
95% CI 2.91-3.33 for PFOA and 11.76 ng/ml; 95% CI 11.01-12.57 for PFOS) (Buck 
Louis et al. 2013). 
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Two previous studies have evaluated the effect of PFOA and PFOS on TTP using a 
retrospective-pregnancy TTP design. Our results are in agreement with those on PFOA 
reported by Fei et al. (2009) in a subset of 1400 women randomly selected from the 
Danish National Birth Cohort; however we did not find an association between TTP and 
PFOS, which might be explained by the differences in exposure. Indeed, while our 
median PFOA level was 1/3 of those reported by Fei, our median PFOS was 1/14 their 
level. The covariates included in our models were similar, except for the consideration of 
parity as a confounder by Fei et al. (2009).  
A second study, a case-control analysis within the Norwegian Mother and Child Cohort, 
reported an increased odds of subfecundity (TTP > 12 months) with elevated PFOA and 
PFOS levels in a model (not adjusted for parity) (Whitworth et al. 2012). A recent 
analysis of the MoBa cohort, using the discrete-time Cox proportional hazard model, also 
reported diminished fecundability at increasing concentrations of PFOA (FOR 0.83; 95% 
CI 0.75-0.91) (Ding et al. 2014). In the study by Whitworth et al. (2012), however, the 
authors considered that reverse causation could account for their reported association in 
parous women (Olsen et al. 2009). Thus, women with longer TTP would have higher 
PFCs levels due only to a longer time since their previous pregnancy, allowing re-
accumulation of the PFCs that had decreased during pregnancy and postpartum through 
placenta transfer and breastfeeding. Based on this assumption, they reported their final 
conclusion according to a second model, stratifying by parity. In this model, the odds 
ratios for subfecundity were elevated only among parous women, which, according to the 
authors, supports the reverse causation hypothesis (Whitworth et al. 2012). However, 
these results were not replicated by Fei et al. (2012) after stratification by parity, where 
 40 
 
 
stronger associations were reported for PFOS and PFOA in nulliparous women, and for 
PFOA in the case of  multiparous women, thus refuting reverse causation. 
Based on our DAG (Figure 2), we considered that neither adjustment nor stratification for 
parity should be conducted when studying the reproductive adverse effects of PFCs, as 
this will introduce over-adjustment through collider-stratification bias (Greenland 2003, 
Schisterman et al. 2009). To describe this type of bias, Greendland (2003) uses the 
example of the effect of exposure to an unopposed estrogen therapy (E) and endometrial 
cancer (D), stratifying (conditioning) on uterine bleeding (C). It was common practice to 
assess the effect of estrogen therapy on endometrial cancer only among women 
presenting with uterine bleeding, as a marker of estrogen use and cancer. However, it was 
demonstrated that the measure of effect among these women would be much smaller than 
the true causal association because of the strong effects of both the therapy and the cancer 
on bleeding risk, and therefore, the bias induced by stratification on bleeding was toward 
the null (Greenland 2003). The same bias would be introduced if the association of PFCs 
(E) and TTP (D) were conditioned on parity (C). 
In addition, we included women in our study who had had fertility treatment for the index 
pregnancy, i.e., 7.3% of the study population, as was also done by Fei et al. (2009). In our 
descriptive phase of analysis, we found that the geometric mean levels of PFOA and 
PFHxS were significantly higher in participants receiving fertility treatment for the index 
pregnancy than those of untreated participants (data not shown). We also noted that half 
of these patients reported a TTP < 12 months, even if these treatments (i.e., ovulation 
induction, intrauterine insemination, and in-vitro fertilization) are rarely prescribed 
before 12 months of attempting pregnancy. Our hypothesis is that some of the women 
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reported their TTP as the number of months since their first cycle of fertility treatment 
until the successful cycle, some considered the number of months of trying before 
starting fertility treatment, and others counted both. Moreover, if they had used fertility 
treatment for a previous pregnancy and therefore were able to access it for this pregnancy 
without having to wait during 12 months of trying, the reported TTP would probably be < 
12 months. This misclassification may have introduced a selection bias in the Whitworth 
et al. (2012) study. For their cases, the authors randomly selected women who reported a 
TTP > 12 months but not according to fertility treatment, leading to the exclusion of, 
according to our study, approximately 50% of the potential cases that received fertility 
treatment but reported a TTP < 12 months. As proof of this misclassification, the authors 
reported that after the selection of cases and controls, they found that 39% of the cases 
(n=163) and 1% of the controls (n=7) had received fertility treatment for the current 
pregnancy. They decided, however, to exclude these 7 controls instead of reclassifying 
them as cases.  
Two additional studies have addressed the association between PFCs and TTP using a 
prospective couple-based cohort design. In a survey conducted among trade union 
workers  in Denmark from 1992 to 1995, no consistent pattern was observed between 
TTP and eight PFCs, including PFOA, PFOS, PFHxS, and PFOSA, measured in the 
serum of 222 women attempting pregnancy for the first time followed for up to six cycles 
of trying (Vestergaard et al. 2012). More recently, Buck Louis et al. (2013) reported the 
results from the LIFE Study, including biomonitoring data from 501 couples followed for 
up 12 months of attempting during 2005 and 2007. Decreased fecundability was observed 
at higher concentrations of PFOSA in females in the adjusted model; however, no 
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association was found for the other 6 PFCs assessed, including PFOA and PFOS in their 
unadjusted analysis. PFOSA was not measured in the MIREC Study. Detection of this 
chemical is currently very low in the United States (Centers for Disease Control and 
Prevention 2009) due to its phasing-out since 2002 (3M 2014). In fact, PFOSA was not 
detected in 90% of the samples from the LIFE Study (Buck Louis et al. 2013).  
Some methodological aspects of our study need to be considered. Firstly, in pregnancy-
based TTP, infertile couples who do not opt for fertility treatment or have no access to it 
and those whose fertility treatment is unsuccessful are excluded from the study, resulting 
in the systematic underrepresentation of infertile women and the selection of a healthier 
population (Joffe et al. 2005). Nonetheless, pregnancy-based TTP studies have been 
successful in identifying environmental exposures that may adversely affect fertility, as it 
is expected that at current levels of exposure, the toxic effect of these contaminants do 
not lead to complete infertility (Weinberg and Wilcox 2008). Secondly, TTP was 
assessed at a mean gestational age of 12 weeks (SD 1.52) in MIREC, similar to the 
gestational age at which TTP was assessed by Fei et al. (2009), but earlier than in 
Whitworth et al. (2012), which was at approximately 17 weeks of gestation. Studies that 
have assessed the validity of this recall have reported reasonable validity if collected at 
the short-term (Zielhuis et al. 1992, Cooney et al. 2009). Thirdly, we used the first 
trimester concentration of PFCs as a surrogate of the preconception exposure. Since the 
half-lives of these chemicals are considerably long (Olsen et al. 2007) and they are 
persistent in the environment, we considered that these concentrations reflected those at 
the time of the pregnancy attempts. In addition, one recent study reported robust 
correlations between two subsequent measures of PFCs in blood samples of 53 men 
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collected 6 years apart, in 2001 and 2007 (Spearman's ρ =0.75 for PFOA and 0.81 for 
PFOS, and PFHxS) (Nost et al. 2014).  
One limitation of our study is that we do not have information on male partner exposure 
to PFCs. The LIFE Study is the only study that has measured concentrations of PFCs in 
both partners (Buck Louis et al. 2013), reporting high correlations between partner 
concentrations.  Since TTP is an epidemiological metric of couple fecundity, we are 
unable to determine if the effects are female, male, or both. Furthermore, we did not 
assess specific endpoints of fecundability such as menstrual cycle characteristics, markers 
of ovulation, or semen quality (Buck Louis et al. 2014).  
With regard to the biological mechanism of action, there are limited toxicological studies 
assessing the effect of PFCs on reproductive outcomes. In vitro, some PFCs have the 
potential to affect estrogen-receptor and androgen-receptor transactivity (Kjeldsen and 
Bonefeld-Jorgensen 2013). In rats, exposure to PFOS has shown estrous cyclicity 
disruption and neurotransmitter imbalance (Austin et al. 2003). In a rainbow trout model 
(Oncorhynchus mykiss), several perfluoroalkyl acids were potent inducers of the 
estrogen-responsive biomarker protein vitellogenin (Vtg) at very high dietary exposures 
(Benninghoff et al. 2011). Although this small number of studies suggests a possible 
endocrine-disrupting effect, additional toxicological studies need to be assessed to 
support an effect and its mechanistic pathway. Recently, PFOA and perfluorononanoic 
acid (PFNA) were reported to be associated with endometriosis in a cohort of 495 women 
undergoing laparoscopy/laparotomy in the ENDO Study (Endometriosis—Natural 
History, Diagnosis and Outcomes Study) (Buck Louis et al. 2012). Endometriosis is a 
condition associated with impaired fecundability. Therefore, endometriosis or its 
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determinants could be on the etiologic or causal pathways of the association between 
PFCs and TTP. 
In conclusion, our results add to the evidence that exposure to PFOA and PFHxS, even at 
lower levels than previously reported, may reduce fecundability, as measured by a longer 
TTP and increased odds of infertility (TTP > 12 months). Future research should focus on 
the mechanisms involved in this potential endocrine-disrupting effect. Methodological 
differences in the causal models of previous studies have impaired possible conclusions 
about the potential adverse effect of PFCs and TTP.  
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Figure 1. Participant’s selection flow-chart 
  
MIREC study  
2001 participants 
Birth control failure 
151 (7.8%) 
Withdrawal 
18 (0.9%) 
1983 (99.1%) 
Missing TTP 
13 (0.1%) 
1970 (98.5%) 
Missing PFCs 
42 (2.1%) 
1928 (96.4%) 
1777 (88.8%) 
 
Sperm, egg donation, 
or male infertility 34 
(1.9%)
TTP and PFCs 
1743 (87.1%) 
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Figure 2. Directed acyclic graph representing covariates in the relationship between 
PFC (Exposure) and TTP (Disease) and the role of parity as a Collider (C) 
Determinants of 
fecundability  Parity 
(C) 
PFCs 
(E) 
TTP 
(D) 
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Table 1. Characteristics of the study population and association with Time to 
Pregnancy: the MIREC Study  
Continuous variables N Mean (SD)* Median Minimum Maximum P value** 
Maternal age (yrs.) 1743 32.83 (4.96) 32.74 18.34 46.35 <0.001 
Paternal age (yrs.) 1510 34.78 (5.68) 34.51 18.66 58.74 <0.001 
Gestational age (wks.) 1741 12 (1.52) 12.43 6 14 0.19 
Categorical variables N % Time to Pregnancy (months) 
Mean (SD)* Median (p25-p75)  
Education     0.46 
Some college or less 236 13.5 5.8 (12.8) 1 (1-5)  
College diploma 399 22.9 5.2 (8.9) 2 (1-5)  
Undergraduate 644 37.0 5.7 (12.2) 2 (1-5)  
Graduate (MSc PhD) 464 26.6 4.3 (6.4) 2 (1-4)  
Country of birth     0.93 
Canada 1412 81.0 5.3 (10.8) 2 (1-5)  
United States 27 1.5 4.7 (6.4) 2 (1-6)  
Mexico 8 0.5 5.1 (4.8) 4.5 (1-9)  
China 17  1.0 3.8 (4.8) 1 (1-5)  
Other 279  16.0 5.1 (8.4) 2 (1-6)  
Household Income      0.06 
  < $60,000 361 20.7 4.5 (10.1) 2 (1-4)  
$60,001 – 100,000 609 35.0 5.2 (9.9) 2 (1-5)  
 > $100,000 691 39.6 5.7 (10.7) 2 (1-6)  
  No response 82 4.7 5.2 (10.9) 2 (1-4)  
Parity conditional on gravidity      <0.001 
No prior pregnancy 501 28.8 6.5 (13.7) 2 (1-6)  
Prior pregnancy 
without live birth(s) 
270 15.5 6.8 (12.1) 2 (1-6)  
Prior pregnancy with 
live birth (s) 
971 55.7 4.2 (7.2) 2 (1-4)  
Maternal smoking     0.85 
Never  1077 62.9 5.1 (8.9) 2 (1-5)  
Former 392 22.5 5.3 (11.8) 2 (1-5)  
Current † 272 15.6 5.7 (13.1) 2 (1-4)  
Pre-pregnancy BMI††     0.003 
<24.9 1034 63.6 4.9 (9.6) 2 (1-5)  
25-29.9 355 21.9 5.2 (11.4) 2 (1-4)  
>30 236 14.5 6.7 (11.3) 3 (1-7)  
Current paternal smoking     0.83 
No 1217 83.0 5.2 (9.9) 2 (1-5)  
Yes 249 17.0 5.6 (12.0) 2 (1-5)  
* Arithmetic mean and standard deviations (SD) 
** P values for the association with Time to Pregnancy: Likelihood ratio for continuous 
variables, Log Rank test for categorical variables. †Includes women that quit during 
pregnancy or one year before. †† Body Mass Index 
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Table 2. Perfluoroalkyl acid levels (ng/ml) in maternal plasma. (n=1743) 
  LOD* n (%) <LOD Median Minimum Maximum GM** (95% CI) 
PFOA 0.1 2 (0.12) 1.7 <LOD 16 1.66 (1.61-1.71) 
PFOS 0.3 2 (0.12) 4.7 <LOD 36 4.59 (4.46-4.72) 
PFHxS 0.2  69 (4.28) 1 <LOD 25 1.01 (0.97-1.05) 
*Limit of Detection (LOD) 
** Geometric Mean 
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Table 3. Crude Fecundity Odds ratios for TTP 
*Chemical plasma concentrations were log-transformed and divided by their standard 
deviations.  
** Wald PHREG Procedure 
† After rounding  
†† Includes those who quit during pregnancy or less than one year prior to the study visit 
 
 
  
 N Crude  FORs 95% Confidence interval P value** 
PFOA ng/ml* 1743 0.91 0.86-0.96 0.001 
PFOS ng/ml* 1743 0.97 0.92-1.03 0.33 
PFHxS  ng/ml* 1743 0.94 0.89-1.00† 0.04 
Age 1743 0.96 0.95-0.97 <0.001 
Gestational Age 1743 0.98 0.94-1.01 0.18 
Pre-pregnancy BMI    0.04 
<24.9 1034 1   
25-29.9 355 1.03 0.89-1.20  
>30 236 0.75 0.63-0.90  
Education    0.68 
Graduate (MSc 
PhD) 
464 1   
Undergraduate 644 0.95 0.82-1.10  
College diploma 399 0.91 0.77-1.08  
Some college or 
less 
236 0.97 0.82-1.21  
Household income     
<60000 361 1  0.04 
60000-100000 609 0.86 0.73-1.01  
>100000 691 0.79 0.67-0.93  
No response 82 0.89 0.65-1.20  
Maternal smoking    0.63 
Never 1077 1   
Former 392 1.05 0.91-1.21  
Current†† 272 1.08 0.91-1.27  
Current paternal smoking    0.68 
No 1217 1   
Yes 249 1.05 0.91-1.21  
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Table 4. Adjusted Fecundity Odds Ratios for TTP (n=1625)* 
Chemical plasma concentrations were log-transformed and divided by their standard 
deviations. 
* 1625 women (118 missing values for pre-pregnancy weight) 
** Wald Chi-square test PHREG Procedure 
 
  
 Adjusted FORs  95% Confidence interval P value** 
    
PFOA (ng/ml) 0.89 0.83-0.94 <0.001 
Age 0.96 0.94-0.97 <0.001 
Pre-pregnancy BMI   0.001 
<24.9 1   
25-29.9 1.03 0.89-1.20  
>30 0.71 0.60-0.86  
    
PFOS (ng/ml) 0.96 0.91-1.02 0.17 
Age 0.96 0.95-0.97 <0.001 
Pre-pregnancy BMI   <0.001 
<24.9 1   
25-29.9 1.03  0.89-1.20  
>30 0.72 0.60-0.86  
    
PFHxS (ng/ml) 0.91 0.86-0.97 0.002 
Age 0.96 0.94-0.97 <0.001 
Pre-pregnancy BMI   <0.001 
<24.9 1   
25-29.9 1.05 0.90-1.22  
>30 0.73 0.61-0.87  
 52 
 
 
Table 5. Adjusted Odd Ratios for Infertility (n = 1625)* 
Chemical plasma concentrations were log-transformed and divided by their standard 
deviations. 
* 1625 women (118 missing values for pre-pregnancy weight) 
 
  
 Odds Ratios 95% Confidence interval P value 
    
PFOA (ng/ml) 1.31 1.11-1.53 0.001 
PFOS (ng/ml) 1.14 0.98-1.34 0.09 
PFHxS (ng/ml) 1.27 1.09-1.48 0.003 
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4.1 Abstract 
Objective: to assess the potential effect of bisphenol A (BPA), triclosan (TCS), and 
phthalates on women’s fecundity, as measured by time to pregnancy (TTP). 
Design: Pregnancy-based retrospective Time to Pregnancy study 
Setting: Ten cities across Canada 
Patients: the MIREC Study (Maternal-Infant Research on Environmental Chemicals) 
recruited 2001 women during the first trimester of pregnancy between 2008 and 2011. 
1742 women were included in our BPA analysis, 1699 in the TCS analysis, and 1597 in 
the phthalates analysis. 
Intervention(s): None 
Main Outcome Measure(s): Fecundability odds ratios (FORs) were estimated using the 
Cox model, modified for discrete time data.  
Results: BPA concentrations were not significantly associated with diminished fecundity 
either in crude or adjusted models. Women in the highest quartile of TCS (>72 ng/ml) 
showed evidence of decreased fecundity (FOR 0.84; 95% CI 0.72-0.97) compared to the 
three lower quartiles used as the reference group. Exposure to phthalates was suggestive 
of a shorter TTP, as indicated by FORs greater than one, although the 95% CI always 
included one. 
Conclusion: elevated TCS exposure may be associated with diminished fecundity. We 
found some indication that exposure to phthalates might be associated with a shorter 
TTP. A major limitation of the study was that only one measurement of exposure was 
available for each woman post conception. Further research is necessary to test these 
findings.  
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4.2 Introduction 
Endocrine-disrupting chemicals (EDCs) are chemicals that have the potential to interfere 
with hormone functions. Their ubiquitous presence in the environment, coupled with the 
detection of several EDCs in large biomonitoring surveys (1, 2), has raised concerns 
about their possible adverse health effects. Since the endocrine system is essential for 
sexual development and reproductive functions, new research has focussed on the effect 
of EDCs on human fecundity, defined as the biological capacity for reproduction (3). 
EDCs include natural and synthetic hormones, pesticides, compounds used in the plastics 
industry and in consumer products, and by-products of other industrial processes. Some 
of these chemicals have long half-lives, allowing bioaccumulation and persistence in the 
environment. On the opposite end of the spectrum are those chemicals with short 
elimination half-lives considered nonpersistent, although their high-volume production 
makes them a common source of human exposure. Bisphenol A (BPA), triclosan (TCS), 
and phthalates belong in this latter group. 
Exposure to BPA is common, with over 90% of the populations of the U.S.A. and 
Canada having detectable urinary concentrations (1, 2). Although BPA has recognized 
endocrine-disrupting properties in animals (4), there is limited information regarding the 
effect of BPA exposure on human fecundity. While several studies conducted in infertile 
couples seeking Assisted Reproductive Technologies (ART) suggest reproductive effects, 
only one study has assessed the impact of BPA on couple fecundity in a population-based 
setting (5). In the context of ART, higher concentrations of BPA have been associated 
with hormonal imbalances in both women and men (6-8), diminished antral follicle 
counts (9), decreased number of oocytes retrieved after ovarian stimulation (10, 11), 
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lower fertilization rate (10), and implantation failure (12). In vitro, exposure of discarded 
human oocytes to BPA was associated with abnormal oocyte maturation (13). At the 
population level, Time to Pregnancy (TTP) has been widely used as an epidemiological 
metric for the study of fecundity (14). The only epidemiological study to date assessing 
the effect of BPA on TTP reported no association between female or male BPA urinary 
concentrations and TTP among participants from the LIFE Study, a prospective cohort of 
couples attempting pregnancy in the U.S.A. (5).  
Triclosan (TCS) is a broad-spectrum phenolic biocide with activity against bacteria and 
fungi. It is widely used in personal care products ranging from soaps, cosmetics, and 
toothpaste to treated textiles and food contact materials (15). TCS was detectable in about 
75% of the urine samples collected as part of the NHANES 2003-2004 survey of the U.S. 
population (16) and the 2009-2011 Canadian Health Measures Survey (2). It has a similar 
structure to known EDCs, including polychlorinated biphenyls (PCBs), polybrominated 
diphenyl ethers (PBDEs), and BPA, and to thyroid hormones (17). These structural 
similitudes, together with some limited evidence in laboratory animals of effects on 
diverse hormones, suggest that TCS may influence endocrine function, and possibly the 
reproductive axis (17). Epidemiological studies on TCS are limited. Two studies reported 
no significant impact of prenatal exposure to TCS on birth size (18, 19). A recent analysis 
of urine samples from NHANES 2003-2008 showed a positive association between TCS 
and body mass index (BMI) (20). No studies assessing the effect of TCS on TTP have 
been conducted to date. 
There is evidence suggesting that several phthalates may be endocrine disruptors (21) and 
affect development and reproduction (22, 23). Phthalates are extensively used in a variety 
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of industrial, consumer, and personal care products. Due to federal regulations, urinary 
concentrations of some phthalates have decreased during the last decade; however, a 
large number of phthalate metabolites are still detectable in more than 95% of the 
populations of the U.S.A. and Canada (2, 24). Reported use of personal care products has 
been positively associated with urinary concentration of multiple phthalate metabolites in 
women of reproductive age (25). Nonetheless, there is a paucity of studies assessing the 
effect of phthalates on women’s fecundity. In Generation R, a large pregnancy cohort 
study conducted in the Netherlands, occupational exposure to phthalates was assessed 
using a job-exposure matrix, and was reported as being suggestive of a longer TTP (26, 
27). In Italy, concentrations of several phthalate metabolites were assessed in 56 infertile 
couples from an ART centre, and were found to be significantly higher than in the control 
group of fertile couples (28).  Recently, in the LIFE Study, no phthalate metabolite in 
female urine was statistically associated with a longer TTP, although one metabolite 
(mono [3-carboxypropyl] phthalate) was associated with a shorter TTP. In men, urinary 
concentrations of monomethyl, mono-n-butyl, and monobenzyl phthalates were 
associated with a longer TTP (5). Of note: while most of the literature assessing the 
adverse health effects of phthalates has focussed on the effect of individual metabolites, 
some studies suggest that simultaneous exposure to multiple phthalates might have a 
cumulative impact (29). 
There is limited research exploring the effects of nonpersistent EDCs on TTP. Most 
studies to date have looked at ART outcomes and male exposure, despite the fact that the 
female reproductive function is also susceptible to hormonally-active chemicals (30). 
Aiming to fill this gap, data from the MIREC Study, a Canadian pregnancy and birth 
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cohort was analyzed to assess the effect of BPA, TCS, and phthalates on women’s 
fecundity, as measured by TTP. 
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4.3 Methods 
Population and study design  
The Maternal-Infant Research on Environmental Chemicals (MIREC) Study is a 
pregnancy cohort of 2,001 women recruited in 10 cities across Canada between 2008 and 
2011 (31). Women were approached during the first trimester of pregnancy at 
participating hospitals and clinics and followed for a total of five visits up to 10 weeks 
postpartum. A detailed questionnaire was administered during the first study visit (< 14 
weeks gestation). Eighteen participants withdrew from the study and all their data and 
samples were destroyed. We excluded women with incomplete data for the specific 
compound/group studied (46 for BPA, 96 for TCS, and 211 for phthalates), TTP (14 for 
BPA and TCS, and 15 for phthalates), and specific gravity (n=3); women requiring egg 
donation (n=4) or reporting male factor infertility (n=26); and women whose index 
pregnancy was the result of birth control failure (148 for BPA, 141 for TCS, and 154 for 
phthalates). Thus, 1742 women were included in our BPA analysis, 1699 in the TCS 
analysis, and 1597 in the phthalates analysis. 
The study was approved by the ethics committees of Health Canada, Sainte-Justine 
University Hospital Centre, and the hospitals affiliated with the study across Canada. 
Written informed consent was obtained from all the participants. 
Data collection and urine sampling 
Besides information on demographics, medical and obstetrical history, and lifestyle 
characteristics, women were asked about their Time to Pregnancy (i.e. number of months 
of unprotected intercourse before conception) by this question: “How long did it take you 
to get pregnant with this pregnancy?” (number of months).  
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As part of the biomonitoring component of MIREC, a spot urine sample was collected in 
polypropylene cups during the first trimester visit. This sample was aliquoted into 30-mL 
Nalgene® tubes, frozen at −20°C within 2 hours of collection, transported on dry ice to 
the MIREC coordinating centre in Montreal to be stored at −30°C, and subsequently 
shipped in batches to the Centre de Toxicologie du Québec of the Institut national de 
Santé Publique du Québec (INSPQ) for analysis. This laboratory is accredited by the 
Standards Council of Canada under ISO 17025.  
Analytical Methods 
As part of the initial MIREC protocol, urine samples were analyzed for bisphenol A 
(BPA) and 11 phthalate metabolites: mono-n-butyl phthalate (MnBP); mono-ethyl 
phthalate (MEP); mono-benzyl phthalate (MBzP); mono-methyl phthalate (MMP); 
mono-cyclo-hexyl phthalate (MCHP); mono-isononyl phthalate (MiNP); mono-n-octyl 
phthalate (MnOP); mono-(3-carboxypropyl) phthalate (MCPP); mono-(2-ethylhexyl) 
phthalate (MEHP); mono-(2-ethyl-5-oxo-hexyl) phthalate (MEOHP); and mono-(2-ethyl-
5-hydroxy-hexyl) phthalate (MEHHP) (32). Additional research funds were obtained for 
the triclosan (TCS) analysis as part of methods development for the U.S. National 
Children’s Study.  
Urinary total BPA (free plus conjugated) concentrations were quantified using an 
established protocol. Samples were analyzed by GC–MS/MS coupled with a tandem 
mass spectrometer. Phthalate metabolites were analyzed by LC–MS/MS with an Ultra 
Performance Liquid Chromatography (UPLC) coupled with a tandem mass spectrometer. 
Further details are described in Arbuckle et al. (32). 
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For the TCS analysis, sensitive LC-MS/MS methods were developed for the analysis of 
free and conjugated forms of TCS in urine at the Centre de Toxicologie du Québec of the 
Institut national de Santé Publique du Québec (32). To account for urine dilution, specific 
gravity was measured in thawed urine samples by a refractometer (UG-1, Atago # 3461, 
Atago U.S.A. Inc., Bellevue, WA). 
Field blanks were included to assess the potential contamination from the material used 
for collection and storage of urine samples as well as from the environment of collection 
sites. Results did not show any evidence of contamination (32, 33). 
Statistical Analysis 
Descriptive statistics, including the percentage detected, medians. and geometric means, 
were computed for all chemicals. Concentrations below the limit of detection (LOD) 
were set to the LOD divided by two. Total TCS was calculated by summing the free and 
conjugated forms.  We considered the effect of total BPA, total TCS, and each individual 
phthalate metabolite independently. In the case of phthalate metabolites, we also 
categorized them into low and high molecular weight, and calculated the sum of their 
molecular weights in each category as a measure of total LMW and HMW phthalates. In 
addition, we calculated the estrogenicity equivalency factor (EEF) as proposed by Braun 
et al (34).  
We also considered different alternatives for modelling exposure. First, biomarker 
concentrations were log-transformed and divided by their standard deviations (35). 
Second, concentrations were categorized a priori into quartiles using the lowest quartile 
as the reference group. In addition, since results from the MIREC cohort have shown that 
BPA and phthalate metabolite concentrations in maternal urine tended to be lower than 
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those reported in other pregnancy cohorts worldwide (32), we grouped the three lower 
quartiles as the reference group and compared it to the highest quartile. We also applied 
this categorization for TCS. 
Fecundability odds ratios (FORs) were estimated using the Cox model modified for 
discrete time data (36). FORs estimate the odds of becoming pregnant each cycle, given 
exposure to the specific compound and conditional on not being pregnant in the previous 
cycle. FORs less than 1 denote reduction in fecundity or a longer TTP, and FORs greater 
than 1 denote a shorter TTP. TTP was censored at the 13th month. Linearity and 
proportional hazard assumptions were verified (36). 
Potential confounders were maternal age, smoking, education, and household income, 
identified as predictors of exposure to BPA, TCS, and phthalates in the MIREC cohort 
(32, 33).  In addition to these covariates that also impact on fecundity, body mass index 
(BMI) was included in the adjusted models (3). We did not include parity in our model, 
as it can lead to an overadjustment bias (37). 
To account for urine dilution, specific gravity was included as a covariate in the 
regression model (38). We also evaluated possible interactions between specific gravity 
and time of urine collection as was evidenced in previous analyses conducted by our 
group (32). However, we did not include interactions in our final models, since none 
were observed. Statistical analysis was performed using STATA 10.0 (Stata Corporation, 
College Station, TX), and SAS 9.3 (SAS Institute Inc., Cary, NC) specifically for the 
discrete-time Cox proportional models.  
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4.4 Results 
The characteristics of the study population are presented in Table 1. The distributions of 
demographic and lifestyle characteristics were similar for the three compounds/group 
studied (i.e., BPA, TCS, and phthalate metabolites). The mean maternal age was 32.8 
years (SD 5.0), while the mean paternal age was 34.7 (SD 5.6). The median gestational 
age at interview was 12 weeks in a range between 6 to 14 weeks. Most participants 
included in the analysis (81%) were born in Canada, approximately two thirds had a 
university degree, and more than one third reported a yearly household income higher 
than $100.000 CAD. More than half of the women had at least one prior pregnancy with 
live birth, and about 15% were obese or active smokers during the preconception period. 
Maternal and paternal age, parity, and pre-pregnancy BMI were associated with TTP.  
Detectable urinary concentrations of total BPA were found in 87% of the samples, while 
total TCS was detectable in more than 99% (Table 2). As for phthalates, five metabolites 
were detected in more than 98% of the samples (MnBP, MEP, MBzP, MEHP, MEOHP, 
MEHHP), while MCPP was detected in 82%. However, four metabolites (MMP, MCHP, 
MiNP, and MnOP) were detected in less than 14% of the samples, and for this reason, 
they were excluded from further analyses. 
As Table 3 reflects, BPA concentrations were not significantly associated with 
diminished fecundity either in crude or adjusted models. This lack of association was 
independent of the manner in which BPA concentrations were considered (i.e., 
continuous, quartiles of BPA, or comparing the highest quartile with the three lower 
quartiles).  
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As for TCS, one standard deviation increase in the log transformed concentrations of 
TCS were associated with shorter TTP; however, the 95% CI included one (FOR 0.94; 
95% CI 0.88-1.01). The same pattern was observed for the highest TCS quartile of 
exposure compared to the lowest quartile (FOR 0.89; 95% CI 0.74-1.07). It is noteworthy 
that when we considered the three lower quartiles as the reference group, women in the 
highest quartile of TCS (>72 ng/ml) showed evidence of decreased fecundity (FOR 0.84; 
95% CI 0.72-0.97) (Table 3, Figure 1).  
All phthalate metabolites had a similar pattern of association with TTP, independently of 
the variable transformation or the variables included in the statistical models. In general, 
exposure to phthalates was suggestive of a shorter TTP, as indicated by FORs greater 
than one, although the 95% CI always included one (Table 4). Total LMW and HMW 
metabolites were positively associated with TTP, although not statistically significant. 
Moreover, their FORs were of similar magnitude to those of the individual metabolites. 
The FORs according to the EEF were also of similar magnitude (data not shown). 
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4.5 Discussion 
The MIREC Study is the largest cohort that has assessed the effect of ubiquitous 
plasticizers such as BPA and phthalates on women’s fecundity as measured by TTP, and 
the first that has examined the potential effect of TCS. We found that urinary 
concentrations of TCS at the highest quartile of exposure were associated with a 16% 
reduction in fecundity. In addition, while BPA was not associated with TTP, it is 
noteworthy that in the case of phthalates, the FORs were almost universally greater than 
1, suggesting a shorter TTP, although the 95% CI included 1.  
Compared to the few studies available worldwide that have assessed concentrations of 
TCS in pregnant women, MIREC reported the highest urinary concentration of TCS 
(6784 μg/L) but had considerably lower median concentrations than other international 
studies (33). Higher socio-economic class and older age were determinants of TCS 
exposure in the MIREC cohort (33). The MIREC population tended to be more highly 
educated than the average woman giving birth in Canada (31). Higher education may be 
associated with postponed childbirth, hence increasing age at the time of pregnancy 
attempt. Despite accounting for all these factors in our statistical models, decreased 
fecundity at the highest quartile of TCS exposure was maintained. Since this is the first 
study conducted at the population level assessing the impact of TCS on TTP, interpreting 
our findings in the context of the available literature is difficult. As recently reviewed by 
Dann and Hontela (17), TCS may have endocrine-disrupting effects. In vitro, several 
studies have demonstrated the potential for TCS to act as an anti‐estrogen and/or 
anti‐androgen (39-41). Animal studies with male rats (42, 43) have shown that TCS 
decreases serum levels of testosterone and the activity of several important steroidogenic 
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enzymes. In addition, TCS has been shown to be a powerful inhibitor of estrogen 
sulfonation in sheep placental tissue (44), which could impair the maintenance of 
pregnancy. Finally, the homeostasis of thyroid hormones, critical for reproductive 
success (45, 46), might also be a target of TCS. The structural similarity of TCS to 
thyroid hormones has prompted experimental studies in this area (17). In vitro, TCS was 
capable of inhibiting sulfation of thyroid hormones (47). In animals, TCS exposure was 
associated with decreased levels of Thyroxine (T4) in female (48) and male rats (42). 
Thus, we believe that the estrogenic and androgenic activity of TCS in rodents and its 
potential impact on thyroid hormones coupled with our finding of decreased fecundity 
warrant additional epidemiologic studies at the population level to elucidate the potential 
impact of TCS on human reproduction.  
As for BPA, the only study that has assessed the effect of BPA on couple’s fecundity 
reported results similar to ours. Neither female nor male BPA concentrations were 
associated with TTP (5). Our sample size is almost three times higher than the size of the 
LIFE Study. This would have helped to find an association if the absence of association 
in the LIFE Study was due to a lack of statistical power. Low BPA concentrations might 
also explain the absence of association in both studies. The geometric mean in our study 
(0.80 μg/L), and in the LIFE Study (0.63 μg/L), were lower than those reported in 
NHANES 2003-2004 for females ≥ 6 years of age (2.41 μg/L) (24) and in the Canadian 
Health Measures Surveys (CHMS) of 2007–2009 (1.26 μg/L) (49) and 2009–2011 (1.2 
μg/L) for women 20–39 years of age (2). Since animal studies suggest that BPA has 
endocrine-disruption capacity, additional epidemiological studies in populations having 
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higher exposures to BPA should be conducted before making firm conclusions about the 
absence of its effect on fecundity. 
With regard to phthalates, the interpretation of our results is even more challenging. Most 
of the FORs exceeded 1, suggesting a shorter TTP, although not statistically significant. 
In the LIFE Study, 9 out of the 14 metabolites assessed in women had FORs exceeding 1 
in the adjusted models; however, with the exception of MCPP, the CI also included 1 (5). 
In the LIFE Study, men’s urinary concentrations of MMP, MnBP, and MBzP were 
associated with a longer TTP (FOR 0.80; 95% CI 0.70-0.93; FOR 0.82, 95% CI 0.70-
0.97; and FOR 0.77, 95% CI 0.65- 0.92, respectively). In general, median phthalate 
metabolite concentrations in maternal urine in MIREC were comparable to those reported 
for women 20–39 years of age in Cycle 2 of the CHMS (2009–2011) (2). Compared to 
female levels in the LIFE Study, MIREC reported similar or lower median 
concentrations.  Some phthalates are recognized for their estrogenic activity, although 
they are weak in this regard when compared to 17B estradiol (50). One hypothesis is that 
this estrogenic activity may counteract the adverse impact of medical conditions 
associated with an androgenic environment (e.g., polycystic ovary syndrome), thus 
decreasing TTP. Furthermore, in-vitro studies have reported direct anti-androgenic 
activity of some phthalates (51, 52). This anti-androgenic effect has been the focus of 
recent epidemiological studies.  In a recent analysis of the NHANES 2011-2012 cycle, 
most urinary female phthalate metabolites were associated with decreased concentrations 
of testosterone, especially in women 40-60 years old (53). In pregnant women, the 
concentrations of DEHP metabolites from samples collected between 1999 and 2002 
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were associated with decreased testosterone among all women, and between MBP and 
testosterone among women carrying female fetuses (54). 
Our study has important limitations that need to be considered. Since this is a pregnancy-
based TTP study, women that were infertile and/or did not have access to infertility 
treatment were excluded by design from our study. Thus, if BPA or phthalates have a 
negative impact on TTP, women with the highest exposures would have been excluded 
from our study. In addition, we measured the concentrations of chemicals only in women, 
and the process of reproduction involves not only the female and the male partner 
individually, but also many factors that are couple-mediated. Furthermore, we are 
assuming that the concentrations measured during the first trimester of pregnancy 
represent the concentrations that were present during the preconception period. A recent 
study evaluated the variability of urinary phthalate metabolites and BPA concentrations 
before and during pregnancy in a cohort of women receiving infertility treatment (55). 
The absolute differences in urinary concentrations for these chemicals were relatively 
small, which, according to the authors, might suggest that the women did not change their 
preconception behaviours to reduce exposure to these chemicals during pregnancy. 
Nonetheless, using the intraclass correlation coefficients (ICCs), the reliability of a spot 
urine sample to predict exposure over a few months is limited for repeated measures of 
BPA (56, 57) and several phthalate metabolites (55, 58-60). With respect to TCS, the 
reliability seems to be better (57, 61, 62). 
In summary, our data suggest that elevated TCS exposure (> 72 ng/ml) may be associated 
with diminished fecundity, as evidenced by a longer TTP. Regarding phthalates and 
BPA, there was no evidence of any negative impact on TTP and even some suggestion 
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that exposure to phthalates might be associated with a shorter TTP. Further studies are 
necessary to test our findings and elucidate the potential impact of nonpersistent 
environmental contaminants on human fecundity. 
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Table 1. Association of study population characteristics with TTP by chemical measured: the MIREC Study 
 BPA (n=1742) TCS (n=1699) Phthalates (n=1597) 
Characteristics N (%)a p value b N (%)a p value b N (%)a p value b 
Maternal age, y (Mean, SD) 32.84 (4.95) <0.001 32.84 (4.91) <0.001 32.85 (4.96) <0.001 
Paternal age, y (Mean, SD) ±   34.76 (5.68) <0.001 34.74 (5.58) <0.001 34.74 (5.69) <0.001 
Gestational age, w (Median, min-max) ± 12 (6-14) 0.04 12 (6-14) 0.03 12 (6-14) 0.05 
Education  0.38  0.31  0.40 
Some college or less 237 (13.6)  229 (13.5)    211 (13.2)  
College diploma 398 (22.8)  389 (22.9)    365 (22.9)  
Undergraduate 644 (37.0)  631 (37.1)  591 (37.0)  
Graduate (MSc PhD) 463 (26.6)  450 (26.5)  430 (26.9)  
Country of birth  0.92  0.93  0.81 
Canada 1.408 (80.8)  1376 (81.0)   1294 (81.0)  
United States 27 (1.6)  27 (1.6)  24 (1.5)  
Mexico 8 (0.5)  8 (0.4)  6 (0.4)  
China 16 (0.9)  15 (0.9)  16 (1.0)  
Other 283 (16.2)  273 (16.1)  257 (16.1)  
Household Income   0.18  0.16  0.21 
  < $60,000 363 (20.8)  353 (20.8)  327 (20.5)  
$60,001 – 100,000 614 (35.3)  602 (35.4)  566 (35.4)  
 > $100,000 685 (39.3)  671 (39.5)  633 (39.6)  
  No response 80 (4.6)  73 (4.3)  71 (4.5)  
Parity conditional on gravidity   0.0001  0.002  0.001 
No prior pregnancy 499 (28.7)  485 (28.5)  459 (28.6)  
Prior pregnancy without live birth(s) 270 (15.5)  266 (15.7)  253 (16.0)  
Prior pregnancy with live birth (s) 972 (55.8)  947 (55.8)  884 (55.4)  
a Values are N(%), unless otherwise stated. b p values for the association with Time to Pregnancy: Likelihood ratio for continuous 
variables, Log Rank test for categorical variables. 
±   Paternal age was missing in 234, 224, and 210 participants for BPA, TCS, and Phthalates, respectively.  Gestational age was missing 
in two participants. 
±±    Includes women who quit smoking during pregnancy or one year before. 
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Table 1. Association of study population characteristics with TTP by chemical measured: the MIREC Study (cont’d) 
 BPA (n=1742) TCS (n=1699) Phthalates (n=1597) 
Characteristics N (%)a p value b N (%)a p value b N (%)a p value b 
Maternal smoking  0.77  0.78  0.54 
Never  1.078 (61.9)  1049 (61.8)  993 (62.2)  
Former 398 (22.9)  390 (23.0)  360 (22.6)  
Current ±±   264 (15.2)  258 (15.2)  242 (15.2)  
Pre-pregnancy Body Mass Index  0.01  0.01  0.01 
<24.9 1.031 (63.5)  1003 (63.3)  960 (64.4)  
25-29.9 354 (21.8)  346 (21.9)  326 (21.8)  
>30 238 (14.7)  234 (14.8)  205 (13.8)  
Paternal smoking  1.00  1.00  0.98 
No 1.219 (83.0)  1191 (83.0)   1117 (82.7)  
Yes 249 (17.0)  244 (17.0)  233 (17.3)  
a Values are N(%), unless otherwise stated. b p values for the association with Time to Pregnancy: Likelihood ratio for continuous 
variables, Log Rank test for categorical variables. 
±   Paternal age was missing in 234, 224, and 210 participants for BPA, TCS, and Phthalates, respectively.  Gestational age was missing 
in two participants. 
±±    Includes women who quit smoking during pregnancy or one year before. 
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Table 2. Bisphenol A, triclosan, and phthalate metabolites (ng/ml) in maternal urine 
Analyte (Abbreviation) LODa n (%) <LOD Median Minimum Maximum GMb (95% CI)
Bisphenol A (BPA), n=1742 0.2 226 (13)   0.8  < LOD 130 0.78  (0.73-0.82)
Triclosan (TCS), n=1699 0.12 20 (0.1) 8.3 < LOD 6784 11.93 (10.67-13.34)
Phthalate metabolites (n=1597) 
Low molecular weight 
Mono-n-butyl phthalate (MnBP) 0.20 4 (0.25) 12 < LOD 3100 11.44 (10.78-12.15)
Mono-ethyl phthalate (MEP) 0.50 2 (0.13) 28 < LOD 13000 32.09 (29.67-34.70)
Mono-benzyl phthalate (MBzP) 0.20 10 (0.63) 5 < LOD 420 5.10 (4.79-5.44)
Mono-methyl phthalate (MMP) 5.0 1375 (86.1) 2.5 < LOD 1000 3.03 (2.95-3.11)
Intermediate molecular weight 
Mono-cyclo-hexyl phthalate (MCHP) 0.20 1482 (92.8) 0.1 < LOD 77 0.12 (0.11-0.12)
High molecular weight 
Mono-isononyl phthalate (MiNP) 0.40 1574 (98.6) 0.2 < LOD 6.2 0.21 (0.20-0.21)
Mono-n-octyl phthalate (MnOP) 0.70 1568 (98.2) 0.35 < LOD 7.9 0.36 (0.36-0.36)
Mono-(3-carboxypropyl) phthalate (MCPP) 0.20 290 (18.2) 0.93 < LOD 370 0.87 (0.81-0.93)
Mono-(2-ethylhexyl) phthalate (MEHP) 0.20 24 (1.5) 2.2 < LOD 340 2.27 (2.14-2.40)
Mono-(2-ethyl-5-oxo-hexyl) phthalate (MEOHP) 0.20 5 (0.31) 6.5 < LOD 980 6.42 (6.06-6.81)
Mono-(2-ethyl-5-hydroxy-hexyl) phthalate (MEHHP) 0.40 14 (0.88) 9.4 < LOD 1200 9.21 (8.65-8.79)
aLimit of Detection (LOD), b Geometric Mean 
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Table 3. Fecundability Odds Ratios (95% CIs) for Bisphenol A and Triclosan 
 Unadjusted Adjusted a Adjusted b 
Bisphenol A (BPA)    
BPA* (ng/ml)  0.99 (0.93-1.05) 0.99 (0.92 1.06) 1.0 (0.92-1.07) 
BPA Quartiles (ng/ml)    
0.1-0.3 1 1 1 
0.4-0.8 0.99 (0.84-1.17) 0.98 (0.83-1.16) 0.98 (0.82-1.18) 
0.81-1.7 1.02 (0.87-1.20) 1.00 (0.83-1.21) 0.96 (0.79-1.17) 
≥1.8 0.93 (0.79-1.10) 0.91 (0.74-1.12) 0.95 (0.77-1.17) 
BPA dichotomized** (ng/ml)    
<1.8 1 1 1 
≥1.8 0.93 (0.81-1.07) 0.92 (0.79 1.07) 0.97 (0.83-1.14) 
Triclosan (TCS)    
TCS* (ng/ml) 0.96 (0.91-1.02) 0.96 (0.90-1.02) 0.94 (0.88-1.01) 
TCS Quartiles (ng/ml)    
0.01-2.14 1 1 1 
2.14-8.28 1.16 (0.98-1.37) 1.16 (0.98-1.39) 1.10 (0.91-1.31) 
8.33-71.6 1.13 (0.95-1.33) 1.14 (0.95-1.36) 1.10 (0.92-1.32) 
≥71.7 0.94 (0.79-1.11) 0.95 (0.79-1.13) 0.89 (0.74-1.07) 
TCS dichotomized** (ng/ml)    
<71.7 1 1 1 
≥71.7 0.86 (0.75-0.99) 0.86 (0.75-0.99) 0.84 (0.72-0.97) 
 a Adjusted for specific gravity. b Adjusted for specific gravity, maternal age, maternal smoking, education, income, BMI 
* log transformed and rescaled by their standard deviation. ** Dichotomized as < 75th percentile versus ≥ 75th percentile 
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Table 4. Fecundability Odds Ratios (95% CIs) for Phthalate metabolites 
Phthalate metabolites (Abbreviation) Unadjusted Adjusted a Adjusted b 
Continuous * (ng/ml)     
Mono-n-butyl phthalate (MnBP) 1.04 (0.97-1.10) 1.04 (0.95-1.14) 1.02 (0.93-1.12) 
Mono-ethyl phthalate (MEP) 1.02 (0.96-1.08) 1.01 (0.94-1.08) 1.00 (0.93-1.08) 
Mono-benzyl phthalate (MBzP) 1.05 (0.99-1.12) 1.06 (0.98-1.14) 1.02 (0.94-1.11) 
Mono-(3-carboxypropyl) phthalate (MCPP) 1.04 (0.98-1.11) 1.05 (0.97-1.13) 1.08 (0.99-1.18) 
Mono-(2-ethylhexyl) phthalate (MEHP) 1.04 (0.98-1.10) 1.04 (0.97-1.13) 1.04 (0.96-1.13) 
Mono-(2-ethyl-5-oxo-hexyl) phthalate (MEOHP) 1.04 (0.98-1.10) 1.04 (0.96-1.13) 1.07 (0.98-1.17) 
Mono-(2-ethyl-5-hydroxy-hexyl) phthalate (MEHHP) 1.03 (0.97-1.09) 1.02 (0.94-1.11) 1.06 (0.97-1.16) 
Quartiles (ng/ml)    
Mono-n-butyl phthalate (MnBP)    
0.1-5.1 1 1 1 
5.2-12 1.02 (0.86-1.21) 1.02 (0.85-1.22) 1.01 (0.84-1.22) 
13-25 1.06 (0.89-1.26) 1.06 (0.86-1.31) 1.08 (0.87-1.35) 
≥26 1.08 (0.91-1.28) 1.08 (0.84-1.38) 1.03 (0.80-1.33) 
Mono-ethyl phthalate (MEP)    
0.25-11 1 1 1 
12-28 0.93 (0.79-1.11) 0.92 (0.76-1.10) 0.89 (0.74-1.08) 
29-89 0.95 (0.80-1.13) 0.93 (0.77-1.12) 0.88 (0.72-1.07) 
≥90 1.09 (0.92-1.30) 1.06 (0.87-1.29) 1.01 (0.82-1.24) 
Mono-benzyl phthalate (MBzP)    
0.1-2.2 1 1 1 
2.3-5.0 0.98 (0.83-1.17) 0.99 (0.83-1.19) 0.90 (0.75-1.09) 
5.1-12 1.10 (0.93-1.31) 1.11 (0.91-1.36) 1.03 (0.84-1.26) 
≥13 1.10 (0.93-1.31) 1.12 (0.90-1.39) 1.00 (0.80-1.26) 
a Adjusted for specific gravity. b Adjusted for specific gravity, maternal age, maternal smoking, education, income, BMI 
* log transformed and rescaled by their standard deviation. ** Dichotomized as < 75th percentile versus ≥ 75th percentile 
 
  
 
 
83 
 
Table 4. Fecundability Odds Ratios (95% CIs) for Phthalate metabolites (cont’d) 
 Unadjusted Adjusted a Adjusted b 
Quartiles (ng/ml)    
Mono-(3-carboxypropyl) phthalate (MCPP)    
0.1-0.3 1 1 1 
0.31-0.92 1.13 (0.95-1.35) 1.13 (0.94-1.35) 1.09 (0.91-1.31) 
0.93-2.1 1.12 (0.94-1.33) 1.11 (0.91-1.35) 1.08 (0.88-1.33) 
≥2.2 1.09 (0.92-1.29) 1.07 (0.86-1.34) 1.10 (0.87-1.38) 
Mono-(2-ethylhexyl) phthalate (MEHP)    
0.1-1.0 1 1 1 
1.1-2.2 1.08 (0.91-1.28) 1.08 (0.91-1.30) 1.07 (0.89-1.29) 
2.3-4.4 1.08 (0.90-1.28) 1.09 (0.88-1.34) 1.06 (0.86-1.32) 
≥4.5 1.13 (0.95-1.35) 1.15 (0.92-1.43) 1.13 (0.90-1.43) 
Mono-(2-ethyl-5-oxo-hexyl) phthalate (MEOHP)    
0.1-2.9 1 1 1 
3.0-6.5 1.09 (0.92-1.29) 1.08 (0.90-1.30) 1.08 (0.89-1.30) 
6.6-13 1.04 (0.88-1.25) 1.04 (0.84-1.29) 1.10 (0.87-1.37) 
≥14 1.11 (0.93-1.31) 1.10 (0.86-1.40) 1.18 (0.92-1.53) 
Mono-(2-ethyl-5-hydroxy-hexyl) phthalate (MEHHP)    
0.2-4.1 1 1 1 
4.2-9.4 1.07 (0.90-1.27) 1.06 (0.88-1.27) 1.08 (0.89-1.31) 
9.5-20 1.04 (0.88-1.24) 1.02 (0.82-1.26) 1.09 (0.87-1.36) 
≥21 1.07 (0.90-1.28) 1.04 (0.82-1.33) 1.14 (0.89-1.47) 
 a Adjusted for specific gravity. b Adjusted for specific gravity, age, smoking, education, income, BMI 
* log transformed and rescaled by their standard deviation. ** Dichotomized as < 75th percentile versus ≥ 75th percentile 
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Table 4. Fecundability Odds Ratios (95% CIs) for Phthalate metabolites (cont’d) 
 Unadjusted Adjusted a Adjusted b 
Quartiles dichotomized (ng/ml) **    
Mono-n-butyl phthalate (MnBP)    
<26 1 1 1 
≥26 1.05 (0.91-1.21) 1.03 (0.87-1.23) 0.98 (0.82-1.17) 
Mono-ethyl phthalate (MEP)    
<90 1 1 1 
≥90 1.14 (0.99-1.31) 1.13 (0.97-1.31) 1.11 (0.95-1.30) 
Mono-benzyl phthalate (MBzP)    
<13 1 1 1 
≥13 1.07 (0.93-1.24) 1.06 (0.91-1.24) 1.02 (0.87-1.21) 
Mono-(3-carboxypropyl) phthalate (MCPP)    
<2.2 1 1 1 
≥2.2 1.01 (0.87-1.16) 0.98 (0.83-1.15) 1.03 (0.87-1.21) 
Mono-(2-ethylhexyl) phthalate (MEHP)    
<4.5 1 1 1 
≥4.5 1.08 (0.93-1.24) 1.07 (0.91-1.25) 1.07 (0.91-1.26) 
Mono-(2-ethyl-5-oxo-hexyl) phthalate (MEOHP)    
<14 1 1 1 
≥14 1.06 (0.92-1.22) 1.04 (0.88-1.23) 1.09 (0.92-1.30) 
Mono-(2-ethyl-5-hydroxy-hexyl) phthalate (MEHHP)    
<21 1 1 1 
≥21 1.04 (0.90-1.20) 1.01 (0.86-1.20) 1.10 (0.89-1.26) 
 a Adjusted for specific gravity. b Adjusted for specific gravity, age, smoking, education, income, BMI 
* log transformed and rescaled by their standard deviation. ** Dichotomized as < 75th percentile versus ≥ 75th percentile 
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Table 5. Fecundability Odd Ratios (95% CIs) for total Phthalate metabolites (umol/L) 
 Unadjusted Adjusted a Adjusted b 
Continuous variable* (umol/L)    
Low molecular weight 1.03 (0.97-1.09) 1.02 (0.95-1.10) 1.02 (0.94-1.10) 
High molecular weight 1.03 (0.97-1.10) 1.03 (0.95-1.13) 1.07 (0.98-1.17) 
    
Quartiles (umol/L)    
Low molecular weight    
0.005-0.12 1 1 1 
0.12-0.28 0.92 (0.77-1.09) 0.90 (0.75-1.08) 0.90 (0.74-1.09) 
0.28-0.69 0.92 (0.76-1.10) 0.90 (0.73-1.09) 0.86 (0.70-1.06) 
≥0.69 1.06 (0.89-1.27) 1.02 (0.82-1.26) 0.98 (0.78-1.23) 
High molecular weight    
0.002-0.03 1 1 1 
0.03-0.07 1.03 (0.87-1.23) 1.03 (0.86-1.24) 1.02 (0.85-1.24) 
0.07-0.14 1.06 (0.89-1.26) 1.05 (0.85-1.31) 1.12 (0.90-1.41) 
≥0.14 1.08 (0.91-1.29) 1.08 (0.85-1.37) 1.17 (0.91-1.51) 
    
Quartiles dichotomized (umol/L)    
Low molecular weight    
<0.69    
≥0.69 1.13 (0.98-1.30) 1.12 (0.96-1.31) 1.10 (0.94-1.29) 
High molecular weight    
<0.14    
≥0.14 1.03 (0.88-1.22) 1.04 (0.88-1.22) 1.08 (0.91-1.29) 
a Adjusted for specific gravity. b Adjusted for specific gravity, age, smoking, education, income, BMI 
* log transformed and rescaled by their standard deviation. ** Dichotomized as < 75th percentile versus ≥ 75th percentile 
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Figure 1. Survivor Function for triclosan concentrations adjusted for specific gravity, age, 
smoking, education, income, BMI 
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5.1 Abstract 
Background: Solid endocrine-sensitive endpoints are needed to test the potential 
reproductive effects of endocrine-modulating chemicals. The 2th- to 4th-finger ratio 
(2D:4D) has been proposed as potential indicator of greater androgen exposure during 
fetal development. 
Objectives: To evaluate the association between female 2D:4D and time to pregnancy 
(TTP) in women from the MIREC Study, a Canadian pregnancy and birth cohort, and to 
assess the effect of prenatal exposure to maternal smoking on the 2D:4D of children born 
to women from the MIREC cohort. 
Methods: Digital pictures of the ventral surface of both hands were obtained in a 
subsample of some 800 mothers from the MIREC Study and their children (2-5 years). 
The 2D:4D was calculated as the ratio of the second and fourth fingers of each hand. The 
final sample included 638 mothers and 672 children (338 girls and 334 boys). Statistical 
analyses included discrete- time Cox proportional hazard models and multiple regression 
models, allowing adjustment for potential confounder factors. 
Results: In women, there was no evidence of diminished/increased fecundability 
according to the 2D:4D, neither on the right, nor on the left hand (FOR 1.01; 95% CI 
0.91-1.12 and 0.95; 95% CI 0.86-1.05, respectively). As for the children, boys had lower 
mean 2D:4Ds compared to girls, statistically significant for the right hand. However, the 
mean 2D:4D did not differ among children whose mothers had smoked during pregnancy 
compared to those whose mothers did not smoke, irrespective of gender. 
 100 
 
 
Conclusions: our data do not support evidence to suggest that 2D:4D could be used as a 
potential reproductive endocrine-sensitive endpoint in women and in their offspring. 
Additional studies are needed.  
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5.2 Introduction 
There is a paucity of solid endocrine-sensitive endpoints that allow the assessment of 
diverse life-course stressors on developmental and reproductive functions (Arbuckle et al. 
2008). A novel endpoint in humans that has been proposed as an indicator of sexual 
development is the 2nd to 4th finger ratio (2D:4D). The 2D:4D ratio reflects sexual 
differentiation early in life and is likely an endpoint for the organizational effects of 
prenatal androgens in the human body (Manning 2002). The 2D:4D is a sexually 
dimorphic trait, with males having relatively shorter 2nd digit lengths than 4th digits 
(Bailey and Hurd 2005). As such, lower 2D:4Ds could be potential indicators of greater 
androgen exposure during fetal development. Associations between digit ratios and 
several health outcomes including male fertility, sexual orientation, physical 
performance, hand preference, and autism have been reported. The direction and 
magnitude of these associations, however, have not been consistent.  
Several cross-sectional studies have reported low sperm counts and impaired hormonal 
status in men having higher digit ratios (i.e., implying low androgen exposure during fetal 
life) (Auger and Eustache 2011; Lu et al. 2012; Manning et al. 1998).  However, several 
studies with larger sample sizes have failed to replicate the associations between 2D:4D 
and hormone levels in adults (Beaton et al. 2011; Honekopp et al. 2007; Neave et al. 
2003), or to establish a number of male reproductive endpoints including semen quality 
(Bang et al. 2005; Firman et al. 2003; Seo et al. 2010). Menarche has also been assessed 
in association with 2D:4D. Two retrospective studies reported associations between 
lower digit ratios and delayed age at menarche (Manning and Fink 2011; Matchock 
2008), while a prospective cohort found lower digit ratios as predictors of early age at 
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menarche (Oberg and Villamor 2012). Concerning fertility, the evidence is sparse and 
usually assessed by means of indirect markers. Thus, lower female digit ratios have been 
associated with low offspring counts (Manning and Fink 2008), congenital adrenal 
hyperplasia (CAH) (Brown et al. 2002; Oswiecimska et al. 2012), and polycystic ovary 
syndrome (PCOs) (Cattrall et al. 2005), although this finding was challenged by Lujan et 
al. (2010a; 2010b). Time to pregnancy (TTP) is an epidemiological metric widely used 
for the assessment of human fecundity (Baird et al. 1986; Buck Louis 2011a). In males, 
one study reported decreased fecundity (i.e., delayed TTP) at a higher 2D:4D (Auger and 
Eustache 2011). However, the predictive role of 2D:4D on TTP has never been assessed 
in females.  
Smoking has a recognized detrimental impact on fertility, both male and female (Baird 
and Wilcox 1985; Buck Louis 2011a). Furthermore, maternal smoking during pregnancy 
has been associated with adverse reproductive outcomes in offspring (Ernst et al. 2012), 
including impaired fecundity (Weinberg et al. 1989). The causal mechanism by which 
smoking adversely affects fertility is still the subject of active research. In rats, prenatal 
exposure to nicotine has been linked to increased testosterone levels (Smith et al. 2003). 
In humans, maternal smoking during pregnancy has been positively associated with 
concentrations of maternal testosterone (Kandel and Udry 1999). Thus, if the adverse 
effect of maternal smoking on the offspring’s subsequent fertility acts through the 
homeostasis of fetal androgens, and under the hypothesis that 2D:4D is an indicator of 
the fetal concentrations of androgens, then 2D:4D might differ among children whose 
mothers smoked during pregnancy compared to those whose mothers did not smoke. 
Only one cross-sectional study has assessed the impact of maternal smoking during 
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pregnancy on 2D:4D (Rizwan et al. 2007), reporting lower digit ratios in boys prenatally 
exposed to smoking, although this association was not observed in females. 
In examining the potential of 2D:4D as a reproductive endocrine-sensitive endpoint, the 
purpose of this study was twofold: firstly, to evaluate the association between female 
2D:4D and fecundity as measured by time to pregnancy (TTP) in women from the 
MIREC Study, a Canadian pregnancy and birth cohort; and secondly, to evaluate the 
effect of prenatal exposure to maternal smoking on the 2D:4D of children born to women 
from the MIREC cohort. 
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5.3 Methods 
Population and study design 
The MIREC Study (Maternal-Infant Research on Environmental Chemicals) is a 
pregnancy cohort conducted in 10 cities across Canada between 2008 and 2011 
(Arbuckle et al. 2013). Approximately 2000 women attending prenatal clinics were 
recruited during the first trimester of pregnancy and followed up to 10 weeks postpartum. 
Subsequent follow-up studies have been conducted for the longitudinal assessment of 
child health and development.  
The present analysis is part of the Early Childhood Biomonitoring and 
Neurodevelopment Study (MIREC-CD Plus), a follow-up study conducted to measure 
growth and development up to age 5 years in a subsample of some 800 MIREC children. 
Baseline demographic and lifestyle characteristics of the women were obtained from data 
collected at the first trimester visit. Gestational age at delivery, birth weight, and gender 
were obtained from the maternal delivery chart.  
One component of MIREC-CD Plus was the measurement of the index (second, 2D) and 
ring (fourth, 4D) digit lengths in mothers and their children to calculate the 2D:4D. 
Digital pictures of the ventral surface of both hands were obtained using a 16-GB iPOD 
TOUCH (Apple Inc., California), placed in a device specially designed to standardize 
this procedure (Figure 1) (Appendix 4). Measurements of the second and fourth digit 
lengths were conducted by a single experienced research assistant with the aid of Adobe 
Photoshop 8 software (Adobe Systems Incorporated, San Jose, CA). As in previous 
studies that had used digital hand-scans (Allaway et al. 2009; Lujan et al. 2010b), when 
needed, the brightness/contrast of each image was subtly modified to improve the 
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visualization of the tips and proximal creases of the fingers. The lengths of the second 
and fourth fingers of each hand were further measured using mouse-controlled calipers. 
Calipers were positioned midline along the finger’s basal crease and expanded to the 
edge of the finger tip. 2D:4D was calculated as the ratio of the second and fourth fingers 
of each hand. In order to assess intra-observer reliability, each measurement was 
performed twice after a period of two weeks, with the observer unaware of the initial 
measurements. We then examined the reliability of the measurements by calculating 
intraclass correlations (ICCs) between the two measures of each finger, separately for 
each hand (Table 1).  
As of August 15, 2014, a total of 716 visits had been conducted (89.5% of the initial 
MIREC-CD Plus target). Sixteen mothers were not present at the time of the child’s visit. 
The hand pictures of three participants (one mother, and three children) were excluded 
because of visible malformations of their fingers (i.e., syndactyly). Eight mothers and 6 
children refused to have the pictures taken. Six pictures were excluded due to poor 
quality (4 mothers, 2 children). Sixteen pairs of twins were excluded from the child 
analysis, although their mothers were included. Forty-six mothers were further excluded 
because the index pregnancy was the consequence of a birth control failure. Four women 
and three children had only one hand picture available and for this reason were excluded. 
This resulted in a sample of 638 mothers and 672 children for the respective analyses. 
Operational definition of variables 
For our first objective, the primary exposure of interest was the 2D:4D of the women 
expressed either as continuous (log-transformed and divided by their standard deviation) 
or categorized by tertiles. The primary endpoint was time to pregnancy (TTP) (i.e. 
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number of months of trying to conceive). TTP was assessed in the MIREC cohort by 
asking women during the first trimester of pregnancy the following question: “How long 
did it take you to get pregnant with this pregnancy?” (number of months). Potential 
confounders were maternal age and smoking, household income, maternal education, and 
BMI before pregnancy. We did not include parity in our model to limit overadjustment 
bias (Buck Louis et al. 2012). 
For our second objective, the primary exposure was self-reported maternal smoking 
during pregnancy, assessed at the first visit of the MIREC Study (6-14 weeks of 
gestational age). The primary outcome was the 2D:4D of the children. Potential 
confounders were child age, gestational age, and birth weight. We also considered the 
effect of the maternal 2D:4D. The analysis was stratified by gender. Although collected 
in MIREC-CD Plus questionnaire, the children’s hand preference (i.e., handedness) was 
not available at the moment of the presence analysis for the whole sample. 
Statistical Analysis 
The reliability of the digit length measurement was evaluated by calculating the intraclass 
correlation coefficient (ICC) using ANOVA analysis. The ICC is calculated by dividing 
the between-subject variability by the sum of the between- and within-subject variability. 
ICC values range from 0 to 1, with the maximum of 1 indicating complete reliability 
(Kirkwood and Sterne 2003). 
The descriptive phase of analysis includes assessment of the distributions of the baseline 
characteristics of the mothers and their children. Fecundability odds ratios (FORs) were 
estimated using the Cox model, modified for discrete time data (Allison PD 2010). FORs 
estimate the odds of becoming pregnant each cycle, given exposure to the specific 
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compound, conditional on not being pregnant in the previous cycle. FORs less than 1 
denote reduction in fecundity or longer TTP, and FORs greater than 1 denote a shorter 
TTP. TTP was censored at the 13th month. Linearity and proportional hazard 
assumptions were verified (Allison PD 2010). To assess the impact of maternal smoking 
during pregnancy on the children’s 2D:4D, mean differences were calculated by unpaired 
t-test. To account for potential confounders, multiple regression analyses were conducted. 
Statistical analysis was performed using STATA 10.0 (Stata Corporation, College 
Station, TX) and SAS 9.3 (SAS Institute Inc., Cary, NC), specifically for the discrete-
time Cox proportional models.  
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5.4 Results 
For this analysis, the mean maternal age at recruitment was 33.50 years (SD 4.67), with a 
median gestational age of 12.43 weeks (minimum of 6.86 weeks and a 90th percentile of 
13.43 weeks). The mean maternal 2D:4D was similar in both hands (right 0.984, ± 0.035 
and left 0.979, ± 0.036). Most of the women were born in Canada, two thirds had a 
university degree, more than half had a prior pregnancy with a live birth, and 15% were 
obese previous to the index pregnancy (Table 2). Seventy-two women (11.3%) reported 
being smokers or having quit after knowing they were pregnant. As shown in Table 2, 
education was the only covariant significantly associated with right hand 2D:4D, with 
women who had less than a college diploma having a smaller ratio. In line with the 
literature, age and obesity were associated with a longer TTP. Differences in TTP were 
also present by country of birth; however, the small number of participants from 
countries other than Canada precludes conclusions about this estimate.  
The probabilities of pregnancy for these women at 1, 6, and 12 months were 0.40 (95% 
CI 0.36-0.44), 0.80 (95% CI 0.76-0.83), and 0.90 (95% CI 0.88-0.92), respectively. As 
presented in Table 3, there was no evidence of diminished/increased fecundability per 
one standard deviation increase in log-transformed 2D:4D, neither on the right, nor on the 
left hand (FOR 1.01; 95% CI 0.91-1.12 and 0.95; 95% CI 0.86-1.05, respectively). In our 
analysis by tertiles, the highest FOR was associated with the smallest ratio in both hands, 
although the 95% CI included the null effect (FOR 1.16; 95% CI 0.90-1.49 in the right 
hand and 1.16; 95% CI 0.91-1.49 in the left hand). 
With regard to the children, their mean age at follow-up was 3.38 years (SD 0.77). The 
mean gestational age at birth was 39 weeks (SD 1.77), with a mean birth weight of 3460 
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grams (SD 507). The gender distribution was similar, as represented by 338 girls (50.3%) 
and 334 (49.7%) boys. As shown in Table 4, boys had lower means 2D:4Ds compared to 
girls. As per exposure to maternal smoking during the first trimester of pregnancy, the 
mean 2D:4D did not differ among children whose mothers had smoked during pregnancy 
compared to those whose mothers did not smoke, irrespective of gender (Table 4). The 
same was observed in the multiple regressions analyses (Table 5), where the only factors 
associated with the child’s 2D:4D were their age and maternal 2D:4D.   
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5.5 Discussion 
To our knowledge, the MIREC Study is the first pregnancy and birth cohort that has 
assessed 2D:4D in association with TTP in women, and the effect of maternal smoking 
on children’s 2D:4D. Our objective was to examine the potential of the 2D:4D as a 
reproductive endocrine-sensitive endpoint. In mothers, we found some evidence of 
association between lower 2D:4D and shorter TTP, although this was not statistically 
significant. In children, exposure to maternal smoking during the first trimester of 
pregnancy, a potential stressor of fecundity in a woman’s progeny, failed to show any 
effect on the 2D:4D, independent of gender. Instead, we found that age and maternal 
2D:4D were strong determinants of the children’s 2D:4D. 
Most of the studies assessing the predictive role of 2D:4D on human reproduction have 
been conducted in men. In relation to fertility/fecundity in women, low 2D:4Ds have 
been related to low offspring count (Manning and Fink 2008) and pathological conditions 
associated with impaired fecundity such as congenital adrenal hyperplasia (CAH) (Brown 
et al. 2002; Oswiecimska et al. 2012), and with polycystic ovary syndrome in one study 
(PCOs) (Cattrall et al. 2005), which was contradicted in Lujan et al. (2010a; 2010b). With 
regard to time to pregnancy, one study reported decreased fecundity in males (i.e., 
delayed TTP) at higher 2D:4D, representing a feminized phenotype (Auger and Eustache 
2011). However, we are unaware of any study focusing on female 2D:4D and time to 
pregnancy (TTP). 
Several critical and sensitive windows essential for human reproduction and development 
are present as early as in the intrauterine period (Buck Louis 2011b). If, as suggested by 
Manning et al. (1998), the 2D:4D is defined in utero by the homeostasis of reproductive 
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hormones, we would have been able to demonstrate some association between 2D:4D 
and TTP. Moreover, one would have expected lower FORs (delayed TTP) in women with 
the lowest 2D:4D, but our results went in the opposite direction (i.e., the highest FORs 
were associated with the lowest 2D:4Ds, although this was not statistically significant). 
This also disagrees with the hypothesis that increased 2D:4D in females may be 
associated with increased fertility/fecundity, as Sutcliffe et al. (2010) proposed after 
finding higher 2D:4D in girls born following intracytoplasmic sperm injection (ICSI) 
compared to naturally conceived controls. 
There are some potential explanations for our failure to support this plausible association. 
First, 2D:4D may not be a precise measure of intrauterine exposure to testosterone in 
women. Although a prenatal reproductive hormonal imbalance might affect female 
fecundity, these hormonal changes might be too subtle to produce a detectable 
association between female 2D:4D and TTP. Second, some methodological aspects of 
our study need to be considered. The MIREC Study is a cohort of pregnant women, and 
therefore, women who are infertile and have no access to or success in infertility 
treatments were excluded by design from our study. If the 2D:4D of this population is 
different in women able to conceive, our study would not have been able to capture this 
association. We did, however, conduct sensitivity analysis in women who had undergone 
infertility treatment for the index pregnancy, and the results remained negative for any 
association between 2D:4D and TTP. Another aspect that needs to be considered is the 
retrospective nature of the assessment of TTP in our study. However, studies have 
reported reasonable validity of recall data if collected in the short-term (Cooney et al. 
2009; Zielhuis et al. 1992).  
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In line with the evidence, we were able to demonstrate that boys have lower mean 2D:4D 
than girls, and that this effect is stronger in the right hand (Manning et al. 1998). In spite 
of this, we were unable to demonstrate any effect on 2D:4D of a potential reproductive-
aggressor in utero such as maternal smoking. The only study that has assessed this 
association to date is a cross-sectional study conducted in children in primary school 
(Rizwan et al. 2007), which reported a significant association between maternal smoking 
during pregnancy and low mean right 2D:4D in male offspring only. Certain aspects of 
our respective studies may account for the different results. Firstly, the children in 
Rizwan et al. were older (mean age 8.3 years, SD 1.7) than the ones in our study. 
Although some authors suggest that 2D:4D is stable during life (Manning et al. 1998), in 
our multiple regressions analyses, the child’s age was significantly associated with 
2D:4D, which is in line with studies in children suggesting that the digit ratio increases 
with age (McIntyre et al. 2005). Secondly, although the prevalence of maternal smoking 
was comparable in both studies (12.9% in MIREC, versus 13% in Rizwan et al. (2007), 
the doses of exposure (i.e., number of cigarettes per day) may have been different. Our 
sample size was not sufficient to test this hypothesis. In fact, our sample size had a 
limited power (i.e., 64%) to detect mean differences in 2D:4D of 0.2 (SD 0.05), with 95% 
confidence (α = 0.05) (Manning et al. 1998).Thirdly, Rizwan et al. (2007) recognized that 
they could not rule out that high fetal testosterone, smoking, and low 2D:4D are 
associated through a relationship of risk-taking behaviour, and that there are studies 
suggesting the heritability of the 2D:4D (Manning et al. 2000). Smoking, a trait of risk-
taking behaviour, is heritable (Vink and Boomsma 2011), raising the possibility that more 
than a proxy of in utero androgen levels, 2D:4D could be a heritable trait. In fact, in our 
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multiple regression models, the respective maternal index of each hand was significantly 
associated with the children’s 2D:4D.  
The method used to measure digit lengths could also account for the differences among 
studies. Most of the studies have measured finger lengths by a physical method, while we 
used digital imaging of the hands. While Rizwan et al. (2007) reported a Pearson 
correlation coefficient of 0.52 using physical measurements, our correlation coefficient 
was 0.88. A high reliability of our measures is also supported by the ICCs, which were 
higher than 0.95 for most of the finger lengths and more than 0.80 for the indexes. Thus, 
the different methods used for the measurements of the digit length could explain why 
our mean 2D:4Ds (Table 4) were lower than those reported in Rizwan et al. (2007), not 
only in girls (right 0.978 ± 0.039 and left 0.999 ± 0.034), but also in boys (right 0.967 ± 
0.035 and left 0.981 ±0.031). In fact, there is evidence suggesting that computer-assisted 
measurements of the 2D:4D are more accurate than physical measurements, photocopies, 
or printed scanned images measured with Vernier calipers (Allaway et al. 2009). This 
may explain why our mean maternal 2D:4Ds (right 0.984 ± 0.035 and left 0.979 ± 0.036) 
are similar to those reported in Lujan et al. (2010b), who also used digital hand scans to 
assess 2D:4D in 96 women with PCOs (right 2D:4D 0.981 ± 0.028 and left 2D:4D 0.982 
± 0.030) versus 48 female controls (right 2D:4D 0.972 ± 0.028 and left 2D:4D 0.974 ± 
0.037).  
Although we did not find associations between maternal smoking during pregnancy and 
the children’s 2D:4D, numerous environmental contaminants were measured in the 
MIREC Study in maternal blood, urine, meconium, breast milk, and more recently, in the 
urine of offspring (Arbuckle et al. 2013). This will allow us to further test the possible 
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impact of potential endocrine disruptors during the prenatal period on children’s 2D:4D. 
In addition, the MIREC biobank offers the future possibility of measuring the hormonal 
profile of mothers and children, a limitation of the present analysis. 
In summary, our data do not support any strong association between 2D:4D and female 
fecundity as measured by TTP. In children, we were able to demonstrate a sexual 
dimorphic trait with boys having lower ratios than girls. As well, we found that age and 
maternal 2D:4D were strong determinants of the children’s 2D:4D. However, we did not 
find an adverse impact of maternal smoking during pregnancy on children’s 2D:4D. 
Thus, whether the 2D:4D is a reliable reproductive endocrine-sensitive endpoint has yet 
to be determined.   
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Table 1. Intraclass correlation coefficient subsample (n=80) 
 Mothers  Children 
 ICC 95% CI ICC 95% CI 
Right hand        
2: index finger 0.98 0.97 0.99 0.98 0.97 0.99 
4: ring finger 0.99 0.98 0.99 0.99 0.98 0.99 
2:4 digit ratio 0.92 0.89 0.96 0.86 0.81 0.92 
Left hand       
2: index finger 0.97 0.95 0.98 0.98 0.97 0.99 
4: ring finger 0.99 0.99 0.99 0.99 0.98 0.99 
2:4 digit ratio 0.88 0.83 0.93 0.87 0.82 0.93 
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Table 2. Digit ratio and estimated time to pregnancy according to baseline characteristics in 638 women: the MIREC Study 
  Digit ratio  TTP 
  Right hand  Left Hand  
Medianc (95% CI) pd Characteristic n (%)a Mean pb  Mean pb  
Age, years   0.59   0.23   <0.001 
<30 142 (22.3) 0.986   0.975   2 (1-4)  
30-34 254 (39.8) 0.985   0.978   2 (1-5)  
35-39 195 (30.5) 0.981   0.979   2 (1-6)  
≥40 47 (7.4) 0.985   0.988   4.5 (1-18)  
Education   0.04   0.90   0.48 
Some college or less 55 (8.6) 0.978   0.977   1 (1-6)  
College diploma 136 (21.3) 0.991   0.978   2 (1-6)  
Undergraduate 270 (42.3) 0.984   0.980   2 (1-5)  
Graduate (MSc PhD) 177 (27.8) 0.981   0.980   2 (1-6)  
Country of birth   0.46   0.63   0.04 
Canada 524 (82.0) 0.985   0.978   2 (1-5)  
United States 11 (2.0) 0.974   0.991   4 (1-12)  
Mexico 3 (0.5) 0.960   0.962   6 (1-12)  
China 4 (0.5) 0.970   0.970   1 (1-1)  
Other 96 (15.0) 0.984   0.981   3 (1-8)  
Household Income    0.13   0.10   0.23 
  < $60,000 115 (18.0) 0.978   0.972   2 (1-5)  
$60,001 – 100,000 242 (38.0) 0.985   0.978   2 (1-5)  
 > $100,000 260 (40.7) 0.986   0.982   2 (1-6)  
  No response 21 (3.3) 0.990   0.985   1 (1-2)  
Parity conditional on gravidity    0.84   0.53   0.10 
No prior pregnancy 193 (30.2) 0.984   0.977   3 (1-6)  
Prior pregnancy without live birth(s) 91 (14.3) 0.983   0.976   2 (1-6)  
Prior pregnancy with live birth(s) 354 (55.5) 0.985   0.980   2 (1-5)  
a Total may be less than 638 because of missing values, b ANOVA F Test, c Median TTP in months, d Log-rank test  
±  Includes women who quit during the first trimester of pregnancy  
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Table 2. Digit ratio and estimated time to pregnancy according to baseline characteristics in 638 women: the MIREC Study 
(cont’d) 
  Digit ratio  TTP 
  Right hand  Left Hand  
Medianc (95% CI) pd Characteristic n (%)a Mean pb  Mean pb  
Maternal smoking   0.70   0.80   0.33 
Never  417 (65.4) 0.984   0.978   2 (1-6)  
Former 149 (23.3) 0.984   0.980   1 (1-4)  
Current ±   72 (11.3) 0.988   0.977   2 (1-5)  
Pre-pregnancy BMI   0.19   0.23   0.07 
<24.9 341 (63.7) 0.985   0.980   2 (1-5)  
25-29.9 98 (20.2) 0.979   0.973   2 (1-6)  
>30 80 (16.1) 0.986   0.980   3 (1-7)  
a Total may be less than 638 because of missing values, b ANOVA F Test, c Median TTP in months, d Log-rank test  
±  Includes women who quit during the first trimester of pregnancy  
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Table 3. Fecundability Odds Ratios (FORs) according to digit ratio in 638 women from the MIREC Study 
 Right hand  Left Hand 
 Crude 
FOR (95% CI) 
Adjusted (n=590)a 
FOR (95% CI) 
 Crude 
FOR (95% CI) 
Adjusted (n=590)a 
FOR (95% CI) 
Digit ratio, continuousb 1.01 (0.92- 1.11) 1.01 (0.91-1.12)  0.95 (0.87-1.05) 0.95 (0.86-1.05) 
      
Age  0.95 (0.93-0.97)   0.95 (0.93-0.97) 
Pre-pregnancy Body Mass Index      
<24.9  Reference   Reference 
25-29.9  0.85 (0.66-1.10)   0.84 (0.65-1.09) 
>30  0.74 (0.56-0.97)   0.74 (0.56-0.98) 
      
Digit ratio tertile (right/left medians)      
1 (0.950/0.944) 1.15 (0.91-1.46) 1.16 (0.90-1.49)  1.17 (0.93-1.49) 1.16 (0.91-1.49) 
2 (0.982/0.979) 1.04 (0.82-1.31) 0.97 (0.75-1.24)  1.09 (0.86-1.38) 1.02 (0.80-1.31) 
3 (1.021/1.011) Reference Reference  Reference Reference 
      
Age  0.95 (0.93-0.97)   0.95 (0.93-0.97) 
Pre-pregnancy Body Mass Index      
<24.9  Reference   Reference 
25-29.9  0.84 (0.65-1.09)   0.84 (0.65-1.08) 
>30  0.73 (0.55-0.96)   0.74 (0.56-0.98) 
a Log-transformed and divided by its standard deviation 
b Due to 48 missing values of Pre-pregnancy Body Mass Index 
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Table 4. Mean 2D:4D in children according to gender and maternal smoking during the first trimester of pregnancy 
 Gender Maternal smoking during 1st trimester of pregnancy 
Digit ratio Female Male p valuea Female p valuea  Male p valuea
 (n=338) (n=334) No (n=299) Yes (n=39)   No (n=296) Yes (n=38)
Right hand   0.001 0.74  0.45
Mean 0.947  0.937  0.947 0.945   0.937 0.932
S.D 0.062 0.040 0.039 0.036   0.039 0.043
Left Hand   0.05 0.38  0.94
Mean 0.943  0.937 0.944 0.938   0.937 0.937
S.D 0.070 0.040 0.038 0.044   0.040 0.041
a t-test 
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Table 5. Adjusted mean changes (β) for the 2D:4D in children per maternal smoking status during the first trimester of 
pregnancy: The MIREC Study 
  Female   Male 
 n β IC 95% p value  n β IC 95% p value 
Right hand 333     328    
Maternal smoking -0.0052 -0.0178, -0.073 0.42  -0.0039 -0.0175, 0.0097 0.57  
Maternal right 2D:4D 0.2986 0.1826, 0.4147 <0.001  0.2518 0.1326, 0.3710 <0.001
Age, years 0.0057 0.0002, 0.0112 0.04  0.0055 0.0001, 0.0109 0.04  
Birth weight, gramsa -0.0019 -0.0069, 0.0031 0.46  0.0004 -0.0052, 0.0059 0.89  
Gestational age, weeks 0.0019 -0.0011, 0.0049 0.22  0.0020 -0.0013, 0.0054 0.23  
Left hand 331   327
Maternal smoking -0.0060 -0.0190, 0.0069 0.36  0.0002 -0.0140, 0.0136 0.98  
Maternal left 2D:4D 0.1915 0.0749, 0.3080 0.001  0.0982 -0.0180, 0.2143 0.10
Age, years 0.0068 0.0012, 0.0125 0.02  0.0051 -0.0003, 0.0106 0.06  
Birth weight, gramsa -0.0019 -0.0070, 0.0033 0.48  -0.0000005 -0.0056, 0.0056 1.00  
Gestational age, weeks 0.0014 -0.0017, 0.0050 0.39   0.0007 -0.0026, 0.0041 0.66  
aLog-transformed and divided by its standard deviation 
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Figure1. Finger digital length image capture and measurement procedure. 
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Chapter 6 -  GENERAL DISCUSSION 
This chapter summarizes the thesis, reviewing the key results, and discusses the more 
general methodological limitations of the research, in complement to the discussion sections 
of the three research articles presented above. The chapter ends with an outline of the 
implications of this research for public health and future research.  
6.1 Overview of the results 
The research undertaken in this thesis represented an effort to: [1] enhance the 
knowledge regarding the potential effect of selected environmental contaminants on female 
fecundity as measured by TTP; and [2] in an effort to validate a novel endocrine-sensitive 
endpoint, to evaluate the potential of 2D:4D as a predictor of later reproductive health in 
women and their offspring. 
To assess the effect of selected ECs on female fecundity, two groups of compounds 
were considered: persistent (perfluorinated compounds -PFOA, PFOS, and PFHxS-) and 
nonpersistent chemicals (Bisphenol A, Triclosan, and Phthalates). As explained above, this 
thesis was developed in the framework of the Maternal-Infant Research on Environmental 
Chemicals (MIREC) study, a pregnancy cohort of 2001 women recruited in ten cities across 
Canada between 2008 and 2011 (30). Upon thesis commencement, a follow-up study was 
planned to measure growth and development up to age five in a subsample of some 800 
MIREC children: the Early Childhood Biomonitoring and Neurodevelopment Study (MIREC-
CD Plus). A contribution of this doctoral work was to add to this project by developing the 
finger-length component of the study, which consisted of measuring the index (2D) and the 
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ring (4D) digit lengths in mothers and children to calculate the 2D:4D ratio. To do this, digital 
pictures of the ventral surface of both hands were obtained using a standardized procedure 
(Figure 1). The purpose of this component of the study was to evaluate the potential of 2D:4D 
as a reproductive endocrine-sensitive endpoint by first analyzing the association between 
female 2D:4D and maternal fecundity, and secondly, by assessing the effect of prenatal 
exposure to maternal smoking on the 2D:4D ratio of the children. 
Overall, the results of this thesis have contributed to the evidence regarding the 
potential adverse effect of several ECs on female fecundity as measured by TTP. Firstly, we 
found that PFOA and PFHxS were associated with diminished fecundity (FORs 0.89; 95% CI 
0.83-0.94 and 0.91; 95% CI 0.86-0.97, respectively), supporting previous evidence that 
suggested a similar effect. Secondly, we assessed for the first time the effect of Triclosan on 
TTP, presenting evidence of delayed fecundity at the highest quartile of exposure (>72 ng/ml; 
FOR 0.84; 95% CI 0.72-0.97). Thirdly, our findings agreed with those of the only study that 
has assessed the effect of BPA on female fecundity, and which showed no effect. Fourthly, we 
found some indication that female exposure to phthalates might be associated with a shorter 
TTP, although this finding did not reach statistical significance. 
In line with the literature (10), the magnitude of FORs reported is smaller than those 
reported for biologic determinants of fecundity such as oligospermia or gynecologic disorders 
(i.e., FORs 0.34 and 0.46, respectively) (99), which were not available in our database. 
However, our estimates are comparable to those reported for other lifestyle factors involved in 
fecundity such as smoking, higher BMI, and parental ages (158, 159). 
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With regard to the potential of the digit length ratio (2D:4D) as an endocrine-sensitive 
endpoint in women and their offspring, our data do not support a strong association between 
2D:4D and TTP. In children, we did not find an adverse impact of maternal smoking during 
pregnancy on children’s 2D:4D. Thus, our data do not support evidence to suggest that 2D:4D 
could be used as a potential reproductive endocrine-sensitive endpoint in women as measured 
by TTP, and in their offspring as measured by exposure to maternal smoking during the first 
trimester of pregnancy. 
6.2 Summary of Key Results 
The results of this thesis support the evidence that exposure to potential endocrine-
disrupting chemicals may have an impact on human reproduction, underscoring the 
importance of continued investigation of ubiquitous environmental chemicals and human 
reproduction and development. Such work will help inform the extent to which such exposures 
might adversely impact population health. 
In regards to persistent ECs, our results add to the evidence that exposure to PFOA and 
PFHxS, even at lower levels than previously reported, may reduce fecundability. Future 
epidemiological studies at current levels of exposure, including male partner concentrations 
should be conducted to strength conclusions about causality. It also be important to follow 
couples trying to attempt pregnancy to obtain data relevant for understanding the 
toxicokinetics of chemicals and their impact on sensitive fecundity endpoints (10). Research 
should also be focused on the identification of strategies to reduce exposure to these chemicals 
in the general population. Controversy exists about how best to model exposures and TTP.  
We used DAGs to support the possibility of collider-stratification bias with the inclusion of 
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parity in models.  Moreover, PFCs are not lipophilic and while placental and lactational 
transfer has been reported, the magnitude of change is minimal relative to lipophilic 
compounds.  In addition, data have been reported for daily exposure to PFCs via diet, 
underscoring the continual exposure for women including pregnant women.  Such exposure 
and toxicokinetic data offer support for the exclusion of parity in models. In this respect, our 
manuscript will help to guide the analytical phase of further studies. 
In the case of non-persistent ECs, our data suggest that elevated TCS exposure (> 72 
ng/ml) may be associated with diminished fecundity, as suggested by a longer TTP. In regards 
to phthalates and BPA, there was no evidence of any negative impact on TTP and even some 
suggestion that exposure to some phthalates might be associated with a shorter TTP. Since this 
is the first study to evaluate TCS in relation to TTP, and the second to evaluate the effect of 
BPA and phthalates we recommend further epidemiological and toxicological studies in order 
to test our findings and elucidate the potential impact of nonpersistent environmental 
contaminants on human fecundity.  
As stated in the Scientific Statement of the Endocrine Society, in the absence of direct 
information regarding cause and effect, the precautionary principle is critical to enhancing 
reproductive and endocrine health, and should be used to inform decisions about exposure to, 
and risk from, potential EDCs (34).  
6.3 Comments on Study Design and Limitations 
The specific limitations of this research have already been described in detail in the 
previous chapters, and therefore, here, as in a recent overview conducted by Buck Louis (10), we 
will focus on the more important methodological limitations that need to be considered in 
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weighing the evidence of the effect of ECs on fecundity. These are: 1) reliance on pregnant 
women, which may exclude women with the highest exposures if related to the inability to 
conceive; 2) retrospectively reported TTP, which may be associated with bi-directional 
reporting errors; and 3) limited attention to male partners or couples’ exposures. 
Firstly, this thesis was developed within the context of the MIREC Study, a Canadian 
pregnancy and birth cohort. Thus, only women who became pregnant spontaneously or who 
opted/had access to ART and succeeded in their treatment were included in the study. 
Numerous studies have shown that women who seek medical help for fertility problems make 
up a highly selective group among women with fertility problems. Data from nationally 
representative surveys in the United States have shown that women with fertility impairments 
who use infertility services are more likely to be married, non-Hispanic white, older, more 
highly educated, and more affluent than non-users (156). The significant cost of medical 
services for infertility is probably the main reason for the disparities in the use of infertility 
services (160). In Canada, health care is the responsibility of the individual provinces. Quebec 
is the only province that universally covers the costs of ART, since August 2010. This new 
policy increased access to these types of treatments, as reflected by a 200% increase in the 
number of IVF cycles performed during the first year of the program compared to the year 
previous to the policy, as shown in our evaluation of this program (161). 
As recently reviewed in Velez et al., (121) disadvantaged populations experience 
greater susceptibility to environmental hazards because of compounding health hazards (poor 
nutrition, poor housing, poor health care, and higher levels of environmental contaminants) 
(162, 163). Exposure to environmental toxicants varies according to race, income, gender, age, 
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and other demographic characteristics (164), in addition to susceptibilities related to genetics 
or physiologic differences related to sex. For example, data from NHANES revealed that non-
Hispanic blacks and Mexican-Americans in the United States have higher levels of MEP, 
MiBP, and MEHP in their urine than non-Hispanic whites (165, 56). Marginalized groups 
disadvantaged by demographic characteristics are at greater risk of experiencing more toxic 
exposures and are more vulnerable to their toxic effects, due to a limited access to political 
power and to the living conditions and services needed to address contaminants in their 
communities (163). Although all social classes use consumer products containing chemicals, 
people with lower socio-economic status are more likely to be exposed to products 
manufactured outside North America that are subject to lower controls by regulatory 
authorities.. These include cosmetics, children’s toys, and food containers, among other 
products (121).  
Participants in MIREC, on average, tended to be older, better educated, born in 
Canada, married, and less likely to be current smokers than the general population of Canadian 
women giving birth in 2009 (31), characteristics that were also observed in our three 
manuscripts. The validity of a study is usually separated into two components: The validity of 
the inferences drawn as they pertain to the members of the source population (internal 
validity) and the validity of the inferences as they pertain to people outside that population 
(external validity or generalizability) (166). Most violations of internal validity can be 
classified into three general categories: confounding, selection bias, and information bias. 
Since information on socio-demographic and life-style characteristics were collected and 
considered in our analysis, we were able to control for potential confounding, a major factor 
affecting internal validity. In order to minimize selection bias we included all the potential 
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participant from the MIREC cohort, excluding women requiring egg donation or reporting 
male factor infertility, as well as women whose index pregnancy was the result of birth control 
failure. Sensitivity analysis including the latter group of women resulted in similar results. 
However, we recognize that since this is a retrospective-TTP study, women that were infertile 
and/or did not have access to infertility treatment were excluded by design from our study. 
Thus, the possibility of selection bias exists since women highly exposed to these chemicals 
were excluded if there is a causal association with infertility. This is acknowledged in the 
manuscripts. Regarding information bias, the retrospective assessment of TTP can introduce 
recall bias; however it is a reliable method when collected in the short term. Moreover, the 
effect of digit preference was addressed, suggesting that this was not a concern. Exposures 
were based on biomonitoring data conducted by an accredited laboratory, which decreases the 
possibility of measurement error. In terms of external validity, considering that the MIREC 
study population is largely Caucasian, more educated and of a higher income group than the 
Canadian population at large, generalization to other ethnic and socioeconomic populations 
should be done with caution. However, given the relatively large sample size in our analysis, 
there still were substantial numbers in the cell for the less economically advantaged women (n 
= 361 < $60,000) to still suggest some inferences for this population. 
Secondly, because MIREC is a pregnancy cohort of women enrolled during the first 
trimester of pregnancy (6 to 14 weeks), TTP was assessed retrospectively. While reliability is 
reported to be good for retrospectively measured TTP, even with a long period of recall (167), 
only short recall periods (i.e., not longer than  20 months), are considered valid (76, 77). 
Therefore, this potential limitation of pregnancy-based retrospective TTP studies is unlikely to 
have biased our results.  
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Digit preference reporting can also affect retrospective TTP studies (168); however, it 
is estimated that stable estimates of the TTP distribution can be obtained with approximately 
200 values per exposure group (21), a number that, due to our large sample size, was always 
attained in the different categories of exposure. Furthermore, to evaluate if digit preference 
had any effect on our results, we applied the method recently proposed in McLain, et al. (169). 
The histogram of our data suggested digit preference at 6, 12 and 18 months.  We estimated a 
piecewise exponential model with three separate knot scenarios, each using seven knots; the 
locations for knot scenarios were {1,2,4,9,18,30, ∞ }, {1,2,4,9,15,27, ∞ }, and 
{1,2,4,10,17,29, ∞ }. The estimates showed little bias (Table 1), suggesting that digit 
preference had little impact in our results.    
Table 1. Digit preference Piecewise knot scenario 
    Piecewise knot scenario  
 MIREC A 
Mean (SD) 
B 
Mean (SD) 
C 
Mean (SD) 
BPA -0.01868 
(0.02872) 
-0.0168 
(0.0242) 
-0.0152 
(0.0246) 
-0.0166 
(0.0244) 
TCS -0.03531 
(0.02820) 
-0.0357 
(0.0238) 
-0.0343 
(0.0238) 
-0.0352 
(0.0236) 
Phthalates     
MnBP 0.03108 
(0.03027) 
0.0317 
(0.0258) 
0.0329 
(0.0253) 
0.0337 
(0.0252) 
MEP 0.02494 
(0.02972) 
0.0169 
(0.0258) 
0.0155 
(0.0258) 
0.0173 
(0.0247) 
MBzP 0.04161 
(0.02978) 
0.0409 
(0.0249) 
0.0396 
(0.0252) 
0.0404 
(0.0256) 
MCPP 0.03087 
(0.02946) 
0.0369 
(0.0249) 
0.0378 
(0.0247) 
0.0378 
(0.0244) 
MEHP 0.03490 
(0.02912) 
0.0389 
(0.0245) 
0.0397 
(0.0244) 
0.0390 
(0.0244) 
MEOHP 0.02987 
(0.02908) 
0.0361 
(0.0244) 
0.0358 
(0.0238) 
0.0350 
(0.0244) 
MEHHP 0.02317 
(0.02914) 
0.0285 
(0.0250) 
0.0287 
(0.0248) 
0.0290 
(0.0246) 
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 Thirdly, another limitation of current studies is the lack of attention given to male 
partners’ or couples’ exposures. In fact, although MIREC collected some demographic and 
lifestyle information regarding the babies’ fathers, we did not collect biological samples in 
males. This could be a limitation, given recent results from the LIFE study reporting 
associations between concentrations of some phthalate metabolites in males and delayed TTP 
(71), as well as some associations between semen quality and exposure to select PFCs, 
although in directions that were not consistent (170). We did, however, take some precautions 
to limit the extent to which male fecundity determinants could affect our results. During our 
sample selection, we excluded participants whose partners had had some type of infertility 
treatment; also, during the statistical analysis, we took into account paternal age and smoking 
status. Paternal and maternal ages were highly correlated (r=0.73); therefore, to avoid 
collinearity, we did not include paternal age in the analyses. However, we conducted 
sensitivity analyses, including paternal age, and this did not modify the associations that we 
reported. Paternal active smoking during the first trimester of pregnancy was not associated 
with TTP, and therefore, was not included in the adjusted models. 
In addition to the previously-mentioned limitations, there are some covariates for 
which we did not have information. One of the main difficulties in studying human fecundity 
is the large behavioural component. There is constant interplay between behaviour and 
biology. The frequency of sexual intercourse (19, 171, 172), as well as the timing of sexual 
intercourse in relation to ovulation, strongly influences the probability of conception (173). 
This information was not available in the MIREC study, which may have affected our results. 
In addition, we did not have information on menstrual cycle histories. TTP was assessed in 
months. However, since a woman can conceive only once in each menstrual cycle, it has been 
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argued that the proper way to measure TTP is in cycles (174). Nonetheless, the majority of 
studies investigating TTP have measured TTP in months. For women with regular menstrual 
cycles of 28 days, the effect of the choice of unit does not impact on the effect estimates. 
However, for women with long menstrual cycles, measuring TTP in months would 
overestimate the true TTP. On the contrary, if a chemical modifies the duration of the cycle, 
then looking only at conception per cycle would underestimate the effect of the exposure on 
TTP. Finally, only data on the first pregnancy can be considered unbiased, as relatively fertile 
couples may tend to have more children, and adverse reproductive experience may influence 
behaviour. This issue should be considered if later pregnancies are studied (21). Although 
detailed information about previous pregnancies of MIREC participants was obtained, no 
information regarding the TTP of previous pregnancies was available. Nevertheless, despite 
recognition of the importance of lifestyle factors in TTP (175), it is likely that at the 
population level, female biological factors, such as age and menstrual cycle length, are more 
important predictors of TTP than lifestyle factors (174). Thus, as previously mentioned, 
biologic determinants of fecundity such as oligospermia or gynecologic disorders (i.e., 
polycystic ovary syndrome, fibroids, and endometriosis among others), which have a higher 
impact on fecundity, were not assessed in MIREC. Furthermore, the hormonal profile of 
women and children, important in the study of reproductive function, was also absent. 
There are additional methodological considerations related to laboratory analytical issues that 
need to be mentioned in this thesis. Additional potential limitations in the exposure assessment 
need to be considered. First, no exposure data was available for 2% of the eligible women for 
BPA, 5% for TCS, and 10% for phthalates. It is considered that complete case analysis is 
unlikely to introduce bias when the incomplete cases are less than about 5% (176). In most of 
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the cases, there was no laboratory result because the woman did not provide sufficient urine 
for all the chemical analyses that were done. More phthalate results were missing because they 
were analysed in the second aliquot of urine, while BPA was analysed in the first.  TCS was 
analysed in the first aliquot, but we lost 2% of women who did not consent to further analyses 
of the biobanked specimens. We consider that the missing values for phthalates as 
consequence of being measured in the second aliquot of urine are independent of both 
observed and unobserved data, which is defined in the literature as “missing completely at 
random” (MCAR), in which case, complete case analysis is an acceptable approach (177). All 
chemical concentrations that were below the LOD were coded as the lowest concentration 
obtained for that congener divided by 2 (178), which has been shown to give similar results to 
division by the square root of 2 (56). However, recent evidence suggests that this simple 
substitution may lead to increased bias and the underestimation of the error variance, which 
results in a lower power for statistical hypothesis testing (179-181). However, simulation 
studies using alternative methods to account for exposures <LOD, have demonstrated that the 
LOD divided by two worked fairly well in simulations with ≤50% exposure data below the 
LOD (181).  Methods have also been proposed for Cox regression models with covariates 
subject to a lower LOD, however they have not provided much improvement over the LOD 
divided by two (182). In our analyses, PFC, TCS and five phthalates metabolites (MnBP, 
MEP, MBzP, MEHP, MEOHP, MEHHP), were detected in at least 95% of the samples, which 
suggests that the probability of bias due to our substitution approach is very low for these 
particular chemicals. In the case of BPA and MCPP, detection rates were also high (87% and 
82%, respectively), which is also reassuring. On the other hand, four phthalate metabolites 
were detectable in less than 14% of the samples (MMP, MCHP, MiNP, and MnOP). These 
 140 
 
 
metabolites were excluded from further analyses, an approach used in large biomonitoring 
surveys when the proportion of results below the LOD is greater than 40% (56). However, an 
analysis of these metabolites as continuous variables showed that the adjusted FORs were 
approximately 1, although not statistically significant for MMP (FOR=1.03, 95% CI 0.96- 
1.10), MiNP (FOR=1.0, 95% CI 0.94- 1.06), and MnOP FOR=1.02, 95% CI 0.96- 1.09) using 
the continuous scale. In the case of MCHP, the FOR was lower than 1, but the 95% CI was 
large and non-significant (FOR=0.93, 95% CI 0.72-1.18). To account for urine dilution in the 
case of nonpersistent chemicals, and to be consistent with current practice, specific gravity 
was included as a covariate in the model (183, 66). Specific gravity has been proposed as a 
more appropriate method than creatinine for adjusting phthalate concentrations because their 
elimination by active tubular secretion might limit the accuracy of creatinine adjustment (184). 
Additionally, creatinine levels may be confounded by muscularity, physical activity, urine 
flow, time of day, diet, and disease states (184). In pregnant women, specific gravity appeared 
to be more effective than creatinine in adjusting for urine dilution late in pregnancy (185). 
Another methodological consideration is the self-reported assessment of smoking. 
Although the MIREC study included the measurement of cotinine concentrations in plasma, 
these results were not available at the time of conducting the analyses for this thesis. However, 
the validity of self-reported smoking during pregnancy has been shown to be high compared to 
plasma levels of cotinine in early pregnancy (186).  
It is also worth recalling that although for persistent environmental chemicals such as 
PFCs, blood samples collected during the first trimester of pregnancy are probably a reliable 
surrogate of periconceptional concentrations due to their long half-lives (93), the same cannot 
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be true for nonpersistent chemicals. Concentrations of BPA, TCS, and phthalates were 
measured in a single spot urine sample collected during the first trimester of pregnancy. As 
these chemicals have a short half-life (hours) and there are multiple sources and routes of 
exposure, intra-individual variability in results are expected. Previous studies have indicated 
that while the intra-class correlation coefficient (ICC) for BPA is low (< 0.25) across 
pregnancy (187-189), the ICC for TCS is better (> 0.47) (57, 61, 62). As for phthalates, the 
extent of the variability depends on the metabolite, with DEHP metabolites often displaying 
more variability than other metabolites (55, 58-60). 
With regard to the assessment of 2D:4D as an endocrine-sensitive endpoint in women 
and their offspring, differences in the methods selected for measuring the digit ratios could in 
part explain divergences in previous studies that have assessed several outcomes, including 
male fertility endpoints such as semen quality, and TTP. In females, however, this is the first 
study that has evaluated TTP according to 2D:4D. Among the methods previously used to 
assess 2D:4D are direct physical measurements with calipers (129), measurements from 
photocopies (190), scanned images (128), radiographs (191, 192), inked handprints (193), 
scaled tubes (194), and digital pictures (195). Digital technology may provide a superior 
alternative to the more traditional techniques for the acquisition of images, and computer-
assisted image enhancement may improve measurement reliability (196). We used Photoshop, 
a graphics editor software that has been shown to have very high precision compared to scales 
and calipers for the measurement of digit lengths (197). 2D:4D evaluations are technique-
dependent and this has serious implications in a field that necessitates a highly precise tool to 
identify relatively small differences among study populations (197). Thus, we believe that our 
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method for capturing and measuring the images does not explain the absence of association 
that we found. 
6.4 Power calculation 
For the assessment of ECs and TTP, the final number of participants included in the 
adjusted models ranged from 1491 to 1625 (Table 2). These samples have a power higher than 
95% (α= 0.05) to detect FORs = 0.90 per one standard deviation increase in log-transformed 
serum concentrations of the respective chemicals, and considering the potential effect of 
additional covariates (r2 =0.14) (174). In the case of our third article, maternal 2D:4D and 
TTP, the power was 66% to detect FOR= 0.90, but higher than 95% to detect FOR = 0.85.  
These power calculations were based on the formula developed by Hsieh and Lavori 
(198), which also corrects  for a variance inflation factor (VIF) (Appendix 5). 
Table 2. Power calculation 
 Exposure N FORs 
0.90 0.85 0.80 
Article 1 Perfluorinated compound 1625 98% 100% 100% 
Article 2      
 Bisphenol A 1623 98% 100% 100% 
 Triclosan 1583 97% 100% 100% 
 Phthalates 1491 97% 100% 100% 
Article 3 2D:4D  590 66% 96% 100% 
 
In relation to the children's 2D:4D, our study had a limited power (i.e. 64%) to detect mean 
differences in digit ratios of 0.2 (SD 0.05), with 95% confidence (α = 0.05) (129). 
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6.5 Public Health Relevance and Future Research Directions 
The MIREC study offers a unique opportunity to examine the effect of several 
environmental contaminants on time to pregnancy in a large Canadian population of pregnant 
women. Overall, the results of this thesis are expected to support public health interventions to 
limit exposure in the general population to select ECs. Awareness of these potential risks may 
lead people to adopt corrective behaviours that should help them maintain their fecundity, 
hence reducing the burden of fertility impairment in Canada and worldwide.  
Fecundity impairments and infertility have important public health implications. Given 
that the injudicious use of many infertility treatments results in twin and higher-order births, 
both mothers and infants are at higher risk for adverse health outcomes (161). While there is 
increasing recognition about the adverse effect of many factors, including environmental 
contaminants, on fecundity, there are still many opportunities to better understand and address 
population-level issues that contribute to infertility in men and women (154). 
As suggested by Buck Louis, two opportunities of research may provide insight 
regarding the effect of ECs on fecundity (10). Firstly, existing pregnancy and/or birth cohorts 
conducted during the last decade, including the MIREC Study (31), have biobanks that may be 
suitable for continued investigation. However, since women who are not able to achieve 
pregnancy are excluded by design from these cohort studies, additional strategies are needed 
to target this population in different settings. Secondly, follow-up studies of children from 
existing birth cohorts can be conducted, with TTP studies being designed when they enter 
their reproductive years. This intergenerational approach will provide information on in utero 
exposures, as well as on exposures at the time of pregnancy attempts. In addition, as 
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recommended by Arbuckle et al. (29), research should continue to search for valid biomarkers 
of endocrine dysfunction, and preferably longitudinally, as we did in our 2D:4D study with 
women and their offspring, measuring additional endpoints such as anogenital distance, breast 
size, menarche, and hormonal profiles at different sensitive windows to facilitate 
comparability between study groups. Finally, further investigation is needed to better 
understand the mechanistic pathways by which select environmental chemicals are able to 
modulate the endocrine system and affect development and reproduction. 
 
6.6 Student’s contribution 
In February 2007, I joined the MIREC coordinating team as a research assistant, a 
position that I held until June 2010. During that time I worked on the implementation of the 
MIREC study in the 10 study sites, including the preparation of the case report forms 
(questionnaires), manual of procedures, ethics submission, research nurses’ training, quality 
control, and participation in the weekly conference call with the principal investigators and co-
investigators of the study. I also worked on a manuscript assessing the effect of phthalates on 
women's reproductive health. This paper was selected by the National Network of 
Environments and Women's Health (NNEWH), a Canadian policy-oriented research centre, as 
a chapter for a book focused on Environmental Health Policy (199).  In addition, I was co-
investigator of a research proposal lead by Dr. Monnier to assess exposure to phthalates in 
children admitted to the pediatric intensive care unit at CHU Sainte-Justine that was funded by 
the Research Center. I started my PhD in September 2008, presented the written general exam 
in August 2009, and the oral defence of the protocol in August 2010. In agreement with Dr. 
Fraser, I started a clinical fellowship in Reproductive Endocrinology and Infertility at 
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Université de Montréal in July 2010 for two years . In addition to my clinical activities, I was 
the main research consultant for my fellow colleagues and residents. Several abstracts were 
presented in National and International meetings, four manuscripts (200-202, 161) and two 
book chapters were published (203, 204).   
In 2012, I joined the MIREC research platform as a co-investigator of the 
anthropometry component of the MIREC-CD Plus Study (follow-up of about 800 MIREC 
children to age 5 years).  During this time, I   obtained a research grant from the CIHR-Quebec 
Training Network in Perinatal Research (QTNPR) to assess the utility of the Finger Digit 
Ratio (2D:4D) as a potential endocrine-sensitive endpoint in women and their offspring. I had 
an active role in the writing of various sections of the MIREC-CD Plus protocol and in its 
submission for ethics approval. For the 2D:4D component, I developed the protocol, questions 
to be included in the case report forms, and designed the device for obtaining standardized 
digital pictures of both hands in mothers and children. I also trained the nurses on how to use 
the device, and developed a detailed manual of procedures.  
The decision about the exposures that were going to be assessed in relation to TTP was 
taken in conjunction with my supervisors Dr. Fraser and Dr. Arbuckle, and was based on the 
scarcity of data for these emerging contaminants and human fecundity. In regards to the 
2D:4D, this ratio was measured in a previous MIREC follow-up study, [MIREC-ID (Infant 
Development)], but only in children, and using a tape metric. I was interested in measuring the 
2D:4D in women in relation to their TTP, since it had never been done, to test the hypothesis 
that it reflects the endocrine environment during the perinatal period. I also wanted to measure 
it in children using a standardized method. 
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I carried out all the data management, statistical analysis and interpretation of results, 
in addition to drafting the manuscripts. I worked closely with my supervisors in the 
interpretation and review of the manuscripts. I submitted the first two manuscripts, first to 
internal approval at Health Canada, and later to the scientific journals. Both of them have were 
accepted for publication in December 2014. The 2D:4D manuscript will be submitted for 
internal review soon after including a few additional participants that were recruited up to 
December 2014 (N=35). The results on the complete sample remained similar to those 
reported in the thesis. 
  
REFERENCES 
 
1. Carlsen E, Giwercman A, Keiding N, Skakkebaek NE. Evidence for decreasing quality of 
semen during past 50 years. BMJ. 1992;305(6854):609-13. 
2. Auger J, Kunstmann JM, Czyglik F, Jouannet P. Decline in semen quality among fertile 
men in Paris during the past 20 years. N Engl J Med. 1995;332(5):281-5. 
3. Irvine S, Cawood E, Richardson D, MacDonald E, Aitken J. Evidence of deteriorating 
semen quality in the United Kingdom: birth cohort study in 577 men in Scotland over 11 years. 
BMJ. 1996;312(7029):467-71. 
4. Zou Z, Hu H, Song M, Shen Y, Guo X, McElreavey K, et al. Semen quality analysis of 
military personnel from six geographical areas of the People's Republic of China. Fertility and 
sterility. 2011;95(6):2018-23, 23 e1-3. 
5. Geoffroy-Siraudin C, Loundou AD, Romain F, Achard V, Courbiere B, Perrard MH, et 
al. Decline of semen quality among 10 932 males consulting for couple infertility over a 20-year 
period in Marseille, France. Asian journal of andrology. 2012;14(4):584-90. 
6. Fisch H, Braun SR. Trends in global semen parameter values. Asian journal of andrology. 
2013;15(2):169-73. 
7. Bray F, Ferlay J, Devesa SS, McGlynn KA, Moller H. Interpreting the international 
trends in testicular seminoma and nonseminoma incidence. Nature clinical practice Urology. 
2006;3(10):532-43. 
8. Skakkebaek NE, Jorgensen N, Main KM, Rajpert-De Meyts E, Leffers H, Andersson 
AM, et al. Is human fecundity declining? International journal of andrology. 2006;29(1):2-11. 
 148 
 
9. Skakkebaek NE, Rajpert-De Meyts E, Jorgensen N, Main KM, Leffers H, Andersson 
AM, et al. Testicular cancer trends as 'whistle blowers' of testicular developmental problems in 
populations. International journal of andrology. 2007;30(4):198-204; discussion -5. 
10. Buck Louis GM. Persistent environmental pollutants and couple fecundity: an overview. 
Reproduction. 2014;147(4):R97-R104. 
11. Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence 
of uterine leiomyoma in black and white women: ultrasound evidence. American journal of 
obstetrics and gynecology. 2003;188(1):100-7. 
12. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence 
and features of the polycystic ovary syndrome in an unselected population. The Journal of 
clinical endocrinology and metabolism. 2004;89(6):2745-9. 
13. Gylfason JT, Kristjansson KA, Sverrisdottir G, Jonsdottir K, Rafnsson V, Geirsson RT. 
Pelvic endometriosis diagnosed in an entire nation over 20 years. American journal of 
epidemiology. 2010;172(3):237-43. 
14. Priskorn L, Holmboe SA, Jacobsen R, Jensen TK, Lassen TH, Skakkebaek NE. 
Increasing trends in childlessness in recent birth cohorts - a registry-based study of the total 
Danish male population born from 1945 to 1980. International journal of andrology. 
2012;35(3):449-55. 
15. Thoma ME, McLain AC, Louis JF, King RB, Trumble AC, Sundaram R, et al. 
Prevalence of infertility in the United States as estimated by the current duration approach and a 
traditional constructed approach. Fertility and sterility. 2013;99(5):1324-31 e1. 
16. Buck Louis GM. Fecundity and Fertility. In: Buck Louis GM, Platt RW, editors. 
Reproductive and perinatal epidemiology. New York: Oxford University Press; 2011. p. 16-61. 
 149 
 
17. Joffe M. Time to pregnancy: a measure of reproductive function in either sex. Asclepios 
Project. Occupational and environmental medicine. 1997;54(5):289-95. 
18. Swan SH. Alternative measures of fertility compromise. Fertility and sterility. 2008;89(2 
Suppl):e27-9. 
19. Baird DD, Wilcox AJ, Weinberg CR. Use of time to pregnancy to study environmental 
exposures. American journal of epidemiology. 1986;124(3):470-80. 
20. Weinberg CR, Wilcox AJ. Methodological Issues in Reproductive Epidemiology. In: 
Rothman KJ, Greenland S, Lash TL, editors. Modern Epidemiology. Philadelphia: Lippincott 
Williams & Wilkins; 2008. p. 620-40. 
21. Joffe M, Key J, Best N, Keiding N, Scheike T, Jensen TK. Studying time to pregnancy by 
use of a retrospective design. American journal of epidemiology. 2005;162(2):115-24. 
22. Gnoth C, Godehardt E, Frank-Herrmann P, Friol K, Tigges J, Freundl G. Definition and 
prevalence of subfertility and infertility. Human reproduction. 2005;20(5):1144-7. 
23. Infertility revisited: the state of the art today and tomorrow. The ESHRE Capri 
Workshop. European Society for Human Reproduction and Embryology. Human reproduction. 
1996;11(8):1779-807. 
24. Bhattacharya S, Hamilton M. Management of Infertility for the MRCOG and Beyond, 
2nd edition. J H, editor. London: RCOG Press; 2006. 
25. Thomson F, Shanbhag S, Templeton A, Bhattacharya S. Obstetric outcome in women 
with subfertility. BJOG. 2005;112(5):632-7. 
26. Buck Louis GM, Cooney MA, Peterson CM. The ovarian dysgenesis syndrome. Journal 
of Developmental Origins of Health and Disease. 2011;2(1):25-35. 
 150 
 
27. Skakkebaek NE, Rajpert-De Meyts E, Main KM. Testicular dysgenesis syndrome: an 
increasingly common developmental disorder with environmental aspects. Human reproduction. 
2001;16(5):972-8. 
28. Zoeller RT, Brown TR, Doan LL, Gore AC, Skakkebaek NE, Soto AM, et al. Endocrine-
disrupting chemicals and public health protection: a statement of principles from The Endocrine 
Society. Endocrinology. 2012;153(9):4097-110. 
29. Arbuckle TE, Hauser R, Swan SH, Mao CS, Longnecker MP, Main KM, et al. Meeting 
report: measuring endocrine-sensitive endpoints within the first years of life. Environmental 
health perspectives. 2008;116(7):948-51. 
30. Manning JT. Digit ratio: a pointer to fertility, behaviour, and health: New Jersey: Rutgers 
University Press; 2002. 
31. Arbuckle TE, Fraser WD, Fisher M, Davis K, Liang CL, Lupien N, et al. Cohort profile: 
the maternal-infant research on environmental chemicals research platform. Paediatric and 
perinatal epidemiology. 2013;27(4):415-25. 
32. US Environmental Protection Agency. Chemical Hazard Data Availability Study: What 
Do We Really Know About the Safety of High Production Volume Chemicals? . Washington, 
DC: US Environmental Protection Agency, Office of Pollution Prevention and Toxic 
Substances., 1998. 
33. Gobas FA, de Wolf W, Burkhard LP, Verbruggen E, Plotzke K. Revisiting 
bioaccumulation criteria for POPs and PBT assessments. Integr Environ Assess Manag. 
2009;5(4):624-37. 
 151 
 
34. Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, Hauser R, Prins GS, Soto AM, et 
al. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev. 
2009;30(4):293-342. 
35. Telisman S, Cvitkovic P, Jurasovic J, Pizent A, Gavella M, Rocic B. Semen quality and 
reproductive endocrine function in relation to biomarkers of lead, cadmium, zinc, and copper in 
men. Environmental health perspectives. 2000;108(1):45-53. 
36. Johnson MD, Kenney N, Stoica A, Hilakivi-Clarke L, Singh B, Chepko G, et al. 
Cadmium mimics the in vivo effects of estrogen in the uterus and mammary gland. Nature 
medicine. 2003;9(8):1081-4. 
37. Pine M, Lee B, Dearth R, Hiney JK, Dees WL. Manganese acts centrally to stimulate 
luteinizing hormone secretion: a potential influence on female pubertal development. 
Toxicological sciences : an official journal of the Society of Toxicology. 2005;85(2):880-5. 
38. Davey JC, Bodwell JE, Gosse JA, Hamilton JW. Arsenic as an endocrine disruptor: 
effects of arsenic on estrogen receptor-mediated gene expression in vivo and in cell culture. 
Toxicological sciences : an official journal of the Society of Toxicology. 2007;98(1):75-86. 
39. Tan SW, Meiller JC, Mahaffey KR. The endocrine effects of mercury in humans and 
wildlife. Critical reviews in toxicology. 2009;39(3):228-69. 
40. Coburn CG, Curras-Collazo MC, Kodavanti PR. Polybrominated diphenyl ethers and 
ortho-substituted polychlorinated biphenyls as neuroendocrine disruptors of vasopressin release: 
effects during physiological activation in vitro and structure-activity relationships. Toxicological 
sciences : an official journal of the Society of Toxicology. 2007;98(1):178-86. 
41. Tsai WT. Human health risk on environmental exposure to Bisphenol-A: a review. J 
Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2006;24(2):225-55. 
 152 
 
42. Gray LE, Jr., Wolf C, Lambright C, Mann P, Price M, Cooper RL, et al. Administration 
of potentially antiandrogenic pesticides (procymidone, linuron, iprodione, chlozolinate, p,p'-
DDE, and ketoconazole) and toxic substances (dibutyl- and diethylhexyl phthalate, PCB 169, 
and ethane dimethane sulphonate) during sexual differentiation produces diverse profiles of 
reproductive malformations in the male rat. Toxicology and industrial health. 1999;15(1-2):94-
118. 
43. Jarrell JF, Villeneuve D, Franklin C, Bartlett S, Wrixon W, Kohut J, et al. Contamination 
of human ovarian follicular fluid and serum by chlorinated organic compounds in three Canadian 
cities. CMAJ : Canadian Medical Association journal = journal de l'Association medicale 
canadienne. 1993;148(8):1321-7. 
44. Gerhard I, Monga B, Krahe J, Runnebaum B. Chlorinated hydrocarbons in infertile 
women. Environmental research. 1999;80(4):299-310. 
45. Younglai EV, Foster WG, Hughes EG, Trim K, Jarrell JF. Levels of environmental 
contaminants in human follicular fluid, serum, and seminal plasma of couples undergoing in 
vitro fertilization. Archives of environmental contamination and toxicology. 2002;43(1):121-6. 
46. de Cock J, Westveer K, Heederik D, te Velde E, van Kooij R. Time to pregnancy and 
occupational exposure to pesticides in fruit growers in The Netherlands. Occupational and 
environmental medicine. 1994;51(10):693-9. 
47. Fuortes L, Clark MK, Kirchner HL, Smith EM. Association between female infertility 
and agricultural work history. Am J Ind Med. 1997;31(4):445-51. 
48. Fernandez M, Bianchi M, Lux-Lantos V, Libertun C. Neonatal exposure to bisphenol a 
alters reproductive parameters and gonadotropin releasing hormone signaling in female rats. 
Environmental health perspectives. 2009;117(5):757-62. 
 153 
 
49. Fernandez MO, Bourguignon N, Lux-Lantos V, Libertun C. Neonatal Exposure to 
Bisphenol A and Reproductive and Endocrine Alterations Resembling the Polycystic Ovarian 
Syndrome in Adult Rats. Environmental health perspectives. 2010. 
50. Axmon A, Rylander L, Stromberg U, Hagmar L. Altered menstrual cycles in women with 
a high dietary intake of persistent organochlorine compounds. Chemosphere. 2004;56(8):813-9. 
51. Langer P, Tajtakova M, Kocan A, Petrik J, Koska J, Ksinantova L, et al. Thyroid 
ultrasound volume, structure and function after long-term high exposure of large population to 
polychlorinated biphenyls, pesticides and dioxin. Chemosphere. 2007;69(1):118-27. 
52. Buck Louis GM, Peterson CM, Chen Z, Hediger ML, Croughan MS, Sundaram R, et al. 
Perfluorochemicals and endometriosis: the ENDO study. Epidemiology. 2012;23(6):799-805. 
53. Ritter L, Arbuckle TE. Can exposure characterization explain concurrence or discordance 
between toxicology and epidemiology? Toxicological sciences : an official journal of the Society 
of Toxicology. 2007;97(2):241-52. 
54. Hertz-Picciotto I. Environmental Epidemiology. In: Rothman KJ, Greenland S, Lash TL, 
editors. Modern Epidemiology. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 598-619. 
55. Needham LL, Calafat AM, Barr DB. Assessing developmental toxicant exposures via 
biomonitoring. Basic Clin Pharmacol Toxicol. 2008;102(2):100-8. 
56. Centers for Disease Control and Prevention. Fourth National Report on Human Exposure 
to Environmental Chemicals. 2009. 
57. Health Canada. Report on Human Biomonitoring of Environmental Chemicals in Canada. 
Results of the Canadian Health Measures Survey Cycle 1 (2007–2009). 2010. Available from: 
http://www.hc-sc.gc.ca/ewh-semt/alt_formats/hecs-sesc/pdf/pubs/contaminants/chms-
ecms/report-rapport-eng.pdf. 
 154 
 
58. Health Canada. Second Report on Human Biomonitoring of Environmental Chemicals in 
Canada. Results of the Canadian Health Measures Survey Cycle 2 (2009–2011). 2013. Available 
from: http://www.hc-sc.gc.ca/ewh-semt/pubs/contaminants/chms-ecms-cycle2/index-eng.php. 
59. Hanning RM, Sandhu R, MacMillan A, Moss L, Tsuji LJ, Nieboer E. Impact on blood Pb 
levels of maternal and early infant feeding practices of First Nation Cree in the Mushkegowuk 
Territory of northern Ontario, Canada. J Environ Monit. 2003;5(2):241-5. 
60. Levesque B, Duchesne JF, Gariepy C, Rhainds M, Dumas P, Scheuhammer AM, et al. 
Monitoring of umbilical cord blood lead levels and sources assessment among the Inuit. 
Occupational and environmental medicine. 2003;60(9):693-5. 
61. Belles-Isles M, Ayotte P, Dewailly E, Weber JP, Roy R. Cord blood lymphocyte 
functions in newborns from a remote maritime population exposed to organochlorines and 
methylmercury. Journal of toxicology and environmental health. 2002;65(2):165-82. 
62. Smargiassi A, Takser L, Masse A, Sergerie M, Mergler D, St-Amour G, et al. A 
comparative study of manganese and lead levels in human umbilical cords and maternal blood 
from two urban centers exposed to different gasoline additives. The Science of the total 
environment. 2002;290(1-3):157-64. 
63. Rhainds M, Levallois P, Dewailly E, Ayotte P. Lead, mercury, and organochlorine 
compound levels in cord blood in Quebec, Canada. Archives of environmental health. 
1999;54(1):40-7. 
64. Lafond J, Hamel A, Takser L, Vaillancourt C, Mergler D. Low environmental 
contamination by lead in pregnant women: effect on calcium transfer in human placental 
syncytiotrophoblasts. Journal of toxicology and environmental health. 2004;67(14):1069-79. 
 155 
 
65. Takser L, Lafond J, Bouchard M, St-Amour G, Mergler D. Manganese levels during 
pregnancy and at birth: relation to environmental factors and smoking in a Southwest Quebec 
population. Environmental research. 2004;95(2):119-25. 
66. Arbuckle TE, Davis K, Marro L, Fisher M, Legrand M, LeBlanc A, et al. Phthalate and 
bisphenol A exposure among pregnant women in Canada--results from the MIREC study. 
Environment international. 2014;68:55-65. 
67. Arbuckle TE, Marro L, Davis K, Fisher M, Ayotte P, Bélanger P, et al. Exposure to Free 
and Conjugated Forms of Bisphenol A and Triclosan among Pregnant Women in the MIREC 
Cohort. Environmental Health Perspectives Accepted for publication. 2014. 
68. Wilcox AJ. Fertility and Fecundability. New York: Oxford University Press; 2010. 
69. Joffe M. Invited commentary: the potential for monitoring of fecundity and the remaining 
challenges. American journal of epidemiology. 2003;157(2):89-93. 
70. Buck GM, Lynch CD, Stanford JB, Sweeney AM, Schieve LA, Rockett JC, et al. 
Prospective pregnancy study designs for assessing reproductive and developmental toxicants. 
Environmental health perspectives. 2004;112(1):79-86. 
71. Buck Louis GM, Sundaram R, Schisterman EF, Sweeney AM, Lynch CD, Gore-Langton 
RE, et al. Persistent environmental pollutants and couple fecundity: the LIFE study. 
Environmental health perspectives. 2013;121(2):231-6. 
72. Buck Louis GM, Sundaram R, Sweeney AM, Schisterman EF, Maisog J, Kannan K. 
Urinary bisphenol A, phthalates, and couple fecundity: the Longitudinal Investigation of Fertility 
and the Environment (LIFE) Study. Fertility and sterility. 2014;101(5):1359-66. 
73. Keiding N, Kvist K, Hartvig H, Tvede M, Juul S. Estimating time to pregnancy from 
current durations in a cross-sectional sample. Biostatistics. 2002;3(4):565-78. 
 156 
 
74. Slama R, Ducot B, Carstensen L, Lorente C, de La Rochebrochard E, Leridon H, et al. 
Feasibility of the current-duration approach to studying human fecundity. Epidemiology. 
2006;17(4):440-9. 
75. Olsen J, Andersen PK. We should monitor human fecundity, but how? A suggestion for a 
new method that may also be used to identify determinants of low fecundity. Epidemiology. 
1999;10(4):419-21. 
76. Zielhuis GA, Hulscher ME, Florack EI. Validity and reliability of a questionnaire on 
fecundability. Int J Epidemiol. 1992;21(6):1151-6. 
77. Cooney MA, Buck Louis GM, Sundaram R, McGuiness BM, Lynch CD. Validity of self-
reported time to pregnancy. Epidemiology. 2009;20(1):56-9. 
78. Weinberg CR, Baird DD, Wilcox AJ. Sources of bias in studies of time to pregnancy. 
Statistics in medicine. 1994;13(5-7):671-81. 
79. Basso O, Juul S, Olsen J. Time to pregnancy as a correlate of fecundity: differential 
persistence in trying to become pregnant as a source of bias. International journal of 
epidemiology. 2000;29(5):856-61. 
80. Cooney MA, Buck Louis GM, Sun W, Rice MM, Klebanoff MA. Is conception delay a 
risk factor for reduced gestation or birthweight? Paediatric and perinatal epidemiology. 
2006;20(3):201-9. 
81. Williams MA, Goldman MB, Mittendorf R, Monson RR. Subfertility and the risk of low 
birth weight. Fertility and sterility. 1991;56(4):668-71. 
82. Joffe M, Li Z. Association of time to pregnancy and the outcome of pregnancy. Fertility 
and sterility. 1994;62(1):71-5. 
 157 
 
83. Henriksen TB, Baird DD, Olsen J, Hedegaard M, Secher NJ, Wilcox AJ. Time to 
pregnancy and preterm delivery. Obstet Gynecol. 1997;89(4):594-9. 
84. Zhu JL, Basso O, Obel C, Bille C, Olsen J. Infertility, infertility treatment, and congenital 
malformations: Danish national birth cohort. BMJ. 2006;333(7570):679. 
85. Basso O, Baird DD. Infertility and preterm delivery, birthweight, and Caesarean section: 
a study within the Danish National Birth Cohort. Human reproduction. 2003;18(11):2478-84. 
86. Basso O, Weinberg CR, Baird DD, Wilcox AJ, Olsen J. Subfecundity as a correlate of 
preeclampsia: a study within the Danish National Birth Cohort. American journal of 
epidemiology. 2003;157(3):195-202. 
87. Zhu JL, Obel C, Hammer Bech B, Olsen J, Basso O. Infertility, infertility treatment, and 
fetal growth restriction. Obstet Gynecol. 2007;110(6):1326-34. 
88. Basso O, Olsen J. Subfecundity and neonatal mortality: longitudinal study within the 
Danish national birth cohort. BMJ. 2005;330(7488):393-4. 
89. U.S. Environmental Protection Agency (EPA). Contaminants of Emerging Concern  
[27.08.2014]. Available from: http://water.epa.gov/scitech/cec/. 
90. ATSDR. Draft Toxicological Profile for Perfluoroalkyls. In: Agency for Toxic 
Substances and Disease Registry, editor. 2009. 
91. DuPont. About PFOA 2013 [08.12.2014]. Available from: 
http://www2.dupont.com/PFOA2/en_US/index.html. 
92. 3M. 2014. [16.06.14]. Available from: 
http://solutions.3m.com/wps/portal/3M/en_US/PFOS/PFOA/Information/phase-out-
technologies/. 
 158 
 
93. Olsen GW, Burris JM, Ehresman DJ, Froehlich JW, Seacat AM, Butenhoff JL, et al. 
Half-life of serum elimination of perfluorooctanesulfonate,perfluorohexanesulfonate, and 
perfluorooctanoate in retired fluorochemical production workers. Environmental health 
perspectives. 2007;115(9):1298-305. 
94. Kjeldsen LS, Bonefeld-Jorgensen EC. Perfluorinated compounds affect the function of 
sex hormone receptors. Environ Sci Pollut Res Int. 2013;20(11):8031-44. 
95. Austin ME, Kasturi BS, Barber M, Kannan K, MohanKumar PS, MohanKumar SM. 
Neuroendocrine effects of perfluorooctane sulfonate in rats. Environmental health perspectives. 
2003;111(12):1485-9. 
96. Fei C, McLaughlin JK, Lipworth L, Olsen J. Maternal levels of perfluorinated chemicals 
and subfecundity. Human reproduction. 2009;24(5):1200-5. 
97. Whitworth KW, Haug LS, Baird DD, Becher G, Hoppin JA, Skjaerven R, et al. 
Perfluorinated compounds and subfecundity in pregnant women. Epidemiology. 2012;23(2):257-
63. 
98. Ding J, Zhou H, Liu Y, Cai J, Longnecker MP. Estimating effect of environmental 
contaminants on women's subfecundity for the MoBa study data with an outcome-dependent 
sampling scheme. Biostatistics. 2014. 
99. Vestergaard S, Nielsen F, Andersson AM, Hjollund NH, Grandjean P, Andersen HR, et 
al. Association between perfluorinated compounds and time to pregnancy in a prospective cohort 
of Danish couples attempting to conceive. Human reproduction. 2012;27(3):873-80. 
100. Ehrlich S, Calafat AM, Humblet O, Smith T, Hauser R. Handling of thermal receipts as a 
source of exposure to bisphenol A. JAMA : the journal of the American Medical Association. 
2014;311(8):859-60. 
 159 
 
101. Calafat AM, Ye X, Wong LY, Reidy JA, Needham LL. Exposure of the U.S. population 
to bisphenol A and 4-tertiary-octylphenol: 2003-2004. Environmental health perspectives. 
2008;116(1):39-44. 
102. Peretz J, Vrooman L, Ricke WA, Hunt PA, Ehrlich S, Hauser R, et al. Bisphenol a and 
reproductive health: update of experimental and human evidence, 2007-2013. Environmental 
health perspectives. 2014;122(8):775-86. 
103. Meeker JD, Calafat AM, Hauser R. Urinary bisphenol A concentrations in relation to 
serum thyroid and reproductive hormone levels in men from an infertility clinic. Environmental 
science & technology. 2010;44(4):1458-63. 
104. Mendiola J, Jorgensen N, Andersson AM, Calafat AM, Ye X, Redmon JB, et al. Are 
environmental levels of bisphenol a associated with reproductive function in fertile men? 
Environmental health perspectives. 2010;118(9):1286-91. 
105. Bloom MS, Kim D, Vom Saal FS, Taylor JA, Cheng G, Lamb JD, et al. Bisphenol A 
exposure reduces the estradiol response to gonadotropin stimulation during in vitro fertilization. 
Fertility and sterility. 2011;96(3):672-7 e2. 
106. Souter I, Smith KW, Dimitriadis I, Ehrlich S, Williams PL, Calafat AM, et al. The 
association of bisphenol-A urinary concentrations with antral follicle counts and other measures 
of ovarian reserve in women undergoing infertility treatments. Reproductive toxicology. 
2013;42:224-31. 
107. Mok-Lin E, Ehrlich S, Williams PL, Petrozza J, Wright DL, Calafat AM, et al. Urinary 
bisphenol A concentrations and ovarian response among women undergoing IVF. International 
journal of andrology. 2010;33(2):385-93. 
 160 
 
108. Ehrlich S, Williams PL, Missmer SA, Flaws JA, Ye X, Calafat AM, et al. Urinary 
bisphenol A concentrations and early reproductive health outcomes among women undergoing 
IVF. Human reproduction. 2012;27(12):3583-92. 
109. Ehrlich S, Williams PL, Missmer SA, Flaws JA, Berry KF, Calafat AM, et al. Urinary 
bisphenol A concentrations and implantation failure among women undergoing in vitro 
fertilization. Environmental health perspectives. 2012;120(7):978-83. 
110. Dann AB, Hontela A. Triclosan: environmental exposure, toxicity and mechanisms of 
action. Journal of applied toxicology : JAT. 2011;31(4):285-311. 
111. Health Canada and Environment Canada. Preliminary Assessment: Triclosan. March 
2012 2012 [August 8, 2014]. Available from: http://www.ec.gc.ca/ese-
ees/default.asp?lang=En&n=6EF68BEC-1. 
112. Calafat AM, Ye X, Wong LY, Reidy JA, Needham LL. Urinary concentrations of 
triclosan in the U.S. population: 2003-2004. Environmental health perspectives. 
2008;116(3):303-7. 
113. Wolff MS, Engel SM, Berkowitz GS, Ye X, Silva MJ, Zhu C, et al. Prenatal phenol and 
phthalate exposures and birth outcomes. Environmental health perspectives. 2008;116(8):1092-7. 
114. Philippat C, Mortamais M, Chevrier C, Petit C, Calafat AM, Ye X, et al. Exposure to 
phthalates and phenols during pregnancy and offspring size at birth. Environmental health 
perspectives. 2012;120(3):464-70. 
115. Lankester J, Patel C, Cullen MR, Ley C, Parsonnet J. Urinary triclosan is associated with 
elevated body mass index in NHANES. PloS one. 2013;8(11):e80057. 
 161 
 
116. NTP-CERHR (National Toxicology Program CftEoRtHR. Monograph on the Potential 
Human reproductive and Developmental Effects of Di(2-Ethylhexyl) Phthalate (DEHP). NIH 
Publication No. 06-4476. 2006. 
117. Heudorf U, Mersch-Sundermann V, Angerer J. Phthalates: Toxicology and exposure. 
International journal of hygiene and environmental health. 2007;210(5):623. 
118. Frederiksen H, Skakkebaek NE, Andersson AM. Metabolism of phthalates in humans. 
Mol Nutr Food Res. 2007;51(7):899-911. 
119. Borch J, Ladefoged O, Hass U, Vinggaard AM. Steroidogenesis in fetal male rats is 
reduced by DEHP and DINP, but endocrine effects of DEHP are not modulated by DEHA in 
fetal, prepubertal and adult male rats. Reproductive toxicology. 2004;18(1):53-61. 
120. Hotchkiss AK, Parks-Saldutti LG, Ostby JS, Lambright C, Furr J, Vandenbergh JG, et al. 
A mixture of the "antiandrogens" linuron and butyl benzyl phthalate alters sexual differentiation 
of the male rat in a cumulative fashion. Biology of reproduction. 2004;71(6):1852-61. 
121. Velez MP, Monnier P, Foster WG, Fraser WD. The Impact of Phthalates on Women’s 
Reproductive Health. In: Scott D, editor. Our Chemicals Selves. In press. Vancouver: University 
of British Columbia Press; 2014. 
122. Saravanabhavan G, Guay M, Langlois E, Giroux S, Murray J, Haines D. Biomonitoring 
of phthalate metabolites in the Canadian population through the Canadian Health Measures 
Survey (2007-2009). International journal of hygiene and environmental health. 
2013;216(6):652-61. 
123. Burdorf A, Brand T, Jaddoe VW, Hofman A, Mackenbach JP, Steegers EA. The effects 
of work-related maternal risk factors on time to pregnancy, preterm birth and birth weight: the 
Generation R Study. Occupational and environmental medicine. 2011;68(3):197-204. 
 162 
 
124. Snijder CA, Brouwers MM, Jaddoe VW, Hofman A, Roeleveld N, Burdorf A. 
Occupational exposure to endocrine disruptors and time to pregnancy among couples in a large 
birth cohort study: the Generation R Study. Fertility and sterility. 2011;95(6):2067-72. 
125. Tranfo G, Caporossi L, Paci E, Aragona C, Romanzi D, De Carolis C, et al. Urinary 
phthalate monoesters concentration in couples with infertility problems. Toxicology letters. 
2012;213(1):15-20. 
126. Wigle DT, Arbuckle TE, Turner MC, Berube A, Yang Q, Liu S, et al. Epidemiologic 
evidence of relationships between reproductive and child health outcomes and environmental 
chemical contaminants. J Toxicol Environ Health B Crit Rev. 2008;11(5-6):373-517. 
127. World Health Organization (WHO). Global Assesment of the State-Of-The-Science of 
Endocrine Disruptors. eds. T. Damstra, S. Barlow, A. Bergman, R. Kavlock, and G. Van Der 
Kraak. Geneva: International Programme on Chemical Safety. WHO/PCS/EDC/02.2., 2002. 
128. Bailey AA, Hurd PL. Finger length ratio (2D:4D) correlates with physical aggression in 
men but not in women. Biological psychology. 2005;68(3):215-22. 
129. Manning JT, Scutt D, Wilson J, Lewis-Jones DI. The ratio of 2nd to 4th digit length: a 
predictor of sperm numbers and concentrations of testosterone, luteinizing hormone and 
oestrogen. Human reproduction. 1998;13(11):3000-4. 
130. Auger J, Eustache F. Second to fourth digit ratios, male genital development and 
reproductive health: a clinical study among fertile men and testis cancer patients. International 
journal of andrology. 2011;34(4 Pt 2):e49-58. 
131. Lu H, Huo ZH, Liu YJ, Shi ZY, Zhao JL. Correlations between digit ratio and infertility 
in Chinese men. Early human development. 2012;88(11):865-9. 
 163 
 
132. Firman RC, Simmons LW, Cummins JM, Matson PL. Are body fluctuating asymmetry 
and the ratio of 2nd to 4th digit length reliable predictors of semen quality? Human reproduction. 
2003;18(4):808-12. 
133. Neave N, Laing S, Fink B, Manning JT. Second to fourth digit ratio, testosterone and 
perceived male dominance. Proceedings Biological sciences / The Royal Society. 
2003;270(1529):2167-72. 
134. Bang AK, Carlsen E, Holm M, Petersen JH, Skakkebaek NE, Jorgensen N. A study of 
finger lengths, semen quality and sex hormones in 360 young men from the general Danish 
population. Human reproduction. 2005;20(11):3109-13. 
135. Honekopp J, Bartholdt L, Beier L, Liebert A. Second to fourth digit length ratio (2D:4D) 
and adult sex hormone levels: new data and a meta-analytic review. Psychoneuroendocrinology. 
2007;32(4):313-21. 
136. Seo H, Kim KY, Rho J. Is the Index Finger and Ring Finger Ratio (2D:4D) Reliable 
Predictor of Semen Quality? Korean journal of urology. 2010;51(3):208-11. 
137. Beaton AA, Rudling N, Kissling C, Taurines R, Thome J. Digit ratio (2D:4D), salivary 
testosterone, and handedness. Laterality. 2011;16(2):136-55. 
138. Matchock RL. Low digit ratio (2D:4D) is associated with delayed menarche. American 
journal of human biology : the official journal of the Human Biology Council. 2008;20(4):487-9. 
139. Manning JT, Fink B. Is low digit ratio linked with late menarche? Evidence from the 
BBC internet study. American journal of human biology : the official journal of the Human 
Biology Council. 2011;23(4):527-33. 
140. Oberg AS, Villamor E. Low digit ratio predicts early age at menarche in colombian 
schoolgirls. Paediatr Perinat Epidemiol. 2012;26(5):448-55. 
 164 
 
141. Manning JT, Fink B. Digit ratio (2D:4D), dominance, reproductive success, asymmetry, 
and sociosexuality in the BBC Internet Study. American journal of human biology : the official 
journal of the Human Biology Council. 2008;20(4):451-61. 
142. Brown WM, Hines M, Fane BA, Breedlove SM. Masculinized finger length patterns in 
human males and females with congenital adrenal hyperplasia. Hormones and behavior. 
2002;42(4):380-6. 
143. Oswiecimska JM, Ksiazek A, Sygulla K, Pys-Spychala M, Roczniak GR, Roczniak W, et 
al. Androgens concentrations and second-to fourth-digit ratio (2D:4D) in girls with congenital 
adrenal hyperplasia (21-hydroxylase deficiency). Neuro endocrinology letters. 2012;33(8):787-
91. 
144. Cattrall FR, Vollenhoven BJ, Weston GC. Anatomical evidence for in utero androgen 
exposure in women with polycystic ovary syndrome. Fertility and sterility. 2005;84(6):1689-92. 
145. Lujan ME, Bloski TG, Chizen DR, Lehotay DC, Pierson RA. Digit ratios do not serve as 
anatomical evidence of prenatal androgen exposure in clinical phenotypes of polycystic ovary 
syndrome. Human reproduction. 2010;25(1):204-11. 
146. Lujan ME, Podolski AJ, Chizen DR, Lehotay DC, Pierson RA. Digit ratios by computer-
assisted analysis confirm lack of anatomical evidence of prenatal androgen exposure in clinical 
phenotypes of polycystic ovary syndrome. Reproductive biology and endocrinology : RB&E. 
2010;8:156. 
147. Baird DD, Wilcox AJ. Cigarette smoking associated with delayed conception. JAMA : 
the journal of the American Medical Association. 1985;253(20):2979-83. 
 165 
 
148. Ernst A, Kristensen SL, Toft G, Thulstrup AM, Hakonsen LB, Olsen SF, et al. Maternal 
smoking during pregnancy and reproductive health of daughters: a follow-up study spanning two 
decades. Human reproduction. 2012;27(12):3593-600. 
149. Weinberg CR, Wilcox AJ, Baird DD. Reduced fecundability in women with prenatal 
exposure to cigarette smoking. American journal of epidemiology. 1989;129(5):1072-8. 
150. Smith LM, Cloak CC, Poland RE, Torday J, Ross MG. Prenatal nicotine increases 
testosterone levels in the fetus and female offspring. Nicotine & tobacco research : official 
journal of the Society for Research on Nicotine and Tobacco. 2003;5(3):369-74. 
151. Kandel DB, Udry JR. Prenatal effects of maternal smoking on daughters' smoking: 
nicotine or testosterone exposure? American journal of public health. 1999;89(9):1377-83. 
152. Rizwan S, Manning JT, Brabin BJ. Maternal smoking during pregnancy and possible 
effects of in utero testosterone: evidence from the 2D:4D finger length ratio. Early human 
development. 2007;83(2):87-90. 
153. Macaluso M, Wright-Schnapp TJ, Chandra A, Johnson R, Satterwhite CL, Pulver A, et al. 
A public health focus on infertility prevention, detection, and management. Fertility and sterility. 
2010;93(1):16 e1-0. 
154. Centers for Disease Control and Prevention. National Public Health Action Plan for the 
Detection, Prevention, and Management of Infertility. Atlanta, Georgia: Centers for Disease 
Control and Prevention; June 2014. 
155. Chandra A, Copen CE, Stephen EH. Infertility and impaired fecundity in the United 
States, 1982-2010: data from the National Survey of Family Growth. National health statistics 
reports. 2013(67):1-18, 1 p following 9. 
 166 
 
156. Chandra A, Copen CE, Stephen EH. Infertility service use in the United States: data from 
the National Survey of Family Growth, 1982-2010. National health statistics reports. 2014(73):1-
21. 
157. Vallombrosa consensus statement on environmental contaminants and human fertility 
compromise. Seminars in reproductive medicine. 2006;24(3):178-89. 
158. Buck Louis GM, Sundaram R, Schisterman EF, Sweeney AM, Lynch CD, Gore-Langton 
RE, et al. Heavy metals and couple fecundity, the LIFE Study. Chemosphere. 
159. Chevrier C, Warembourg C, Gaudreau E, Monfort C, Le Blanc A, Guldner L, et al. 
Organochlorine pesticides, polychlorinated biphenyls, seafood consumption, and time-to-
pregnancy. Epidemiology. 2013;24(2):251-60. 
160. Smith JF, Eisenberg ML, Glidden D, Millstein SG, Cedars M, Walsh TJ, et al. 
Socioeconomic disparities in the use and success of fertility treatments: analysis of data from a 
prospective cohort in the United States. Fertility and sterility. 2011;96(1):95-101. 
161. Velez MP, Connolly MP, Kadoch IJ, Phillips S, Bissonnette F. Universal coverage of 
IVF pays off. Human reproduction. 2014;29(6):1313-9. 
162. Gupta S, Ross NA. Under the Microscope: Health Disparities within Canadian Cities.: 
Health Canada; 2007. Available from: http://www.hc-sc.gc.ca/sr-sr/pubs/hpr-rpms/bull/2007-
people-place-gens-lieux/index-eng.php. 
163. Haluza-DeLay R, O'Riley P, Cole P, Agyeman J. Introduction. Speaking for Ourselves, 
Speaking Together: Environmental justice in Canada. In: Agyeman J, Cole P, Haluza-DeLay R, 
O'Riley P, editors. Speaking for Ourselves: Environmental justice in Canada. Vancouver: 
UBC:Press; 2009. p. 1-26. 
 167 
 
164. Sexton K, Olden K, Johnson BL. "Environmental justice": the central role of research in 
establishing a credible scientific foundation for informed decision making. Toxicology and 
industrial health. 1993;9(5):685-727. 
165. Centers for Disease Control and Prevention. Third National Report on Human Exposure 
to Environmental Chemicals. Atlanta (GA): CDC: 2005. 
166. Rothman KJ, Greenland S, Last TL. Modern epidemiology. 3rd ed. Philadelphia: Wolters 
Kluwer | Lippincott Williams & Wilkins; 2008. x, 758 p. p. 
167. Joffe M, Villard L, Li Z, Plowman R, Vessey M. Long-term recall of time-to-pregnancy. 
Fertility and sterility. 1993;60(1):99-104. 
168. Ridout MS, Morgan BJ. Modelling digit preference in fecundability studies. Biometrics. 
1991;47(4):1423-33. 
169. McLain AC, Sundaram R, Thoma M, Buck Louis GM. Semiparametric modeling of 
grouped current duration data with preferential reporting. Statistics in medicine. 
2014;33(23):3961-72. 
170. Buck Louis GM, Chen Z, Schisterman EF, Kim S, Sweeney AM, Sundaram R, et al. 
Perfluorochemicals and Human Semen Quality: The LIFE Study. Environmental health 
perspectives. 2014. 
171. Cole DC, Wainman B, Sanin LH, Weber JP, Muggah H, Ibrahim S. Environmental 
contaminant levels and fecundability among non-smoking couples. Reproductive toxicology. 
2006;22(1):13-9. 
172. Buck Louis GM, Dmochowski J, Lynch C, Kostyniak P, McGuinness BM, Vena JE. 
Polychlorinated biphenyl serum concentrations, lifestyle and time-to-pregnancy. Human 
reproduction. 2009;24(2):451-8. 
 168 
 
173. Wilcox AJ, Weinberg CR, Baird DD. Timing of sexual intercourse in relation to 
ovulation. Effects on the probability of conception, survival of the pregnancy, and sex of the 
baby. N Engl J Med. 1995;333(23):1517-21. 
174. Axmon A, Rylander L, Albin M, Hagmar L. Factors affecting time to pregnancy. Human 
reproduction. 2006;21(5):1279-84. 
175. Rothman KJ, Wise LA, Sorensen HT, Riis AH, Mikkelsen EM, Hatch EE. Volitional 
determinants and age-related decline in fecundability: a general population prospective cohort 
study in Denmark. Fertility and sterility. 2013;99(7):1958-64. 
176. Graham JW. Missing data analysis: making it work in the real world. Annual review of 
psychology. 2009;60:549-76. 
177. Hendry GM, Naidoo RN, Zewotir T, North D, Mentz G. Model development including 
interactions with multiple imputed data. BMC medical research methodology. 2014;14(1):136. 
178. Arbuckle TE, Kubwabo C, Walker M, Davis K, Lalonde K, Kosarac I, et al. Umbilical 
cord blood levels of perfluoroalkyl acids and polybrominated flame retardants. International 
journal of hygiene and environmental health. 2013;216(2):184-94. 
179. Richardson DB, Ciampi A. Effects of exposure measurement error when an exposure 
variable is constrained by a lower limit. American journal of epidemiology. 2003;157(4):355-63. 
180. Schisterman EF, Vexler A, Whitcomb BW, Liu A. The limitations due to exposure 
detection limits for regression models. American journal of epidemiology. 2006;163(4):374-83. 
181. Cole SR, Chu H, Nie L, Schisterman EF. Estimating the odds ratio when exposure has a 
limit of detection. International journal of epidemiology. 2009;38(6):1674-80. 
 169 
 
182. May RC, Ibrahim JG, Chu H. Maximum likelihood estimation in generalized linear 
models with multiple covariates subject to detection limits. Statistics in medicine. 
2011;30(20):2551-61. 
183. Barr DB, Wilder LC, Caudill SP, Gonzalez AJ, Needham LL, Pirkle JL. Urinary 
creatinine concentrations in the U.S. population: implications for urinary biologic monitoring 
measurements. Environmental health perspectives. 2005;113(2):192-200. 
184. Hauser R, Meeker JD, Park S, Silva MJ, Calafat AM. Temporal variability of urinary 
phthalate metabolite levels in men of reproductive age. Environmental health perspectives. 
2004;112(17):1734-40. 
185. Adibi JJ, Whyatt RM, Williams PL, Calafat AM, Camann D, Herrick R, et al. 
Characterization of Phthalate Exposure among Pregnant Women Assessed by Repeat Air and 
Urine Samples. Environmental health perspectives. 2008;116(4):467-73. 
186. George L, Granath F, Johansson AL, Cnattingius S. Self-reported nicotine exposure and 
plasma levels of cotinine in early and late pregnancy. Acta Obstet Gynecol Scand. 
2006;85(11):1331-7. 
187. Braun JM, Kalkbrenner AE, Calafat AM, Bernert JT, Ye X, Silva MJ, et al. Variability 
and predictors of urinary bisphenol A concentrations during pregnancy. Environmental health 
perspectives. 2011;119(1):131-7. 
188. Meeker JD, Cantonwine DE, Rivera-Gonzalez LO, Ferguson KK, Mukherjee B, Calafat 
AM, et al. Distribution, variability, and predictors of urinary concentrations of phenols and 
parabens among pregnant women in Puerto Rico. Environmental science & technology. 
2013;47(7):3439-47. 
 170 
 
189. Philippat C, Wolff MS, Calafat AM, Ye X, Bausell R, Meadows M, et al. Prenatal 
exposure to environmental phenols: concentrations in amniotic fluid and variability in urinary 
concentrations during pregnancy. Environmental health perspectives. 2013;121(10):1225-31. 
190. Manning JT, Fink B, Neave N, Caswell N. Photocopies yield lower digit ratios (2D:4D) 
than direct finger measurements. Archives of sexual behavior. 2005;34(3):329-33. 
191. Paul SN, Kato BS, Hunkin JL, Vivekanandan S, Spector TD. The big finger: the second 
to fourth digit ratio is a predictor of sporting ability in women. British journal of sports medicine. 
2006;40(12):981-3. 
192. Robertson J, Zhang W, Liu JJ, Muir KR, Maciewicz RA, Doherty M. Radiographic 
assessment of the index to ring finger ratio (2D:4D) in adults. Journal of anatomy. 
2008;212(1):42-8. 
193. Hall LS, Love CT. Finger-length ratios in female monozygotic twins discordant for 
sexual orientation. Archives of sexual behavior. 2003;32(1):23-8. 
194. Nicholls ME, Orr CA, Yates MJ, Loftus AM. A new means of measuring index/ring 
finger (2D:4D) ratio and its association with gender and hand preference. Laterality. 
2008;13(1):71-91. 
195. Pokrywka L, Rachon D, Suchecka-Rachon K, Bitel L. The second to fourth digit ratio in 
elite and non-elite female athletes. American journal of human biology : the official journal of 
the Human Biology Council. 2005;17(6):796-800. 
196. Allaway HC, Bloski TG, Pierson RA, Lujan ME. Digit ratios (2D:4D) determined by 
computer-assisted analysis are more reliable than those using physical measurements, 
photocopies, and printed scans. American journal of human biology : the official journal of the 
Human Biology Council. 2009;21(3):365-70. 
 171 
 
197. Kemper CJ, Schwerdtfeger A. Comparing indirect methods of digit ratio (2D:4D) 
measurement. American journal of human biology : the official journal of the Human Biology 
Council. 2009;21(2):188-91. 
198. Hsieh FY, Lavori PW. Sample-size calculations for the Cox proportional hazards 
regression model with nonbinary covariates. Controlled clinical trials. 2000;21(6):552-60. 
199. Velez MP, Monnier P, Foster WG, Fraser WD. The Impact of Phthalates on Women’s 
Reproductive Health. In: Scott D, editor. Our Chemicals Selves. In press. Vancouver: University 
of British Columbia Press; 2015. 
200. Jamal W, Velez MP, Zini A, Phillips S, Hemmings R, Kadoch IJ. Surgically retrieved 
spermatozoa versus ejaculated spermatozoa in modified natural IVF-ICSI cycles. Reproductive 
biomedicine online. 2012;25(3):242-7. 
201. Velez MP, Kadoch IJ, Phillips SJ, Bissonnette F. Rapid policy change to single-embryo 
transfer while maintaining pregnancy rates per initiated cycle. Reproductive biomedicine online. 
2013;26(5):506-11. 
202. Lehmann P, Velez MP, Saumet J, Lapensee L, Jamal W, Bissonnette F, et al. Anti-
Mullerian hormone (AMH): a reliable biomarker of oocyte quality in IVF. Journal of assisted 
reproduction and genetics. 2014;31(4):493-8. 
203. Monnier P, Velez MP, Forges T. IVF and Perinatal Outcomes. In: Vaillancourt JLC, 
editor. Pregnancy disorders and perinatal outcomes: Bentham Science Publishers; 2012. 
204. Velez MP, Kadoch IJ, Phillips S, Bissonnette F. One plus one equals two at once: the 
importance of presenting cumulative pregnancy rates as the ideal outcome in eSET programs. In: 
Sills ES, editor. Transferring the Single Euploid Embryo: Molecular Genetics in Reproductive 
Medicine. In press. Switzerland: Springer; 2015. 
 172 
 
APPENDIX 1. COHORT PROFILE: THE MATERNAL-INFANT 
RESEARCH ON ENVIRONMENTAL CHEMICALS RESEARCH 
PLATFORM 
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APPENDIX 2. VARIABLES ASSESSED IN MIREC AT EACH VISIT 
Measures 6-12 
weeks 
16-21 
weeks 
32-34 
weeks 
Delivery 1-2 days 
postnatal 
2-10 
weeks 
postnatal 
(breastmilk)
Demographics       
Maternal age, education, ethnicity, 
employment 
      
Paternal age, education, ethnicity, 
occupation 
      
Marital status, income       
Obstetric History       
Pregnancy history, time to preg       
Use of ART and contraceptive       
Pregnancy outcome       
Family Medical History       
Current Medications       
Nutritional Supplements       
Environmental Exposures       
Hobbies, work, home renovations, 
cooking ustentils 
      
Lifestyle       
Active and passive smoking      
Alcohol consumption      
Residential History       
Addresses, home characteristics       
Activities       
Diet        
Meat        
Fish      
Food Frequency      
Maternal anthropometric measures      
Blood pressure       
Protein urine dipstick test       
Placenta weight       
Co-factor Biomonitoring       
pyridinium, creatinine,  selenium, 
glutathione peroxidase 
      
oxidative stress, markers, endothelins       
minerals, vitamins, fatty acids, 
enzymes 
     
Chemical Biomonitoring       
Metals      
Plasticizers      
Brominated flame retardants      
Surface coatings      
OP Pesticides      
POPs (PCBs, OCs)      
Cotinine      
Genetic Polymorphisms        
ALAD, VDR (fokI, bsmI, apaI, taqI), 
APOE (1-4), HFE (C282Y, H63D), 
metallothionein 
      
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APPENDIX 3: MIREC DATA COLLECTION 
 
 
 
 
Prenatal Visit 1
(6-13 wks)
CRF #1
Maternal Blood
PFCs, cotinine, heavy 
metals, PCBs, PBDEs, 
OC Pesticides, selenium, 
glutathione peroxidase, 
Vit D, PTH, lipids, 
endothelins, oxidative 
stress markers, SNPs, 
proteomics, 
cardiovascular markers
Medical Record √
Maternal Urine
phthalates, 
arsenic speciation, 
bisphenol-A, 
OP pesticides, 
specific gravity, 
telopeptide bone 
resorption, pyridinium, 
creatinine,
oxidative stress markers,
proteomics
Prenatal Visit 2
(16-21 wks)
Maternal Urine
Biobank
CRF #2
Medical Record √
Maternal Blood
cotinine, endothelins, 
oxidative stress markers, 
proteomics, cardiovacular
markers
Postpartum Day 1 
or 2
Meconium
heavy metals, 
cotinine
CRF #5
Chart Review √
Post delivery
(2-8 wks)
CRF #6
Breast Milk
heavy metals, ochratoxin
A, PBDEs, OCs, PCBs, 
PFCs, bisphenol A, 
phthalates, perchlorate, 
Ca, Mg, P, K, Na, Al, Ba, 
Be, Cr, Cu, Fe, Li, Mo, Tl, 
U,  vanadium, Zn, 
secretory IgA, lactoferrin, 
lysozyme, prolactin, 
cytokine IL-6, vitamin D, E, 
carotanoids, total folate, 
folic acid, fatty acids 
profile, antioxidant 
enzymes, heterocyclic 
aromatic amine
Maternal Hair
total mercury
(for mothers who will 
breast feed)
Prenatal Visit 3
(32-34 wks)
CRF #3
Medical Record √
Maternal Blood
cotinine, selenium, 
glutathione peroxidase, 
Vit D, PTH, endothelins, 
oxidative stress markers
Maternal Urine
pyridinium, creatinine, 
oxidative stress, 
telopeptide bone 
resorption
Delivery
CRF #4
Medical Record √
Maternal Blood
cotinine, selenium, 
glutathione peroxidase, 
Vit D, PTH, endothelins, 
oxidative stress marker, 
proteomics, cardiovascular 
markers
Cord Blood
heavy metals, PBDEs, 
OCs, PCBs, PFCs, 
cotinine, lipids, Vit D, PTH, 
bone resorption, 
Maternal Urine
pyridinium, creatinine, 
teleopeptide bone 
resorption, oxidative 
stress markers, 
proteomics
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APPENDIX 4. MANUAL OF PROCEDURES FINGER DIGIT RATIO. 
6.6.1 Measuring Fingers length using the iPod Touch 
A novel endpoint that is showing promise as an indicator of sexual development is the 2nd to 4th finger digit 
ratio (2D:4D). The 2D:4D ratio shows sexual differentiation (lower in males) and is likely a biomarker for the 
organizational (permanent) effects of prenatal androgens on the human brain and body. Some evidence has 
suggested that low 2D:4D is related to high fetal testosterone. Several studies have suggested associations 
between 2D:4D and a multiplicity of sex-dependent traits. Furthermore, evidence is starting to emerge about 
the predictive role of 2D:4D on later reproductive health. For example, in regards to the age of menarche, an 
endpoint of the influence of the hormonal intrauterine environment, a recent prospective cohort study in pre-
menarcheal girls (5-12 years) reported a lower median age at menarche for girls in the lowest digit ratio tertile 
of the right hand compared with those in the highest. Additionally, the 2D:4D has been linked to sperm counts 
and hormonal status in men with impaired fertility. 
 
The TapForms application will be used for finger measurements. Seven fields will be entered for each 
participant; for information on entering data in the form, see Appendix 14: 
 
• ID Participant refers to the Biospecimen ID -
99999). 
• Mother’s ID (from a pick list) refers to the 
study ID (99-999-ABC). 
• The date is filled automatically. 
• Mother’s right hand image. 
• Mother’s left hand image. 
• Child’s right hand image. 
• Child’s left hand image. 
 
 
 
 
The same application allows Transferred data, either by e-mail, web page or DropBox application, see Appendix 
14. You must transfer the hand scans on a regular basis (e.g. every 2 weeks) in order to minimize any risk of 
potentially losing information, should unforeseen circumstances occur (ie. ipod is lost or stolen, etc). To follow 
each transfer and make sure that the files were really dropped, you must advise Gabriel Abad or Stéphanie 
Bastien of the upcoming transfer. Stéphanie will make sure that the files were transferred in the DropBox and 
if not, you will be informed. NEVER delete the transferred images. If you have any problem with the iPod, please 
contact Stéphanie. 
  
The biometric measurements of the photos will be performed at the SCC. 
 
Taking the hand pictures: 
• Open the application and enter the Participant ID (Biospecimen ID: 99999), the Mother’s ID (study ID: 
99-999-ABC) and place the iPod Touch into the structure. 
• You can start with the mother or with the child, depending on the situation; usually, it is easier to start 
with the mother. 
• Place the structure on a table and position yourself face to face with the mother. 
• Remove rings, if the mother is wearing any. 
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• Put the mother’s right hand on the structure, with the palm facing down, within the ruled area, see 
figure K below. For the mother’s hand, leave the thumb outside of the ruled area (note that for child’s 
pictures, the thumb must be included, refer to figure M). 
• Take the picture following the steps of the application, see Appendix 14. 
• Repeat for the left hand. 
• Ask the mother to place the child for each picture and to press on the hand to ensure the flateness of 
the child’s hand, refer to figure L. For the child’s hand, keep the thumb within the ruled area, see 
figure M.  
• Remember that an image can be repeated if required. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure K: Positioning mother’s hand   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure L: Positioning child’s hand. 
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Figure M: Child’s picture example. 
 
NOTE: there is no impact if the fingers are touching each other. Just make sure that the fingers are not “folded” 
and that they touch the acrylic surface.” 
 
 
 
 
 
 
 
 
 
 
 
 181 
 
Using the Hand Scan application: 
1. Find “Tap Forms” icon: 
 
2. On the Forms tab, you have the form “MIREC-
CD Plus Hand Scan” available, tap on it. 
.  
 
3. You see the list of records that you have. To 
add one record tap “+”. 
 
 
4. You have seven fields for each record. The 
date is already filled. Tap “ID Participant”. 
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5. Enter the 5 digits “ID Participant” (this 
corresponds to Biospecimen Identifier) and tap 
“Save”. 
 
6. Tap on the pick list icon of the next field to 
enter choose “Mother’s ID” (this is the study ID 
minus the site number; e.g 999-ABC). You could 
tap over the title of the field and enter the ID with 
keyboard, but the pick list is ready to help you. 
 
7. Choose the Mother’s ID and Tap “Done”
 
8. For the first picture tap “Mother’s right hand”
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9. Choose “Camera” like image source.
 
10.  This iPod has two cameras, be sure you are 
using the front camera, otherwise switch it. When 
the hand is well placed, take the picture. 
 
11. Confirm the picture by tapping “Use” or 
repeat with “Retake”. 
 
12.  Take the four pictures of the mother and the 
infant. With the form completed, you can block 
“Edit the fields”. The data is saved. 
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To export your data, be sure you have an Internet connection: 
 
1.  In the participants list, you will find the icon to 
export or email the whole data base. 
 
Note:  In the view of a particular patient, the icon 
for exporting a single record is present. But, we 
do not use it. 
 
2. Tap on “Export Records” to generate a ZIP file 
of date base including the images. The “Delete 
All Records” option is too visible, avoid touching 
it, if you do by mistake, you can cancel the 
operation. 
3.  You will have a confirmation message, tap OK. 
The zip file is on the Exports folder of the Files 
tab ready to be sent, tap the File tab icon.   
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4. The application keeps all the export files. Tap 
on the Transfer icon of your latest file. 
5. Choose “Upload to Dropbox” to transfer your 
data. 
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APPENDIX 5 . SAMPLE-SIZE METHOD FOR NONBINARY 
COVARIATES 
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